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ABSTRACT 
 
The stereoselective 1,3-dipolar cycloaddition reaction of cyclic nitrones with 
ephedrine-derived alkylidene morpholinones provided the corresponding spiro 
isoxazolidines which were converted to naturally occurring indolizidine and quinolizidine 
alkaloids. A detailed investigation of the cycloaddition reaction and the conversion of the 
isoxazolidine intermediates to (+)-epilupinine and (+)-epitashiromine is described in 
Chapter 2.  In a separate study, haloalkylidene morpholinones were used as substrates for 
metal-catalyzed cross-coupling reactions to provide diastereomerically pure, substituted 
alkylidene morpholinones. These were subjected to a stereoselective Prins reaction to 
provide diastereomerically pure spirodioxolane intermediates which were converted to β-
hydroxy carboxylic acids with a quaternary stereocenter at the α carbon. This methodology 
is described in Chapter 3. Investigations of alkylidene dioxolanones, as potential substitutes 
for the ephedrine-derived alkylidene morpholinones employed in Chapters 2 and 3, are 
described in Chapter 4. 
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Chapter 1 
Introduction 
1. Indolizidine and Quinolizidine Alkaloids
A large number of alkaloids which contain indolizidine and quinolizidine 
frameworks exhibit notable biological activities.1 The wide array of biological activities 
includes antiviral,2 antiarrhythmic,2c antimalarial,2d,2e and platelet antiaggregating 
activities.2f The structural diversity arising from varying degrees of substitution on either 
ring of the bicyclic core makes these alkaloids interesting targets for the development of 
new synthetic strategies.3  
Figure 1.1 Examples of indolizidine and quinolizidine alkaloids. 
A review of the classical literature reveals several methodologies for the synthesis 
of indolizidine and quinolizidine alkaloids, each focused on a specific reaction to install 
the required stereochemistry in the target molecule.  Since a vast amount of literature is 
available on the subject, the focus of the following literature survey is only on 
methodologies reported after 2008. In addition, since one of the objectives, which will be 
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described in this thesis, is the synthesis of targets 1, 2, 5 and 6, the total syntheses or formal 
syntheses of any one or more of these target alkaloids (Figure 1.1) will be presented. 
Individual studies have addressed the total synthesis of various target alkaloids, as well as 
analogs or congeners of the natural product. Hence, a synthetic tactic-based analysis is 
presented as follows: 
1.1. Ring formation via nucleophilic displacement or addition reactions: 
1.1.1. Nitrogen-carbon cyclization reactions  
1.1.2. Carbon-carbon cyclization reactions 
1.2 Ring formation employing ring closing metathesis reaction 
1.3 Asymmetric cycloaddition based strategies 
1.4 Iminium ion-based approaches 
1.5 Organocatalytic approaches 
 
1.1 Ring formation via nucleophilic displacement or addition reactions 
1.1.1 Nitrogen-carbon cyclizations  
1.1.1.1 Nitrogen-carbon cyclization with preformed azacycles as starting materials 
Pilli and coworkers4 have reported a synthesis of (+)-epitashiromine which begins 
with stereoselective nucleophilic functionalization of N-Boc-2-methoxypyrrolidine (9) 
using a chiral thiazolidinone derived nucleophile (Scheme 1.1). The titanium enolate 
generated from 8, reacts with 9, to provide the intermediate 10 (10:1 dr). This reaction 
installs the two stereocenters in epitashiromine. Reduction of 10 with lithium borohydride 
provided 11 as a mixture. Treatment of the crude product with acid removed the N-Boc 
group. Basification of the resulting salt provided (+)-epitashiromine (2). An analog of 8 
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bearing an N-chlorobutyryl group was converted to (+)-isoretronecanol following a similar 
synthetic sequence.  
 
 
Scheme 1.1 Synthesis of (+)-epitashiromine (2) by nucleophilic alkylation of N-Boc-2-
methoxypyrrolidine. 
 An asymmetric vinylogous Mannich reaction was employed by Santos in a 
synthesis of (−)-lupinine (6) (Scheme 1.2).5 The 2-methoxypiperidine derivative 12 when 
treated with the silyloxyfuran 13 in the presence of trimethylsilyl triflate provides the 
corresponding Mannich product (9.7:1 dr), hydrogenation of which generates 14. Use of 
1-butyl-3-methylimidazolium tetrafluoroborate (BMI·BF4) as an additive is necessary for 
good diastereoselectivity in the Mannich reaction. Removal of the protecting group in 14 
with sodium methoxide resulted in intramolecular acylation of the piperidine with the 
butyrolactone moiety to provide 15. Mitsunobu inversion of the secondary alcohol in 15 
provided 16 which was reduced to 17 with alane. Cyanation of 17 by conversion to the 
mesylate and treatment with potassium cyanide gave 18. Hydrolysis of the nitrile followed 
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by reduction of the corresponding acid provided (−)-lupinine (6). This asymmetric 
vinylogous Mannich reaction strategy was also employed in a synthesis of                             
(−)-epiquinamide. 
 
Scheme 1.2 Synthesis of (−)-lupinine (6) employing a chiral carbamate-protected 
methoxypiperidine as the starting material. 
 
1.1.1.2 Nitrogen-carbon cyclizations with open chain precursors 
 The methodologies utilizing cyclization of open chain precursors to the target ring 
systems appear more frequently in the literature compared to the cyclization reactions using 
preformed azacycles. This is probably due to the ready availability of starting materials for 
the synthesis of appropriately functionalized precursors. These precursors provide access 
to a wide variety of fused ring systems ([5, 5], [5, 6], [6, 6], [6, 7]) with varying degrees of 
substitution.  
An efficient strategy using an imino-aldol reaction was reported by Brown and 
coworkers for the synthesis of (−)-epilupinine and (−)-tashiromine.6 A stereoselective 
imino-aldol reaction of (S)-tert-butylsulfinyl imines 20 and 21 (Scheme 1.3) with the 
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enolate of phenyl 5-chloropentanoate, generates syn imino-aldol products 22 and 23 
respectively, with good yield and high diastereoselectivity.  
 
Scheme 1.3 Stereoselective imino-aldol strategy for the synthesis of (−)-tashiromine (1) 
and (−)-epilupinine (5). 
Removal of the tert-butylsulfinyl protection in 22 and 23 followed by sequential 
cyclization of the primary amine onto the chloroalkyl side chains provided 24 and 25. 
These were converted into (−)-tashiromine and (−)-epilupinine respectively by reduction 
of the phenyl ester to a primary alcohol. 
 
 
 
6 
 
1.1.2 Carbon-carbon cyclizations  
1.1.2.1 Carbon-carbon cyclizations with preformed azacycles as starting materials 
Pohmakotr et al. have reported a general synthetic route to 1-azabicyles by using 
-sulfinyl carbanions for intramolecular carbon-carbon bond forming reactions.7 This 
tactic relies on the susceptibility of cyclic amides to nucleophilic addition reactions.  
 
Scheme 1.4 Sulfinyl-carbanion cyclization-based approaches to (±)-lupinine (6) 
and (±)-epilupinine (5). 
N-Alkylation of 2-pyrrolidinone (26) and 2-piperidinone (27) with                                 
4-bromobutylphenylsulfane followed by oxidation, provided the sulfoxides 28 and 29 
respectively (Scheme 1.4). Deprotonation of the sulfoxides followed by cyclization 
generated 30 and 31. The reduction of 31 followed by acylation  to the sulfoxide provided 
32 as a mixture of diastereomers. A sulfoxide elimination in 32 provided 33, which was 
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converted to (±)-epilupinine and (±)-lupinine by following two different reduction 
protocols. Hydrogenation of 33 followed by reduction of the ester with LAH provided      
(±)-lupinine as a single diastereomer. Alternatively, reduction of 33 with Mg in MeOH 
followed by epimerization of the ester and reduction with LAH provided (±)-epilupinine 
as a single diastereomer. This strategy relies on epimerization of the reduction product 
obtained from 33 to the thermodynamically stable β-form of the ester.  
 
 
Scheme 1.5 Sulfinyl-carbanion cyclization-based approaches to (±)-tashiromine (1). 
As with 31, the reduction of 30 provided 34, which was converted to 35 in an aldol-
type reaction with paraformaldehyde (Scheme 1.5). Sulfoxide elimination in 35 followed 
by hydrogenation provided diastereomerically pure (±)-tashiromine. This strategy was also 
applied to the syntheses of related indolizidine alkaloids.  
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1.1.2.2 Carbon-carbon cyclizations via azacyclic intermediates 
Szymoniak and coworkers reported a synthetic strategy that follows a 
hydrozirconation / iodination / cyclization protocol for the formation of the piperidine ring 
in (+)-epilupinine (5).8  The same group has also reported a synthesis of (±)-lupinine by 
employing a hydrozirconative cyclization of a functionalized pyridine moiety.8b For the 
synthesis of epilupinine, enantiomerically enriched amine 37 was used as the starting 
material. Conjugate addition of lithiated 37 to the enoate 38 generated 39 as a single 
diastereomer (Scheme 1.6).   
 
Scheme 1.6 A hydrozirconation / iodination / cyclization approach to (+)-epilupinine (5). 
Hydrozirconation of the N-allyl group in 39 followed by treatment with iodine 
generated the corresponding primary iodide. Treatment of this iodoester intermediate with 
LiHMDS resulted in an intramolecular alkylation of the ester enolate to provide 40. This 
strategy was also used in the synthesis of other trans-2,3-disubstituted piperidines. 
Hydrogenation of 40 generated the corresponding amino alcohol. This was converted to 
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the corresponding primary chloride which cyclized to provide 41. Reduction of the ester in 
41 provided (+)-epilupinine (5). 
 
1.2 Syntheses employing ring closing metathesis as a key transformation 
Various research groups have investigated a ring closing metathesis (RCM) 
strategy for construction of azabicyclo alkaloid motifs. Most of the RCM strategies involve 
construction of one (for indolizidine motifs) or both (for quinolizidine motifs) of the six 
membered rings. Strategies involving construction of a five membered ring using RCM are 
rare.   
Rao and coworkers9 reported (S)-proline-based formal syntheses of the indolizidine 
alkaloids (−)-tashiromine and (−)-epitashiromine employing RCM as a key step (Scheme 
1.7). Their approach begins with (S)-Boc methyl prolinate 42. The stereocenter in proline 
becomes the ring junction stereocenter in the target. Reduction of 42 with LAH followed 
by Swern oxidation gave the corresponding aldehyde. Wittig methylenation of the 
aldehyde furnished 43. Dihydroxylation of 43 followed by chemoselective protection of 
the diol provided 44 which furnished 45 on oxidation to the ketone and Wittig 
methylenation. Replacing the Boc group with an appropriate N-acyl group provided the 
RCM precursor 46 which, upon treatment with the Grubbs II catalyst, furnished 47.  
 
 
10 
 
 
Scheme 1.7 (S)-Proline-based approach to (−)-tashiromine (1) and (−)-epitashiromine (2) 
involving RCM. 
Hydrogenation of 47 followed by benzoylation of the resulting primary alcohol 
provided a mixture of separable diastereomers 48 and 49 (Scheme 1.8). Debenzoylation of 
48 and 49 provided 50 and 51 respectively. These can be converted to the targets by 
reduction of the cyclic amide. 
 
Scheme 1.8 Conversion of 47 to (−)-epitashiromine and (−)-tashiromine. 
 
11 
 
1.3 Asymmetric cycloaddition-based strategies 
In view of the numerous syntheses of aza sugars and their analogs employing 
cycloaddition reactions of functionalized nitrones, it is surprising that similar strategies 
involving cycloaddition reactions for the synthesis of indolizidine and quinolizidine motifs 
are not as common. The few studies reported rely on [2+2],10 and [4+2]11 cycloaddition 
reactions of alkenes, nitrile oxide cycloaddition reactions12 and inter-13 and intramolecular 
1,3-dipolar cycloaddition reactions of acyclic nitrones14.  Hu, Wang and coworkers 
reported a synthesis of (+)-epilupinine (5) starting with the enantiomerically enriched 2-
vinyl piperidine 52 and utilizing a nitrile oxide cycloaddition as the pivotal step (Scheme 
1.9).12,15 The piperidine 52 was prepared in four steps by a procedure reported by the same 
authors.15  
 
Scheme 1.9 Synthesis of (+)-epilupinine (5) via an intramolecular nitrile oxide 
cycloaddition reaction. 
N-Alkylation of 52 with 3-chloropropanol, elaboration of the alcohol into the                   
N-tosyl-O-TBS hydroxyl amine derivative 53 (Fukuyama procedure16), followed by 
treatment with CsF generated the oxime 54. The nitrile oxide generated on oxidation of 54 
12 
 
with NaOCl underwent an intramolecular [3+2] cycloaddition to provide the isoxazoline 
55 as a single diastereomer. Reductive N-O bond cleavage in 55 followed by in situ 
hydrolysis of the resulting imine furnished the intermediate 56.  Conversion of 56 to             
(+)-epilupinine (5) was achieved by reducing the dithiolane obtained from the ketone. 
 
1.4 Iminium ion-based approaches 
   Remuson has recently reviewed the applications of N-acyliminium ions in the 
synthesis of alkaloids containing a piperidine ring3d and hence only studies reported after 
this review will be summarized below. Strategies utilizing N-acyliminium ions are among 
the most concise and are unique for their rapid assembly of the heterocyclic rings from 
acyclic precursors. 
Martin and coworkers17 have developed a strategy for the syntheses of                      
(±)-epilupinine, (±)-tashiromine and (−)-epimyrtene (Scheme 1.10), which relies on the 
intramolecular N-alkylation and allylation of a preformed imine. Their synthetic sequence 
begins with the aminosilane 57 which was condensed with the monoprotected dialdehyde 
58 or 59 to provide the corresponding imine 60. Treatment of 60 with TFA generated an 
oxonium ion that reacted further with the adjacent imine moiety to form compound 61. The 
resulting iminium ion underwent an intramolecular allylation to provide the bicyclic N,O-
acetal 62. The iminium ion obtained from 62 was reduced with triethylsilane to provide 
either 63 or 64 depending on the aldehyde used (58 or 59). Ozonolysis of 63 and 64 
followed by reduction of the corresponding aldehydes provided (±)-epilupinine and (±)-
tashiromine, respectively.  
13 
 
 
Scheme 1.10 Intramolecular, iminium ion silylation strategy for (±)-epilupinine (5),  
(±)-tashiromine (1). 
Marsden and McElhinney reported a synthesis of (±)-tashiromine which uses an   
N-acyliminium ion-based intermediate for construction of the six membered ring.18 The 
iminium ion precursor was prepared from succinimide 65 (Scheme 1.11). N-Alkylation of 
65 with 5-bromo-1-pentene followed by cross metathesis of the resultant N-alkenyl 
succinimide with allyltrimethylsilane provided 66. The hydroxy lactam (67) obtained by 
partial reduction of 66 furnished the indolizidinone 69 on treatment with TFA. The authors 
suggested that the intramolecular capture of the iminium ion generated from 67 proceeded 
via a chair-like transition state 68 to provide 69 with the shown stereochemistry. Reductive 
ozonolysis of 69 and subsequent reduction provided (±)-tashiromine. 
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Scheme 1.11 Stereoselective intramolecular N-acyliminium ion capture in the synthesis 
of (±)-tashiromine (1). 
 
1.5 Organocatalytic Approaches 
MacMillan and coworkers reported a short synthesis of (−)-tashiromine based on 
organo-SOMO catalysis.19 Lactone 70 on treatment with the magnesium salt of pyrrole 
(prepared in situ by deprotonation of pyrrole with MeMgBr) followed by oxidation of the 
alcohol product provided aldehyde 71 (Scheme 1.12). The key step of the synthesis, -
arylation of the aldehyde, was performed by converting the aldehyde to the corresponding 
iminium ion by exposure to a catalytic amount of the imidazolidinone salt 72 and oxidizing 
the iminium ion with ceric ammonium nitrate. 
15 
 
 
 
Scheme 1.12 Enantioselective intramolecular aldehyde -arylation-based synthesis of    
(−)-tashiromine (1). 
 The resulting radical cation underwent an enantioselective, intramolecular -
arylation reaction to ultimately provide the tetrahydroindolizinone 73 (93% ee) after 
rearomatization. Reduction of the aldehyde and the lactam followed by hydrogenation of 
the pyrrole in 73 provided (−)-tashiromine.  
Fustero, del Pozo and coworkers reported syntheses of (−)-lupinine (6),                       
(+)-myrtene and a formal synthesis of (−)-epiquinamide (7) by using an enantiomerically 
pure piperidine as the starting material.20 An intramolecular aza-Michael reaction of the N-
Boc amino enal 74 catalyzed by the (S)-diarylprolinol derivative 75 furnished the 2-(2-
oxoethyl)piperidine derivative 76 with high enantioselectivity (Scheme 1.13).  
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Scheme 1.13 Synthesis (−)-lupinine (6) relying on an organocatalytic intramolecular  
aza-Michael reaction. 
Oxidation of the aldehyde to the acid followed by esterification provided the 
intermediate 77. A highly diastereoselective allylation of 77 provided 78 with both of the 
stereocenters in the target. Primary alcohol 79, obtained from 78, on activation and 
cyclization provided the quinolizidine 80. Reduction of the ester in 80 provide                       
(−)-lupinine (6) which has been converted to (−)-epiquinamide (7), via oxidation of the 
primary alcohol followed by Curtius rearrangement, by Fitch et al.21 Hence, the above 
synthetic route constitutes a synthesis of (−)-lupinine (6) as well as a formal synthesis of 
(−)-epiquinamide (7). 
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All of the methodologies presented in the sections 1.1-1.5 and all of the reported 
methodologies in the literature deal with the synthesis of stereochemically related alkaloids 
i.e. tashiromine (1)/epilupinine (5) or epitashiromine (2)/lupinine (6). Strategies giving 
easy access to diastereomeric alkaloids (1 and 6 or 2 and 5) are very few, and they rely on 
one of two strategies: i) the separation of diastereomeric intermediates at an early stage in 
the synthesis, or ii) a thermodynamically favorable enolization of an intermediate to one of 
the alkaloids. In addition, the lack of cycloaddition strategies employing cyclic nitrones is 
surprising. It may be noted that a cycloaddition with cyclic nitrones can install the 
contiguous stereocenters as well as more than half of the required bicyclic framework of 
the target molecules (Figure 1.2) in a single step. Based on these considerations, our 
objective was to examine the utility of nitrone cycloaddition reactions with chiral alkenes 
as the pivotal step in the synthesis of 1, 2, 5 and 6.  
 
 
Figure 1.2 Synthetic targets in this thesis work. 
We chose to examine these cycloaddition reactions with ephedrine-derived 
alkylidene morpholinones. Apart from cycloaddition reactions, our second objective was 
to develop a unique strategy that can give access to diastereomeric alkaloids without the 
need of separation of diastereomeric intermediates or enolization (Scheme 1.14). Details 
of these studies are provided in Chapter 2 of this thesis. 
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Scheme 1.14 Stereochemically flexible strategy for the synthesis of 1, 2, 5 and 6. 
 
1.6 Quaternary Stereocenters 
The  structural complexity of many natural products poses challenges to synthetic 
chemists, and is an impetus to develop new and efficient synthetic strategies.22 The 
development of new synthetic methodologies has made many syntheses possible, which 
could not have been accomplished decades ago.23 Many natural products contain one or 
more quaternary stereocenters, the synthesis of which have attracted the interest of many 
research groups. The enantioselective synthesis of quaternary stereocenters is a continuing 
challenge for synthetic chemists due to steric demands during the successive construction 
of new carbon-carbon bonds and the reliability of these carbon-carbon bond forming 
reactions.24  
A variety of strategies for constructing quaternary stereocenters have appeared in 
the literature. These strategies can be generally divided into two major types: 
enantioselective and diastereoselective approaches.25 The enantioselective C-C bond 
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formation from prochiral substrates is involved in reactions such as Diels-Alder reactions, 
catalytic asymmetric conjugate addition reactions, and alkylation reactions. Although the 
enantioselective synthesis of quaternary stereocenters has been investigated extensively, 
most of the strategies require specialized substrates and reactants. The diastereoselective 
approach is more attractive and widely applicable provided the preparation of 
enantiomerically enriched starting materials is easy. Examples of diastereoselective 
approaches include the Claisen rearrangement, auxiliary mediated alkylation and conjugate 
addition reactions.25  
Of the various C-C bond-forming reactions, the reactions listed below23,26 appear 
frequently in synthetic methodologies reported for the construction of quaternary 
stereocenters. 
1) Aldol and Mannich reactions 
2) Addition to chiral carbon electrophiles 
3) Carbonyl α-alkylation reactions 
4) Conjugate addition reactions 
5) Cycloaddition reactions 
6) Cyclopropanations 
7)  Metal catalyzed cyclizations 
8)  The Heck reaction 
The key reaction in our approach to quaternary stereocenters is a Prins reaction 
which closely resembles an aldol reaction. Hence, the following literature review covers 
only the aldol-type approaches to quaternary stereocenters. 
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1.6.1 Aldol Reactions 
Strategies that employ an aldol reaction for the synthesis of quaternary 
stereocenters are relatively few. In general, the aldol reactions suffer from low 
stereoselectivity and poor yields when a quaternary stereocenter is formed in the product. 
This is due to steric congestion in the aldol products with quaternary stereocenters which 
favours the retroaldol reaction under acidic or basic conditions.27 In view of these 
limitations, modified aldol reactions have been devised. These methods allow the 
construction of quaternary stereocenters in good yield as well as good stereoselectivity. 
Nonetheless, it should be noted that due to the specialized nature of these reactions, most 
of them do not provide the classical aldol products which can be obtained by a conventional 
intermolecular aldol reaction of carbonyl substrates.  
Marek and coworkers recently reported a strategy that gives access to acyclic 
systems with quaternary stereocenters. Their method uses enolates formed from ynamides 
such as 85 (Scheme 1.15). Conjugate addition of a cuprate to the ynamide 85 generates 86 
or 87 which furnishes intermediate 88 on treatment with t-butyl hydroperoxide. 1,2-
Metalate rearrangement of 88 furnishes the enolate 89. Reaction of the enolate with an 
aldehyde provides the corresponding aldol product 90 with a quaternary stereocenter.28 In 
a related process, reaction of 89 with an imine provides the corresponding Mannich 
product. 
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Scheme 1.15 Synthesis of quaternary stereocenters from ynamides. 
The transition state assembly (TS I) involved in the formation of aldol adducts is 
shown in Scheme 1.15. The authors suggest that the oxazolidine moiety chelates with 
copper forming a ‘second pseudo-heterocycle’ and then the approach of the aldehyde from 
the Re face of the enolate (anti to the benzyl group in the oxazolidinone) and with the R2 
group of the aldehyde in a pseudo-equatorial position, leads to the observed 
diastereoselectivity. 
Greaney and coworkers29 reported the synthesis of carbocycles and heterocycles 
with vicinal quaternary and tertiary stereocenters using an intramolecular iodo-aldol 
reaction. The iodo-aldol reaction is synthetically useful due to its excellent atom economy, 
and its generation of complex structures in a single step with the incorporation of up to 
three chiral centers. The strategy employed by Greaney utilizes α-substituted enolates for 
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the construction of cyclopentanes or cyclohexanes bearing a quaternary stereocenter. 
Accordingly, the substrate 91 furnished carbocycles 92-95 in good yields. Aldehydes were 
particularly good substrates in this reaction. In all of the reactions only a single 
diastereomer of the product was observed. This can be explained from the transition state 
models shown in Scheme 1.16. 
 
 
Scheme 1.16 Synthesis of carbocycles with vicinal tertiary and quaternary stereocenters. 
In TS-II, the bulky CH2I group is placed in a pseudo-equatorial position, which is 
more favored than the pseudo-axial position in TS-III. Hence, TS-II leads to the products 
with the observed diastereoselectivity. The strategy was also employed in the synthesis of 
heterocycles (Scheme 1.17). The substrates for these reactions were prepared in two steps 
from ethyl or methyl α-bromomethylacrylates. The use of simple prochiral substrates and 
formation of heterocycles with functional groups for further conversion to complex natural 
products makes this strategy a versatile tool.  
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Scheme 1.17 Synthesis of heterocycles containing vicinal tertiary and quaternary 
stereocenters. 
Xu and coworkers30 reported cascade sulfa-Michael/aldol reactions of β-
disubstituted enones to synthesize quaternary stereocenters bearing a trifluoromethyl 
substituent. The incorporation of a -CF3 group into organic molecules remarkably alters 
their biological properties and such compounds have potential applications in agricultural 
and medicinal chemistry.30 Thus, research activity has increased in the area of asymmetric 
synthesis of functionalized molecules with incorporation of a -CF3 group. Xu and 
coworkers developed a strategy to trifluoromethylated tetrahydrothiophenes using a 
trifluoromethyl-activated enone as the starting material. 
1,4-Dithiane-2,5-diol (101) reacted with different β-aryl-β-trifluoromethyl enones 
102 to furnish tetrahydrothiophenes 104 in moderate to good yields and high 
enantioselectivity (up to 89% ee). The reaction proceeds smoothly in the presence of 
various bifunctional squaramides as catalysts with the quinine-derived squaramide catalyst 
103 giving the best results (Scheme 1.18).   
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Scheme 1.18 Synthesis of quaternary stereocenters with trifluoromethyl substituent. 
The reaction tolerates various aryl substituents, heteroatomic rings as well as 
sterically demanding naphthyl rings in the enone 102. The substitution pattern on the aryl 
rings has no effect on enantioinduction, but has a small effect on the yield.30 
 Enantioselective strategies using aldol reactions of trimethylsilyl enol ethers with 
aldehydes, i.e. the Mukaiyama aldol reaction, have attracted considerable attention in 
recent years. Many examples are reported for Lewis acid-catalyzed Mukaiyama aldol 
reactions.31 Following a similar trend, Lewis base-catalyzed aldol reactions are also being 
investigated with considerable success. Nakajima and coworkers reported aldol reactions 
of trichlorosilyl enol ethers catalyzed by chiral N-oxides32 and phosphine oxides33 for the 
synthesis of quaternary, as well as tertiary stereocenters. However, trichlorosilyl enol 
ethers are extremely sensitive to moisture, which limits the application of this 
methodology. Recently, Nakajima and coworkers reported lithium binaphtholate catalyzed 
aldol reactions of trimethoxysilyl enol ethers with aldehydes (Scheme 1.19).27  
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Scheme 1.19 Mukaiyama aldol reaction for the synthesis of quaternary stereocenters. 
The trimethoxysilyl enol ether derived from 2-methylcyclohexanone (105) 
furnished anti 107b as the major aldol product under anhydrous conditions while a slight 
excess of the syn aldol product 107a was obtained in the presence of water. Nakajima also 
reported an improved synthesis for the trimethoxysilyl enol ethers. The substrate 108 
furnished syn aldol products in good yields and excellent stereoselectivity. 
Overman et al.34 reported the synthesis of 3,3-disubstituted oxindoles by employing 
a Mukaiyama aldol reaction of 3-substituted 2-siloxyindoles with enantiopure aldehydes 
(Scheme 1.20). The 3-substituted 2-siloxyindoles 110 (prepared from corresponding isatin 
in three steps) furnished the aldol product 112, with Garner’s aldehyde, in good to excellent 
yields with high diastereoselectivity.  
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Scheme 1.20 Mukaiyama aldol reaction of 3-alkyl 2-siloxyindoles. 
In a related reaction, the substrate 110 furnished the aldol adduct 114, with (R)-
glyceraldehyde acetonide 113, in good yield and high diastereoselectivity. In both of these 
reactions, the stereoselectivity of product formation was very high when the substituent at 
C3 in the indole was an electron-rich aryl substituent. Later, Overman and Shin reported 
the synthesis of (+)-glicoaladin C employing the Mukaiyama aldol reaction of 115 and   
ent-111 to set the quaternary stereocenter in the target alkaloid (Scheme 1.20).35  
The synthesis of quaternary stereocenters using organocatalytic aldol reactions 
employing S-proline derived enamines has received limited attention. Tanaka, Barbas III 
and Mase36 reported a direct aldol reaction catalyzed by a diamine salt for the synthesis of 
quaternary stereocenters. Various combinations of chiral amines and Lewis, Brønsted and 
organic acids were screened. The use of carboxylic acids as additives favored the formation 
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of the key enamine intermediate. The catalysts were screened using a high-throughput 
fluorescence-based screening.  
 
 
Scheme 1.21 Organocatalytic aldol reaction using bifunctional chiral amine/acid catalyst. 
Following the optimized reaction conditions, α, α-dialkyl aldehydes 117 furnished 
the aldol products 120 with a quaternary stereocenter at the α-carbon atom in high yields 
and enantioselectivities (Scheme 1.21). The stereochemistry of aldol adducts was assigned 
S by the Mosher ester derivation method.37 Thus, the enamine attacks the Re-face of the 
aldehyde as shown in the proposed transition state TS IV by Tanaka et al. A limitation of 
this methodology is the need for a non-enolizable aldehyde as one of the reactants. To 
address this limitation of the organocatalytic aldol reactions, Mahrwald and coworkers 
reported a cross-aldol reaction using 2,2-dimethoxyacetaldehyde (121, an enolizable 
aldehyde) as the electrophile in the aldol reaction.38 The use of L-histidine as the catalyst 
furnished aldol adducts 122 with high stereoselectivities (Scheme 1.22). The aldol adducts 
obtained using this strategy are not accessible by other organocatalytic approaches. This 
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methodology gives an easy access to poly-functionalized intermediates as well as 
branched-chain carbohydrates.  
 
 
Scheme 1.22 Asymmetric aldol addition of dimethoxyacetaldehyde to enolizable 
aldehydes. 
Mahrwald and coworkers employed their methodology in the syntheses of              
(R)-pantolactone, 2-hydroxymethyl-D-lyxose and 5-deoxy-2-methyl-L-lyxose.     
Overman and coworkers39 reported a Prins-pinacol methodology for the 
stereoselective synthesis of acetyltetrahydrofurans bearing a quaternary stereocenter. The 
acetals of unsymmetrical ketones with 3,4-dimethyl-4-penten-2,3-diol were used as 
substrates in this method. The acetals 123a-e rearranged respectively to 
acyltetrahydrofurans 124a-e, with a quaternary stereocenter at C2, in the presence of SnCl4 
with good stereoselectivity (Scheme 1.23). The stereoselectivity of the reaction was 
controlled by the size of the R1 group in the methyl ketone series 124a - d. The observed 
stereoselectivity was in accordance with the proposed transition state models. Thus, the 
substituent R1 prefers a pseudo-equitorial position in the Prins cyclization step, leading to 
the formation of the observed products. The methodology was applied in the synthesis of 
(−)-citreoviral from the intermediate 126 prepared by a Prins-pinacol rearrangement.39 
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Scheme 1.23 Prins-pinacol rearrangement of acetals of unsymmetrical ketones. 
The Pansare group approach to quaternary stereocenters is based upon two pivotal 
reactions of haloalkylidene morpholinones 127 (Scheme 1.24).  
 
Scheme 1.24 Synthetic strategy for the synthesis of functionalized quaternary 
stereocenters. 
These reactions are: i) synthesis of diastereomerically pure, unsymmetrical 
alkylidene morpholinones 128 employing a cross-coupling reaction, and ii) an asymmetric 
Prins reaction of the alkylidene morpholinone. The second reaction is the key C-C bond 
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forming reaction which installs the fourth carbon atom to form the quaternary stereocenter 
in 129. Details of this methodology are provided in Chapter 3 of this thesis.   
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Chapter 2 
Synthesis of (+)-Epitashiromine and (+)-Epilupinine 
2.1 Introduction 
The indolizidine and quinolizidine alkaloids constitute a prominent group of 
alkaloids containing nitrogen-bridged bicyclic ring systems.1 These alkaloids are isolated 
from natural sources including various animals and plants,1a and are known for their 
notable biological activities such as antiviral,2 antiarrythmic,3 antimalarial,4 and platelet 
antiaggregating activities.5 In particular, ( ̶ )-epilupinine is known for its  in vitro inhibitory 
activity against P-388 (LD50 = 28 μg/mL) and L1210 (LD50 = 20 μg/mL) cell lines.6 In 
addition, it is also used as an intermediate in drug discovery where molecules containing 
the epilupinyl unit can be used as ligands for 5-HT3, 5-HT4 or Sigma receptors.
7 The 
indolizidine alkaloids are also known for their insecticidal, fungicidal and antibacterial 
acitivities.8 In addition to these biological properties, these alkaloids also serve as potential 
targets for validation of synthetic methodologies which adds to their synthetic 
importance.8b  
The objective of this investigation was the development of a synthetic route to the 
diastereomeric indolizidine alkaloids (+)-tashiromine (1) and (+)-epitashiromine (2) and 
the structurally related, diastereomeric quinolidine alkaloids (+)-epilupinine (3) and 
( ̶ )-lupinine (4, Figure. 2.1). 
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Figure 2.1 Diastereomeric pairs of indolizidine and quinolizidine alkaloids. 
 The strategy employed for the synthesis of 1-4 is based on an asymmetric 
nitrone/alkene 1,3-dipolar cycloaddition reaction. Interestingly, there are no methodologies 
reported for the synthesis of alkaloids 1 and 2 using 1,3-dipolar cycloaddition reactions of 
nitrones. Hence, only the strategies employed by others that resulted in the synthesis of the 
target alkaloids 3 and/or 4 are presented. Notably none of these methods are 
enantioselective. 
2.2 Nitrone/Alkene 1,3-Dipolar Cycloaddition for the Synthesis of 3 and 4 
2.2.1 Tufariello’s Synthesis of (±)-Epilupinine and (±)-Lupinine 
 Tufariello and Tegeler reported a synthesis of (±)-epilupinine (3) and (±)-lupinine 
(4) using a piperidine-derived cyclic nitrone 5.9 Their synthesis begins with a cycloaddition 
reaction between the nitrone 5 and (E)-methyl-5-((methylsulfonyl)oxy)pent-2-enoate (6, 
Scheme 2.1). The cycloaddition reaction afforded the adduct 7 which spontaneously 
cyclized to provide the salt 8 in good yield.  
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Scheme 2.1 
The mesylate salt 8 was reduced to the corresponding β-hydroxy ester which, on 
dehydration with POCl3, furnished the α,β-unsaturated ester 9. Catalytic hydrogenation of 
9 furnished (±)-methyl lupinate 10. Further reduction of 10 with lithium aluminum hydride 
provided (±)-lupinine (4, Scheme 2.1). (±)-Epilupinine (3) was obtained by reduction of 
methyl epilupinate 11 which was obtained by epimerisation of (±)-methyl lupinate 10 using 
sodium methoxide in methanol (Scheme 2.2). 
 
 
Scheme 2.2 
 
2.2.2 Kakisawa’s Synthesis of (±)-Isoretronecanol and (±)-Lupinine 
 Kakisawa and co-workers employed a nitrone cycloaddition reaction for the 
syntheses of (±)-lupinine (4) and (±)-isoretroneacanol (21, Scheme 2.3).10  
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Scheme 2.3 
The cycloaddition reaction of dihydrofuran 13 with nitrone 12 furnished the adduct 
15 in good yield as a mixture of diastereomers (exo:endo 31:1). In a related sequence of 
reactions, dihydropyran 14 furnished the adduct 16 on reaction with nitrone 5. Reduction 
of cycloadducts 15 and 16 with lithium aluminium hydride furnished the amino diols 17 
and 18 respectively. These were silylated using N,N-diethyl-1,1,1-trimethylsilanamine and 
the resulting silyl ethers were then converted to primary iodides 19 and 20. The selective 
formation of iodides 19 and 20 is due to reaction of the iodide at the sterically less-hindered 
carbon. Treatment of crude 19 or 20 with benzyltrimethylammonium fluoride furnished 
the alkaloids (±)-isoretronecanol (21) and (±)-lupinine (4, Scheme 2.3), respectively.  
2.2.3 Brandi’s Formal Syntheses of (±)-Epilupinine and (±)-Lupinine 
Brandi and co-workers reported a methodology employing the cycloaddition of 
cyclic nitrones 12 and 5, with methylenecyclopropane 22.11 Nitrone cycloaddition provided 
the regioisomeric isoxazolidines 23a/23b and 24a/24b (Scheme 2.4), each as a mixture of 
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diastereomers (23a/23b, 1:2.1 and 24a/24b, 1:2.3). The regioisomeric adducts were 
separated and 23b and 24b were carried further.  
 
 
Scheme 2.4 
Adducts 23b and 24b rearranged to compounds 25 and 26 under flash vacuum 
pyrolysis conditions (Scheme 2.5). Reduction of the ketone with sodium borohydride 
provided the corresponding β-hydroxy esters 27 and 28. The ester 28 has been converted 
to the alkaloids (±)-epilupinine (3) and (±)-lupinine (4) by Tufariello and co-workers as 
shown in Schemes 2.1 and 2.2.9 
 
 
Scheme 2.5 
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2.3 Objectives  
The synthetic strategies presented in Chapter 1 and Section 2.2 highlight the early 
synthetic interest in the indolizidine and quinolizidine alkaloids. As is evident, most of the 
reported studies towards 1-4 have addressed the synthesis of stereochemically-related 
targets; namely 1 and 3 or 2 and 4. This is an inherent limitation, since the structural variety 
of indolizidine and quinolizidine alkaloids derives not only from differences in substitution 
on the rings but also from the stereochemistry of the stereogenic carbons. For the synthesis 
of diastereomeric alkaloids, namely 1 and 2 or 3 and 4, the reported methods rely on one 
of one of two strategies: 1) a thermodynamically favorable isomerization of enolizable 
intermediates12 or 2) separation of stereoisomeric intermediates at an early stage in the 
synthesis.8,13 Syntheses that provide access to diastereomeric alkaloids without employing 
these two strategies are rare.14 The synthetic strategy described in this Chapter addresses 
this limitation.15 
The approach described in this thesis relies on stereoselective, 1,3-dipolar 
cycloaddition reactions of cyclic nitrones with chiral alkylidene morpholinones to install 
contiguous stereocenters in the targets (Scheme 2.6). The cycloadducts obtained were 
converted to the corresponding alkaloids by following two different modes of ring 
construction (Path A or B, Scheme 2.6). A change in the mode of cyclization gives easy 
access to diastereomeric alkaloids without the need for diastereomeric cycloadducts. Thus, 
even though only one set of contiguous stereocenters is constructed, the approach 
ultimately provides access to either diastereomer of the targets.15 
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Scheme 2.6 Synthetic strategy employed in this Chapter. 
 
2.4 Results and Discussion  
The study began with the synthesis of chiral alkylidene morpholinones which were 
obtained from the ephedrine-derived morpholine dione 3416 (Scheme 2.7). Dione 34 was 
readily prepared from (1R,2S)-ephedrine hydrochloride and ethyl-2-chloro-2-oxoacetate. 
Reaction of dione 34 with carbethoxymethylenetriphenylphosphorane provided alkene 
35.16c The alkene 37 was obtained by dehydration of hemiacetal 36 (dr = 4:1) obtained 
from a reaction of dione 34 with ethylmagnesium bromide.17  
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Scheme 2.7 Synthesis of alkylidene morpholinones. 
In a related sequence of reactions, dione 34 was converted to the alkylidene 
morpholinone 42 (Scheme 2.8). Treatment of 34 with the Grignard reagent obtained from 
the THP-protected 4-bromobutanol furnished hemiacetal 38 as a mixture of diastereomers 
(4:1) in good yield. However, dehydration of hemiacetal 38 suffered from competitive 
cleavage of the tetrahydropyranyl ether in 38, to generate the alcohol 40. In addition, 
column chromatography was not effective for separation of dihydropyran-derived 
impurities from the desired product 39. Hence a change of the hydroxyl protecting group 
was necessary. Accordingly, replacement of the THP protection by an acetate group and 
dehydration of the hemiacetal provided the alkylidene morpholinone 42 (Scheme 2.8).  
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Scheme 2.8 Synthesis of alkylidene morpholinone 42. 
The alkylidene morpholinones 35, 37 and 42 were assigned the Z stereochemistry 
by analogy to other alkylidene morpholinones prepared in the Pansare group.18 
The 1,3-dipolar cycloaddition reactions of alkenes 35 and 37 were then examined. 
It should be noted here that the cycloaddition of a nitrone and an alkene can proceed with 
the formation of regioisomeric products, the regiochemistry of the nitrone addition being 
dependent on the nature of the alkene (Scheme 2.9).  
 
Scheme 2.9. Regiochemistry of 1, 3-dipolar cycloaddition of nitrones to alkenes. 
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For electron-deficient alkenes such as 43, the nitrone oxygen adds to the β-carbon 
of the dipolarophile giving a 3,4-substituted isoxazolidine 45 as the major product (Scheme 
2.9). For electron-rich alkenes such as 46, the nitrone oxygen adds to the α-carbon of the 
dipolarophile giving a 3,5-substituted isoxazolidine 47 as the major product. The formation 
of a particular regioisomeric isoxazolidine may or may not be favoured over the other, and 
results may vary depending on individual alkenes. For example, the cycloaddition reactions 
summarized in Sections 2.2.1 and 2.2.2 proceed with formation of only one regioisomer 
(Scheme 2.1 and 2.3). However, the cycloaddition reaction reported by Brandi and co-
workers provided both regioisomers of the product isoxazolidine (Scheme 2.4). 
 For the alkylidene morpholinones examined in this study, it was predicted that 
cycloaddition of nitrones with alkenes 35 and 37 would give cycloadducts 49 and 50 
(Scheme 2.10). This outcome was based on the observation that, although alkenes 35, 37 
and 42 could be considered to be enamides, the reactivity of these alkenes resembles those 
of enol ethers rather than enamides. For example, alkylidene morpholinones related to 35, 
37 and 42 can be epoxidized with m-CPBA17 and can also undergo Prins reactions.16a As 
anticipated, the cycloaddition of alkenes 35 and 37 with nitrone 4819 furnished the 
spiroisoxazolidines 49 and 50 (Scheme 2.10). Based on a characteristic resonance at ~100 
ppm for the spiroacetal carbon in the spiroisoxazolidines, and the predicted reactivity of 
alkylidene morpholinones 35 and 37, the regiochemistry of the nitrone cycloaddition was 
assigned as shown. The regioisomeric cycloadducts would have a spiro carbon which is 
expected to appear at ~75-80 ppm (as seen for compounds 74, 76 and 85). Attempts to 
assign the stereochemistry and diastereomeric excess of the spiroisoxazolidines 49 and 50 
45 
 
by 1H NMR spectroscopy were not successful. This was due to line brodening in the 1H 
NMR spectra of spiroisoxazolidines 49 and 50 due to pyramidal inversion at the nitrogen.20 
 
 
Scheme 2.10 1, 3-Dipolar cycloaddition reactions of alkenes 12 and 14 with the acyclic 
nitrone 48. 
Given the low yields of spiroisoxazolidines 49 and 50, we decided to optimize the 
conditions for the cycloaddition reaction and explore the use of different catalysts in order 
to improve the yield.21 It may be noted that, since the alkenes 35 and 37 behave like enol 
ethers, the electron-deficient component in the 1,3-dipolar cycloaddition is most likely the 
nitrone. The Lewis acid could, in principle, coordinate with the alkylidene morpholinone 
or the nitrone. If it coordinates with the nitrone, an increase in the electrophilicity of the 
nitrone is expected. However, the use of Lewis acids known to catalyze nitrone 
cycloadditions21a had no beneficial effect on the reaction of nitrone 48 with alkenes 35 or 
37. In fact, the use of Ti(OiPr)4 in toluene at 60 °C had a detrimental effect on the thermal 
reaction and only unreacted 37 was recovered. This may indicate deactivation of the alkene 
in the presence of Ti(OiPr)4. These results with the use of different catalysts and conditions 
are summarized in Table 2.1.  
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Table 2.1 Survey of catalysts and different reaction conditions for the 1, 3-dipolar 
cycloaddition reaction of nitrone 48. 
Substrates Catalyst Time Solvent  Result 
 
35 
 
nonea  24 h toluene 49 (46%) 
ZnCl2
b 5 d CH2Cl2 35 recovered 
microwavea 30 min toluene 49 (40%) 
 
 
 
nonea 24 h toluene 50 (15%) 
ZnCl2
b 5 d CH2Cl2 37 recovered 
Sc(OTf)3
b 5 d CH2Cl2 37 recovered 
In(OTf)3
b 5 d CH2Cl2 37 recovered 
Ti(OiPr)4
c 24 h toluene 37 recovered 
MgBr2.OEt2
b 5 d CH2Cl2 37 recovered 
microwavea 30 min toluene 50 (20%) 
a reflux. b room temperature. c toluene, 60 °C. 
A few reports on nitrone cycloaddition reactions suggest the use of microwave 
irradiation to increase the reaction rate.21b,22 For the reactions of 35 and 37, the use of 
microwave irradiation reduced the reaction time to 30 minutes with a marginal effect on 
the yields. Hence, we decided to use these conditions for the reactions of 35, 37 and 42 
with the cyclic nitrones 12 and 5. Nitrones 12 and 5 were prepared by the oxidation of 
pyrrolidine and piperidine respectively, according to the reported procedure.23  
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Scheme 2.11 1, 3-Dipolar cycloaddition reactions of alkene 35, 37 and 42 with cyclic 
nitrones 12 and 5. 
Thus, following the optimized reaction conditions, alkenes 35, 37 and 42 furnished 
spiroisoxazolidines 51 – 54 (Scheme 2.11) with nitrones 12 and 5. The tentative 
stereochemical assignments for the spiroisoxazolidines 51 – 54 were based on two 
assumptions: 1) approach of the nitrone exo to the alkene substituent (‘R’ as shown in 
Scheme 2.11) to minimize steric interactions, and 2) reaction of the alkene from the face 
opposite to the methyl and phenyl groups in the morpholinone. The facial selectivity of the 
alkene is based on other transformations of the ephedrine-derived morpholinone system 
which have indicated a strong preference for reactions from the less-hindered face of the 
morpholinone.17-18 As seen previously for the spiroisoxazolidines 49 and 50, attempts to 
determine the diastereomeric excess for spiroisoxazolidines 51 – 54 were unsuccessful due 
to line brodening of 1H NMR spectra. However, the diastereomeric excess of 53 and 54 
was readily determined by conversion of 53 to 53a by deacetylation (Scheme 2.11), and of 
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54 to 54a by deacetylation and reduction (Scheme 2.11), since these derivatives did not 
show line broadening in their 1H NMR spectra.  
The next step in the sequence was N-O bond cleavage in the spiroisoxazolidines to 
the obtain the corresponding amino alcohols. Curiously, spiroisoxazolidine 51 did not 
furnish the amino alcohol 55 under various N-O bond cleavage conditions  (Table 2.2). 
Instead, in most of these reactions, only the formation of compound 56 (Scheme 2.12) was 
observed by 1H NMR analysis of the crude product. Although the precise reasons for the 
formation of 56 are unclear, it seemed possible that the electron-withdrawing ester group 
in 28 favored a cleavage of the C-N bond resulting in loss of the piperidine ring (Scheme 
2.12). Some evidence for this hypothesis was provided by the formation of 57 from 52 in 
which the ester is replaced by a methyl group (Scheme 2.12).  
 
Scheme 2.12 N-O Bond cleavage studies. 
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Table 2.2 N-O Bond cleavage studies of spiroisoxazolidine 51. 
 Reagent Conditions Result 
Indium powder reflux, 15 h, THF 51 recovered 
Zn/AcOH 80 °C, 2 h 56 major 
Pd/C, H2 rt, 15 h, EtOH 56 major 
Raney Ni, H2 rt, 15 h, EtOH 51 recovered 
Pd(OH)2/C, H2 rt, 15 h, EtOH 56 major 
SmI2 -40 °C, 9 h, THF complex mixture 
As a result of these observations, the ester group in 35 was reduced to a primary 
alcohol which, upon methylation, provided the methyl ether 58. The alkene 58 provided 
spiroisoxazolidines 59 and 60 on cycloaddition reactions with nitrones 12 and 5, 
respectively. Spiroisoxazolidine 60 provided the amino hemiacetal 61 as a single 
diastereomer on reduction (Scheme 2.13).24 
 
 
Scheme 2.13 
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2.4.1 Synthesis of (+)-Epilupinine (3) 
The synthesis of (+)-epilupinine (3) was now initiated from 61, and the immediate 
objective was the construction of the second six-membered ring in the epilupinine 
quinolizidine ring system. Initially, we decided to pursue an enamine-based approch for 
construction of the second ring. We reasoned that, in the presence of a Lewis acid, the 
hemiacetal in 61 may form an oxocarbenium ion which can be trapped by an internal 
nucleophile.16c,17-18,25 Hence, the objective was to convert the amine in 61 to an enamine 
62 or 63 (Scheme 2.14), which would serve as an internal nucleophile for capturing the 
oxocarbenium ion 64 obtained from the hemiacetal in 62 (Scheme 2.14). Reduction of the 
iminium ion generated after cyclization of 64 would furnish the tricyclic intermediate 65 
or 66 with the required azabicyclic framework for (+)-epilupinine.  Treatment of 61 with 
acetaldehyde resulted in formation of the N,O-acetal 68. The probable mechanism for 
formation of 68 through the iminium ion 67 is shown in Scheme 2.14. Unfortunately, 68 
was stable to a variety of Lewis acids and hence its conversion to 65 was not achieved. 
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Scheme 2.14 
In a related reaction, treatment of 61 with 1,1,2-trimethoxyethane in methanol also 
resulted in formation of the N,O-acetal 70 (through intermediate 69) which was also stable 
to a variety of Lewis acids (ZnCl2, InCl3, Sc(OTf)3, In(OTf)3, MgBr2•OEt2). The enamine-
mediated cyclization strategy was therefore not pursued further.  
The use of a reductive amination strategy which would require an intermediate such 
as 71 was next explored (Scheme 2.15). However, the reaction of 61 with vinyloxy 
trimethylsilane was unsuccessful and 71 was not obtained (Scheme 2.15). 
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Scheme 2.15 
As an alternative to the approaches described above, the possibility of 
intramolecular C-C bond formation by reaction of an oxocarbenium ion with an enolate 
was pursued. To this effect, the conversion of 61 to 72 was investigated (Scheme 2.16). 
Treatment of amino hemiacetal 61 with methyl-3-chloro-3-oxopropanoate under a variety 
of conditions generated a mixture of mono-acyl 72 and bis-acyl 73 (Scheme 2.16 and Table 
2.3) that was separable by column chromatography. Efforts to obtain either 72 or 73 
exclusively were unsuccessful. In all of these attempts, longer reaction times did not result 
in the conversion of 72 to 73. The exact reasons behind the formation of a mixture of 72 
and 73 are unclear. Ultimately, acylation of 61 in CH2Cl2 with aqueous 10% K2CO3 
solution (entry 3, Table 2.3) as a base26 proved to be the best conditions for a maximum 
yield of 73 (50%). A brief solvent survey for this conversion indicated that the reaction 
proceeds only in halogenated solvents, with CH2Cl2 being the solvent of choice in terms of 
conversion, and the ratio of 73 to 72 (entries 3-6, Table 2.3). Optimization of the base 
revealed that using aqueous K2CO3 as the base (10% solution, entry 3, Table 2.3) provided 
the best yield of 73 (50%). Increasing the concentration of this base (30% solution, entry 
6, Table 2.3) reduced the reaction time from 12 h to less than 3 h with minimal effect on 
the yield of 73. Although, acylation of 61 in CH2Cl2 with aqueous 10% K2CO3 solution 
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(entry 3, Table 2.3) as a base26 provided a marginally higher yield of 73 (50%), 30% aq. 
K2CO3 was used as the base for all subsequent reactions due to the significantly shorter 
reaction times with only a negligible reduction in the yield of 73 (47%). 
 
Scheme 2.16 
Table 2.3 Optimization studies for the acylation of 61. 
 
No 
 
Base 
 
Conditions 
 
Time (h)  
Yields (%) 
72 73 
1 Et3N DMAP, CH2Cl2, rt 24 18 9 
2 Hunig’s base DMAP, THF, rt 24 9 2 
3  
 
 
10%  aq. K2CO3 
CH2Cl2, rt 12 20 50 
4 CHCl3, rt 12 55
a 45a 
5 THF, rt 12 61 recovered  
6 EtOAc, rt 12 61 recovered 
7 30%  aq. K2CO3 CH2Cl2, rt 3 21 47 
a  1H NMR of the crude product. 
Gratifyingly, the bis-acyl morpholinone 73 provided tricyclic compound 74 as a 
single diastereomer on treatment with BF3•OEt2 in CH2Cl2. The stereochemistry of the 
newly-formed spiro-stereocenter in 74 was assumed to be as shown, and is based on the 
known preference for the oxocarbenium ion such as TS-1 to react from the Re face.16c,17-
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18,25 The stereochemistry at the ester-bearing carbon was not determined in this study. In 
addition to 74, the deacylation product 72 was also formed as a byproduct in this reaction 
(Scheme 2.17). The formation of 72 was an indication of complete oxocarbenium ion 
formation from the acetal in 73, but an incomplete intramolecular capture of this 
oxocarbenium ion.  
 
 
Scheme 2.17 
A brief survey of various Lewis acids for the cyclization reaction was also 
conducted. However, only BF3•OEt2 was effective as a catalyst for the conversion of 73 to 
74 (Table 2.4). The use of other metal-based Lewis acids resulted only in deacylation of 
73 to provide 72 as the sole product. In addition, the cyclization reaction proceeded only 
in CH2Cl2 as the solvent. These results are summarized in Table 2.4. 
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Table 2.4. Catalyst survey for the cyclization of 73 to 74. 
No Substrate Catalyst Solvent  Time Result 
1  
 
 
BF3•OEt2a CH2Cl2 24 h 74 (46%) + 72 (49%) 
2 ZnCl2
a THF 24 h 72 c   
3 InCl3
a  THF 24 h 72 c 
4 In(OTf)3
a CH2Cl2 24 h 72
 c 
5 Sc(OTf)3
a CH2Cl2 24 h 72
 c 
6 MgBr2.OEt2
a CH2Cl2 24 h 72
 c 
7 TiCl4
b CH2Cl2 24 h complex mixture 
8 BF3•OEt2d BF3•OEt2d 
+ CH2Cl2
e 
5 d 
5 d 
72 c + 74 (20%) f 
a room temp., b -78 °C to room temp., c analysis of 1H NMR of crude product, d room temp., 
e added after 5 days. f formed after addition of CH2Cl2. 
In a related reaction, we attempted to suppress the formation of 72 by carrying out 
cyclization reaction of 73 in neat BF3•OEt2 (entry 8, Table 2.4). Surprisingly, analysis of 
an aliquot of this reaction indicated complete conversion to the deacylation product 72 after 
5 days. Interestingly, the addition of CH2Cl2 to this reaction mixture resulted in cyclization 
of some of the deacylation product to the required product 74 (20%) after an additional 5 
days. While this result highlights the importance of CH2Cl2 for the formation of 74, it is 
unclear why the reactions that are initiated with CH2Cl2 as the solvent provide 74 at a faster 
rate.  
In order to maximize the overall conversion of 61 to 74, attempts were undertaken 
to cyclize the mono-acyl compound 72 to 74. However, exposure of 72 to a variety of 
Lewis acids failed to furnish any of the cyclized product 74 (Scheme 2.18). 
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Scheme 2.18 
In order to facilitate oxocarbenium ion formation from 72, its conversion into an 
acetimidate derivative was attempted.27 Deprotonation of 72 followed by treatment with 
trichloacetonitrile furnished the acetimidate derivative 75 (Scheme 2.19) only in low yield. 
Surprisingly, treatment of 75 with various Lewis acids did not furnish any of the cyclized 
product 74. Attempts to recycle 72 by acylation to obtain the bis-acyl compound 73 were 
also unsuccessful. The only effective transformation of 72 was its hydrolysis to the amino 
hemiacetal 61, which was recycled by conversion to 73 (Scheme 2.19). 
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Scheme 2.19 
The synthetic efforts towards epilupinine were now continued further. Krapcho 
decarboxylation28 of 74 provided 76 which has the required azabicylic framework for 
epilupinine (Scheme 2.20). Removal of the ephedrine portion from 76 was achieved by a 
dissolving-metal reduction (Na/NH3) to provide the hydroxy amide 77.  
 
 
Scheme 2.20 
Reduction of 77 (LiAlH4) furnished the aminoalcohol 78, oxidative cleavage of 
which provided the aminoketone 79. Demethylation of 79 furnished 80 which is a known 
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intermediate to (+)-epilupinine (3, Scheme 2.21). Since (+)-Epilupinine (3) can be obtained 
by reduction of the dithiolane derived from 80,29 the synthesis outlined in Scheme 2.21 
constitutes a formal synthesis of  (+)-epilupinine (3).  
  
 
 
Scheme 2.21 
The stereochemistry of 80 confirms the stereochemistry of the spiroisoxazolidine 
60 (Scheme 2.13) and it also validates the stereochemical assumptions regarding the [3+2] 
cycloaddition of the alkylidene morpholinones and nitrones examined in this study 
(Schemes 2.11 and 2.13). 
As a logical extension of the studies described above, it is reasonable to expect that 
the spiroisoxazolidine 59 will provide the indolizidine alkaloid (+)-tashiromine (1, Scheme 
2.22). N-O Bond cleavage in 59 should provide the corresponding amino hemiacetal which 
upon bis-acylation to 81 and subsequent cyclization, will yield 82. Reductive removal of 
the ephedrine portion in 82 and further transformations as outlined for 77 (Scheme 2.21) 
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will lead to (+)-tashiromine (1). In general, the construction of the second ring in the 
azabicycle through the intramolecular oxonium ion capture procedure should provide 
access to indolizidine and quinolizidine alkaloids with cis orientation of the ring junction 
hydrogen and the adjacent hydroxymethyl group. 
 
 
Scheme 2.22 
 
2.4.2 Synthesis of (+)-Epitashiromine (2) 
As mentioned earlier, one of the objectives of this investigation was to develop a 
stereochemically flexible route to diastereomeric indolizidine and quinolizidine alkaloids. 
To this effect, the utility of the nitrone cycloaddition strategy, described above, in the 
synthesis of (+)-epitashiromine (2) was examined. In this approach, construction of the six 
membered ring of epitashiromine by an intramolecular N-alkylation reaction was chosen 
(Scheme 2.23). The substituent (‘R’) in the alkene 31 serves as the alkyl fragment for 
intramolecular N-alkylation to construct one ring of the target alkaloid. Depending on the 
length of the carbon chain, a five- or a six-membered ring can be constructed. 
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Scheme 2.23 
The synthesis of (+)-epitashiromine was initiated with the preparation of the 
spiroisoxazolidine 53 (Scheme 2.11) by the reaction of alkylidene morpholinone 52 and 
the nitrone 12. Hydrolysis of the acetate in 53 and subsequent mesylation of the alcohol 
provided 83. Due to the unstable nature of 83, the crude mesylate was immediately reduced 
with Zn-AcOH. During the reduction, an in-situ cyclization of the secondary amine, 
obtained after N-O bond cleavage in 83, furnished the indolizidine 84 (Scheme 2.24). With 
the required azabicylic framework for (+)-epitashiromine (2) available in 84, it was 
subjected to a dissolving metal reduction (Na/NH3), the usual protocol for removal of the 
ephedrine portion. However, it was observed that 84 was resistant to the reduction. 
Previous studies in the Pansare group had indicated that morpholinone derivatives with 
free hydroxy groups were not good substrates for the dissolving-metal reduction protocol. 
It was therefore decided that reduction of the hemiacetal in 84 was necessary. Accordingly, 
treatment of 84 with BF3•OEt2 and Et3SiH furnished 85. 
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Scheme 2.24 
As anticipated, the dissolving-metal reduction of 85 successfully generated the 
hydroxy amide 86 (Scheme 2.25). Conversion of 86 to (+)-epitashiromine (2) was achieved 
by reduction of the hydroxy amide to the amino alcohol 87, oxidative cleavage of the amino 
alcohol 87 to the aldehyde 88 and in situ reduction of 88 to the primary alcohol (Scheme 
2.25).  The formation of (+)-epitashiromine confirms the stereochemistry of 53. 
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Scheme 2.25 
The racemic version of the aldehyde intermediate obtained from 88 has previously 
been converted to (±) tashiromine via epimerization (Scheme 2.26) by Stille and 
Paulvannan.12a Thus, the present synthesis of (+)-epitashiromine (2) also constitutes a 
formal synthesis of (+)-tashiromine (1). 
Scheme 2.26 
It is reasonable to expect that the quinolizidine 89 will be obtained by following a 
synthetic sequence similar to the one described above for (+)-epitashiromine (2), but 
starting with the spiroisoxazolidine compound 54 (Scheme 2.11). Compound 89 should 
provide ( ̶ )-lupinine (4, Scheme 2.27) by following the sequence of reactions described in 
Scheme 2.25 for (+)-epitashiromine (2). 
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Scheme 2.27 
 
2.5 Conclusions 
In conclusion, a stereodivergent synthetic strategy, employing a 1,3-dipolar 
cycloaddition reaction of achiral nitrones with chiral dipolarophiles, was developed for the 
synthesis of selected indolizidine and quinolizidine alkaloids. The methodology was 
applied in the total synthesis of (+)-epitashiromine (2, 6.2% yield over 14 linear steps) and 
in the formal syntheses of (+)-epilupinine (3) and (+)-tashiromine (1).  
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2.6 Experimental Section  
 All commercially available reagents were used without purification. All reactions 
requiring anhydrous conditions were performed under an atmosphere of dry nitrogen using 
oven dried glassware. CH2Cl2 and THF were distilled from CaH2 and 
sodium/benzophenone respectively. Commercial precoated silica gel plates were used for 
TLC. Silica gel for flash column chromatography was 230-400 mesh. For column 
chromatographic purifications employing CH2Cl2/MeOH/aq. NH3, the eluent was dried 
over Na2SO4 before use. All melting points are uncorrected. Optical rotations were 
measured at the sodium D line on a digital polarimeter at ambient temperature. A CEM 
Discover® microwave reactor was used for the microwave experiments. All reactions 
involving microwave heating were conducted in sealed reaction vessels. The temperature 
of the reaction mixture was monitored with an infrared sensor and the mixture reached the 
preset temperature (110 oC) in approximately 60s. Compounds 34,16a 35,16c and 3717 were 
prepared according to literature methods. 
General procedure for the preparation of cyclic nitrones 5 and 12:23 
 To the solution of amine (10 mmol) in acetone (25 mL) was added SeO2 (0.5 mmol) 
at 0 °C under nitrogen. To this mixture was added dropwise an aqueous solution of H2O2 
(50% soln., 1.5 mL, 22 mmol) and the reaction mixture was warmed to room temperature 
and stirred for 3 h at room temperature. Acetone was removed under reduced pressure and 
the resulting mixture was extracted with CH2Cl2 (5 x 20 mL). The combined organic layers 
were dried (Na2SO4) and concentrated under reduced pressure. 
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2,3,4,5-Tetrahydropyridine 1-oxide (5): 
 
This was prepared according to the general procedure. The crude product was 
purified by flash chromatography (9:1 CH2Cl2/MeOH) to obtain 285 mg of 5 (25%) as a 
yellowish solid. 
1H NMR (500 MHz, CDCl3): δ 7.18 (m, 1H, =CH), 3.80 (m, 2H, NCH2), 2.44 (m, 2H, 
=CCH2), 1.98 (m, 2H, CH2), 1.74 (m, 2H, CH2). 
3,4-dihydro-2H-pyrrole-1-oxide (12): 
 
This was prepared according to the general procedure. The crude product was of 
sufficient purity and was directly used in the reactions with alkylidene morpholinones.  
1H NMR (500 MHz, CDCl3): δ 6.91 (m, 1H, =CH), 3.99-3.98 (m, 2H, NCH2), 2.76-2.73 
(m, 2H, =CCH2), 2.32-2.22 (m, 2H, CH2). 
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(Z)-N-Ethylidene-1-phenylmethanamine oxide (48):19 
 
 
To a solution of benzaldehyde (10.0 g, 0.094 mol) and hydroxylamine 
hydrochloride (21.81 g, 0.314 mol) in ethanol (90%, 315 mL) was added powdered NaOH 
(34 g, 0.85 mol) in small portions. The mixture was allowed to stir at 25 °C for 30 min and 
then heated to reflux for additional 30 min. The reaction mixture was then cooled to 25 °C 
and poured into a mixture of concentrated HCl (38 mL) and water (145 mL). The acidic 
solution was carefully concentrated to one third of the original volume and extracted with 
CH2Cl2 (3 x 50 mL). The organic layer was washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. The crude product (yellow oil) was purified by 
Kugelrohr distillation (b.p. 71 °C, 0.5 mmHg) to give 5.5 g (48%) benzaldehyde oxime as 
a colorless oil which slowly crystallized below 20 °C.  
To a solution of benzaldehyde oxime (5.4 g, 0.045 mol) and NaBH3CN (4.776 g, 0.076 
mol) in 60 mL MeOH at 0 °C, HCl (12 N, 7.5 mL, 0.09 mol) was added drop wise. The 
reaction mixture was then stirred at 25 °C for 4 h and basified to pH ~ 9 with NaOH (6 M). 
The mixture was concentrated under reduced pressure and the product was extracted with 
CH2Cl2. The combined extracts were washed with brine, dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The residue obtained was recrystallized 
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(hexanes/MeOH, 4:1) to provide 4.8 g (87%) of N-benzyl-hydroxylamine as colorless 
crystals.  
To a solution of N-benzyl hydroxylamine (4.71 g, 38.2 mol), in CH2Cl2 (100 mL) at 0 °C 
under an argon atmosphere, were added freshly distilled acetaldehyde (10.7 mL, 76.4 mol), 
Na2SO4
 
(5.42 g, 38.2 mol) and NaHCO3 (0.178 g, 1.91 mol) and the mixture was stirred 
for 1 h. The mixture was then filtered and the filtrate was concentrated under reduced 
pressure to afford 5.5 g (97%) of (Z)-N-ethylidene benzylamine N-oxide (48) as a colorless 
solid. 
1H NMR (500 MHz, CDCl3): δ 7.41-7.38 (m, 5H, ArH), 6.73-6.70 (q, 1H, J = 5.8, NCH), 
4.89 (s, 2H, PhCH2), 2.00-1.99 (d, 3H, J = 5.8, CH3). 
 
(Z)-4-((5S,6R)-4,5-Dimethyl-3-oxo-6-phenylmorpholin-2-ylidene)butyl acetate (42): 
 
To a suspension of the dione 34 (1.4 g, 6.4 mmol) in THF (25 mL) at 0 oC, was 
added the Grignard reagent prepared from 2-(4-bromobutoxy)tetrahydro-2H-pyran (3.77 
g, 15.9 mmol) and magnesium metal (388 mg, 15.9 mmol) in THF (10 mL) and the mixture 
was stirred at ambient temperature for 12 h. A saturated aqueous solution of ammonium 
chloride was added and the mixture was extracted with ethyl acetate (3 x 10 mL). The 
combined extracts were dried (Na2SO4) and concentrated to provide 2.2 g (91 %) of the 
hemiacetal 38. This was pure (1H NMR) and was used further without purification. 
68 
 
1H NMR (300 MHz, CDCl3): δ 7.39-7.29 (m, 5H, ArH), 5.52-5.51 (d, 1H, J = 2.9, PhCH), 
4.62-4.59 (m, 1H, OCHO), 3.92-3.74 (m, 2H, ring OCH2 or alkyl OCH2), 3.54-3.40 (m 
overlapped with dq, 3H, CHCH3 and ring OCH2 or alkyl OCH2), 3.15 (br s, 1H, OH), 3.04 
(s, 3H, NCH3), 2.20-2.07 (m, 1H, CH2), 2.02-1.93 2.20-2.07 (m, 1H, CH2), 1.88-1.47 (m, 
12H, CH2), 0.97 (d, 3H, J = 6.5, CHCH3). 
Visible peaks of minor diastereomer: 5.19-5.18 (d, 1H, J = 2.8, PhCH), 4.55-4.51 (m, 1H, 
OCHO), 3.03 (s, 3H, NCH3), 1.35 (d, 3H, J = 6.5, CHCH3). 
A solution of the hemiacetal 38 (2.1 g, 5.6 mmol) in MeOH (10 mL) was cooled to 
0 oC and p-TsOH (2.64 g, 13.9 mmol) was added. The solution was stirred at room 
temperature for 12 h and the MeOH was removed under reduced pressure. The residue was 
taken up in water and the mixture was neutralized with saturated aqueous NaHCO3. The 
resulting mixture was extracted with CH2Cl2 (3 x 30 mL) and the combined extracts were 
dried (Na2SO4) and concentrated to provide the 1.5 g (92%) of the primary alcohol 41. This 
was dissolved in CH2Cl2 (15 mL) and the solution was cooled to 0°C. To this were added 
DMAP (0.03 g, 0.3 mmol), followed by triethylamine (1.78 mL, 12.8 mmol) and acetyl 
chloride (0.55 mL, 7.74 mmol) and the mixture was stirred for 12 h at ambient temperature. 
Water (5 ml) was added, the mixture extracted with CH2Cl2 (3 x 15 mL) and the combined 
extracts washed with water and sat. NaHCO3 solution, dried (Na2SO4) and concentrated to 
provide 1.54 g (90%) of the crude acetate.  
The acetate was dissolved in CH2Cl2 (10 mL), the solution was cooled to -78 
oC 
and BF3.OEt2 (1.70 mL, 13.8 mmol) was added. The solution was stirred at ambient 
temperature for 12 h and cold water (5 mL) was added. The mixture was extracted with 
CH2Cl2 (3 x 30 mL) and the combined extracts were dried (Na2SO4) and concentrated. The 
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residue was purified by flash chromatography on silica gel (1:1 EtOAc/hexane) to provide 
1.15 g (79%, 65% from the OTHP hemiacetal) of 42 as a colorless gum. 
IR (neat): 1732, 1633, 1481, 1447, 1400, 1304, 1241, 1209, 1164, 1045, 1014 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.44-7.28 (m, 5H, ArH), 6.05 (t, 1H, J = 7.8, CHCH2), 
5.23-5.22 (d, 1H, J = 2.7, PhCH), 4.15-4.03 (m, 2H, OCH2), 3.59-3.51 (dq, 1H, J = 2.7, 
6.6, CHCH3), 3.09 (s, 3H, NCH3), 2.41-2.28 (m, 2H, CH2CH), 1.97 (s, 3H, CH3CO), 1.84-
1.74 (m, 2H, CH2CH2), 0.98 (d, 3H, J = 6.6, CHCH3). 
 13C NMR (75 MHz, CDCl3): δ 171.1 (OC=O), 159.5 (NC=O), 144.6 (C=C-C=O), 137.0 
(ArCipso), 128.5 (2 x ArC), 128.0 (ArC), 125.5 (2 x ArC), 115.0 (C=CH), 77.1 (Ph-CH), 
63.9(CH2OAc), 58.6 (NCH), 33.6 (NCH3), 27.8 (CH2), 21.3 (CH2), 20.9 (CH3CO), 11.7 
(CHCH3). 
MS (APCI, pos.): m/z 318.1 (M+H)+. 
HRMS (EI): m/z 317.1630 (317.1627 calc. for C18H23NO4 (M
+)). 
 
(Z,5S,6R)-2-(2-Methoxyethylidene)-4,5-dimethyl-6-phenylmorpholin-3-one (58): 
 
 To a stirred solution of (Z)-ethyl-2-((5S,6R)-4,5-dimethyl-3-oxo-6-
phenylmorpholin-2-ylidene)acetate (35, prepared from the morpholine dione 34 and 
carbethoxymethylenetriphenylphosphorane,16c 2.20 g, 7.60 mmol) in CH2Cl2 (10 mL) at -
78 ºC was added DIBAL-H (27.3 mL of 1 M soln. in CH2Cl2, 27.3 mmol) drop wise. The 
70 
 
resulting mixture was stirred at room temperature for 5 h, then cooled to 0 °C and aqueous 
HCl (3 M, 5 mL) was added. The resulting mixture was warmed to room temperature and 
then extracted with CH2Cl2 (4 x 25mL). The combined organic layers were dried (Na2SO4) 
and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (ethyl acetate) to provide 1.15 g (61%) of (Z,5S,6R)-2-(2-
Hydroxyethylidene)-4,5-dimethyl-6-phenylmorpholin-3-one as a colorless oil. 
IR (neat): 3393 (br), 1624, 1444, 1397, 1303, 1157, 1038, 998 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.42-7.30 (m, 5H, ArH), 6.21 (t, 1H, J = 6.5, CHCH2), 5.27 
(d, 1H, J = 2.6, PhCH), 4.50-4.36 (dd, 2H, J = 6.5, 14.5, OCH2), 3.57-3.53 (dq, IH, J = 2.6, 
6.6, CHCH3), 3.10 (s, 3H, NCH3), 1.95 (br s, 1H, OH), 1.00 (d, 3H, J = 6.6, CHCH3). 
13C NMR (125 MHz, CDCl3): δ 159.1 (C=O), 144.3 (C-C=O), 136.5 (ArCipso), 128.5 (2 x 
ArC), 128.1 (ArC), 125.4 (2 x ArC), 115 (C=CH), 77.3 (Ph-CH), 58.6 (NCH), 57.0 
(CH2OH), 33.7 (NCH3), 11.8 (CHCH3). 
MS (APCI, pos.): m/z 248.1 (M+H)+. 
HRMS (EI): m/z 247.1216 (247.1208 calc. for C14H17NO3 (M
+)). 
To a suspension of NaH (323 mg (95%), 12.8 mmol) in THF (5 mL), was added a 
solution of the above alcohol (2.10 g, 8.49 mmol) in THF (10 mL) at 0 °C. The mixture 
was stirred for 30 min at 0 °C and MeI (0.74 mL, 11.9 mmol) was added. The mixture was 
stirred at ambient temperature for 3 h and water (5 mL) was added. The resulting mixture 
was extracted with EtOAc (3 x 25 mL), the combined extracts were dried (Na2SO4) and 
concentrated under reduced pressure to give 1.9 g (85%) of the ether 58 as a colorless oil. 
This was pure by 1H NMR and was used further without purification. An analytical sample 
was obtained by flash chromatography on silica gel (EtOAc/hexanes, 7:3). 
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IR (neat): 2980, 2929, 1634, 1488, 1445, 1394, 1307, 1157, 1112, 1073, 1025 cm-1. 
 1H NMR (300 MHz, CDCl3): δ 7.44-7.33 (m, 5H, ArH), 6.16 (t, 1H, J = 6.7, CHCH2), 5.27 
(d, 1H, J = 2.6, PhCH), 4.29-4.18 (dd, 2H, J = 6.7, 13.4, CH2O), 3.57-3.53 (dq, 1H, J = 
2.6, 6.6, CHCH3), 3.37 (s, 3H, OCH3), 3.10 (s, 3H, NCH3), 1.00 (d, 3H, J = 6.6, CHCH3). 
13C NMR (125 MHz, CDCl3): δ 158.9 (C=O), 145.2 (C-C=O), 136.6 (ArCipso), 128.6 (2 x 
ArC), 128.1 (ArC), 125.4 (2 x ArC), 111.9 (C=CH), 77.4 (Ph-CH), 66.1 (OCH2), 58.6 
(OCH3), 58.1 (NCH), 33.7 (NCH3), 11.7 (CHCH3). 
MS (APCI, pos.): m/z 262.1 (M+H)+. 
HRMS (EI): m/z 261.1375 (261.1365 calc. for C15H19NO3 (M
+)). 
 
(7R,8S)-Ethyl-2-benzyl-3,8,9-trimethyl-10-oxo-7-phenyl-1,6-dioxa-2,9-
diazaspiro[4.5]decane-4-carboxylate (49): 
 
 
A solution of 35 (0.05 g, 0.17 mmol) and nitrone 48 (0.052 g, 0.35 mmol) in toluene 
(2 mL) was heated by microwave irradiation in a sealed reaction vessel for 30 min at          
110 °C. The mixture was cooled to ambient temperature and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexanes, 
5:5) to afford 0.033 g (40%) of the spiroisoxazolidine 49 as a pale yellow foam. 
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IR (neat): 1735, 1666, 1495, 1450, 1377, 1243, 1197, 1024, 892, 746 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.40-7.31 (m, 3H, ArH), 7.25-7.15 (m, 7H, ArH), 5.51-
5.50 (d, 1H, J = 2.9, PhCH), 4.34-4.27 (m, 1H, OCH2), 4.15-4.10 (m, 1H, OCH2), 4.07 (d, 
1H, J = 11.3, PhCH2), 4.04 (d, 1H, J = 9.9, PhCH2), 3.84 (br s, 1H, NCH), 3.47 (dq, 1H, J 
= 3.2, 6.5, NCHCH3), 3.02, (s, 3H, NCH3), 1.32 (d, 3H, J = 6.2, CHCH3), 1.28 (t, 3H, J = 
7.2, CH2CH3), 0.89 (d, 3H, J = 6.5, CHCH3). 
13C NMR (75 MHz, CDCl3): δ 168.0 (OC=O), 162.6 (NC=O), 137.1 (ArCipso), 136.9 
(ArCipso), 129.1 (2 x ArC), 128.5 (2 x ArC), 128.1 (2 x ArC), 127.8 (ArC), 127.2 (ArC), 
125.4 (2 x ArC), 104 (OC-C(O)), 76.04 (OCH2), 71.3 (PhCH), 61.6 (NCH), 61.1 (PhCH2), 
58.9 (C(O)NCH), 34.2 (NCH3), 18.26 (CHCH3), 14.1 (CH2CH3), 12.4 (CHCH3).  
MS (APCI, pos.): m/z 439.4 (M+H)+. 
HRMS (EI): m/z 438.2145 (438.2155 calc. for C25H30N2O5 (M
+)).  
 
(7R,8S)-2-Benzyl-3,4,8,9-tetramethyl-7-phenyl-1,6-dioxa-2,9-diazaspiro[4.5]decan-
10-one (50): 
 
A solution of 37 (0.05 g, 0.22 mmol) and nitrone 48 (0.065 g, 0.44 mmol) in toluene 
(2 mL) was heated by microwave irradiation in a sealed reaction vessel for 30 min at         
110 °C. The mixture was cooled to ambient temperature and concentrated under reduced 
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pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexanes, 
4:6) to afford 0.020 g (20%) of the spiroisoxazolidine 50 as a yellowish foam. 
IR (neat): 1654, 1550, 1495, 1453, 1320, 1252, 1151, 1029, 917 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.43-7.38 (m, 2H, ArH), 7.35-7.31 (m, 3H, ArH), 7.24-
7.23 (br d, 2H, ArH), 7.20-7.13 (m, 3H, ArH), 5.55-5.54 (d, 1H, J = 2.8, PhCH), 4.02-3.99 
(d, 1H, J = 13.7, PhCH2), 3.97-3.94 (d, 1H, J = 13.7, PhCH2), 3.47 (m, 1H, NCHCH3), 
3.05-3.02 (br m, 2H, NCH, CHCH3), 3.00, (s, 3H, NCH3), 1.18-1.17 (d, 3H, J = 5.5, 
CHCH3), 1.14-1.13 (d, 3H, J = 6.6, CHCH3), 0.93 (d, 3H, J = 6.4, CHCH3). 
13C NMR (75 MHz, CDCl3): δ 137.7 (ArCipso), 137.4 (ArCipso), 129.1 (2 x ArC), 128.4 (2 
x ArC), 128.1 (2 x ArC), 127.7 (ArC), 127.1 (ArC), 125.5 (2 x ArC), 104.2 (C-C(O)), 70.7 
(PhCH), 66 (PhCH2), 58.9 (C(O)NCH), 50.7 (CHCH), 34.1 (NCH3), 16.61 (CH), 13.0 
(CH2CH3), 10.3 (CHCH3). 
MS (APCI, pos.): m/z 381.4 (M+H)+. 
HRMS (EI): m/z 380.2103 (380.2100 calc. for C23H28N2O3 (M
+)). 
 
(5'S,6'R)-Ethyl-4',5'-dimethyl-3'-oxo-6'-phenylhexahydrospiro[isoxazolo[2,3-
a]pyridine-2,2'-morpholine]-3-carboxylate (51): 
 
A solution of 35 (0.145 g, 0.501 mmol) and nitrone 5 (0.100 g, 1.002 mmol) in 
toluene (2 mL) was heated by microwave irradiation in a sealed reaction vessel for 30 min 
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at 110 °C. The mixture was cooled to ambient temperature and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexanes, 
4:6) to afford 0.165 g (85%) of the spiroisoxazolidine 51 as a yellowish foam. 
IR (neat): 2935, 1736, 1662, 1449, 1379, 1309, 1237, 1191, 1145, 995, 754 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.34-7.19 (m, 5H, ArH), 5.53 (br s, 1H, PhCH), 4.34-4.25 
(m, 1H, OCH2), 4.16-4.11 (m, 1H, OCH2), 3.81-3.75 (m, 1H), 3.70-3.43 (m, 2H), 3.50 (m, 
1H, NCH), 3.22-3.20 (m, 1H, NCH), 3.00, (s, 3H, NCH3), 2.20-2.14 (br m, 1H, CH2) 
2.01(br m, 1H, CH2), 1.74 (br s, 2H, CH2), 1.58-1.52 (br m, 2H, CH2), 1.42-1.41 (m, 1 H, 
CH2), 1.29-1.22 (m, 4H, CH2), 0.90 (d, 3H, J = 6.6, CHCH3). 
MS (APCI, pos.): m/z 389.2 (M+H)+. 
HRMS (CI): m/z 388.1989 (388.1998 calc. for C21H28N2O5 (M
+)). 
 
(5'S,6'R)-3,4',5'-Trimethyl-6'-phenylhexahydrospiro[isoxazolo[2,3-a]pyridine-2,2'-
morpholin]-3'-one (52): 
 
A solution of 37 (0.1 g, 0.43 mmol) and nitrone 5 (0.086 g, 0.86 mmol) in toluene 
(2 mL) was heated by microwave irradiation in a sealed reaction vessel for 30 min at 110 
°C. The mixture was cooled to ambient temperature and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexanes, 
4:6) to afford 0.11 g (77%) of the spiroisoxazolidine 52 as a colorless foam. 
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1H NMR (500 MHz, CDCl3): δ 7.37-7.26 (m, 5H, ArH), 5.52 (br s, 1H, PhCH), 3.49-3.44 
(m, 1H, NCH), 3.34 (m, 1H, NCH), 3.21 (m, 1H, NCH2), 3..06 (s, 3H, NCH3), 2.00-1.91 
(br m, 2H, CH2), 1.74-1.68 (br d, 4H, CH2), 1.49 (br m, 1H, CH2), 1.39-1.37 (br m, 1H, 
CH2), 1.26 (br s, 1H, CH2), 1.13 (d, 3H, J = 6.6, CHCH3), 0.95-0.94 (d, 3H, J = 6.6, 
CHCH3). 
 
3-((5S,6R)-4,5-Dimethyl-3-oxo-6-phenyltetrahydro-3'H-spiro[morpholine-2,2'-
pyrrolo[1,2-b]isoxazol]-3'-yl)propyl acetate (53): 
 
 A solution of 42 (2.00 g, 6.29 mmol) and nitrone 12 (1.07 g, 12.6 mmol) in toluene 
(8 mL) was heated by microwave irradiation in a sealed reaction vessel for 30 min at         
110 °C. The mixture was cooled to ambient temperature and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexanes, 
6:4) to afford 1.82 g (71%) of the spiroisoxazolidine 53 as a pale yellow foam. 
IR (neat): 1735, 1659, 1449, 1236, 1148, 1040 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.37-7.25 (m, 5H, ArH), 5.62-5.61 (d, 1H, J = 3.2, PhCH), 
4.17-4.04 (m, 2H, OCH2), 3.68-3.62 (m, 1H, CHNO), 3.55-3.48 (dq, 1H, J = 3.2, 6.5, 
CHCH3), 3.38-3.30 (m, 1H), 3.11-3.07 (m, 1H),  3.04 (s, 3H, NCH3), 3.03-2.97 (m, 1H), 
2.06 (s, 3H, CH3CO), 1.97-1.92 (m, 1H, CH2CH), 1.89-1.78 (m, 3H, CH2CH2), 1.72-1.61 
(m, 4H, CH2CH2) 0.94 (d, 3H, J = 6.5, CHCH3). 
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13C NMR (75 MHz, CDCl3): δ 171.1 (OC=O), 164.0 (NC=O), 137.4 (ArCipso), 128.3 (2 x 
ArC), 127.6 (ArC), 125.6 (2 x ArC), 104.9 (OCO), 70.9 (Ph-CH), 69.6 (NCH), 64.4 
(CH2OAc), 59.0 (NCH), 56.9 (NCH2), 55.2 (CHCH2), 34.3 (NCH3), 29.9 (CH2), 27.2 
(CH2), 24.2 (CH2), 23.0 (CH2), 21.0 (CH3CO), 12.9 (CHCH3). 
MS (APCI, pos.): m/z 403.2 (M+H)+. 
HRMS (EI): m/z 402.2150 (402.2155 calc. for C22H30N2O5 (M
+)). 
 
(5S,6R)-3'-(3-Hydroxypropyl)-4,5-dimethyl-6-phenyltetrahydro-3'H-
spiro[morpholine-2,2'-pyrrolo[1,2-b]isoxazol]-3-one (53a): 
 
 To the solution of the spiroisoxazolidine 53 (1.82 g, 4.52 mmol ) in THF (10 mL) 
was added NaOH (18.1 mL of 2.5 M soln. 45.24 mmol) and the mixture was heated to 
reflux for 16 h (monitored by TLC). The mixture was then cooled to ambient temperature 
and extracted with CH2Cl2 (5 x 20 mL). The combined extracts were dried (Na2SO4) and 
concentrated under reduced pressure to provide 1.52 g (93%) of the alcohol 53a as a white 
foam. This was pure by 1H NMR and was used further without purification. 
IR (neat): 3395, 1650, 1448, 1189, 1146, 1017 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.44-7.29 (m, 5H, ArH), 5.62-5.61 (d, 1H, J = 3.2, PhCH), 
3.69-3.61 (m, 3H, OCH2 and CHNO), 3.54-3.46 (dq, 1H, J = 3.2, 6.5, CHCH3), 3.37-3.29 
(m, 1HNCH), 3.11-3.06 (m, 1H, NCH2) 3.03 (s, 3H, NCH3), 3.03-2.97 (m, 1H, CHCH2), 
77 
 
2.1-2.01 (m, 1H, CH2), 1.98-1.86 (m, 4H, CH2), 1.81-1.68 (m, 2H, CH2CH2), 1.66-1.55 (m, 
2H, CH2CH2), 0.95 (d, 3H, J = 6.5, CHCH3). 
13C NMR (75 MHz, CDCl3): δ  164.2 (NC=O), 137.5 (ArCipso), 128.3 (2 x ArC), 127.6 
(ArC), 125.7 (2 x ArC), 105.2 (OCO), 70.9 (Ph-CH), 69.7 (NCH), 62.7 (CH2OH), 59.0 
(NCH), 56.9 (NCH2), 55.3 (CHCH2) 34.3 (NCH3), 31.0 (CH2),  39.0 (CH2), 24.0 (CH2), 
23.0 (CH2), 13.0 (CHCH3). 
MS (APCI, pos.): m/z 361.1 (M+H)+. 
HRMS (EI): m/z 360.2048 (360.2049 calc. for C20H28N2O4 (M
+)). 
 
3-((3R,3aR,5'S,6'R)-4',5'-Dimethyl-3'-oxo-6'-phenylhexahydrospiro[isoxazolo[2,3-
a]pyridine-2,2'-morpholin]-3-yl)propyl acetate (54): 
 
A solution of 42 (100 mg, 0.32 mmol) and nitrone 5 (63.0 mg, 0.64 mmol) in 
toluene (3 mL) was heated by microwave irradiation in a sealed reaction vessel for 30 min 
at 110 °C. The mixture was cooled to ambient temperature and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexanes, 
6:4) to afford 90 mg (70%) of the spiroisoxazolidine 54 as a pale yellow foam. 
IR (neat): 2938, 1734, 1655, 1447, 1237, 1146, 1100, 986 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.44-7.28 (m, 5H, ArH), 5.60 (br s, 1H, PhCH), 4.11-4.02 
(br m, 2H, OCH2), 3.57-3.47 (m, 2H, NCH and NCHCH2), 3.42-3.27 (m, 1H), 3.11-2.99 
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(s superimposed on a m, 4H), 2.51-2.35 (m, 3H), 2.08-2.02 (s superimposed on a m, 4H), 
1.97-1.92 (m, 2H), 1.77-1.69 (m, 5H), 0.94 (d, 3H, J = 6.5). 
13C NMR (75 MHz, CDCl3): δ 171.1 (COOCH3), 165.4 (CONCH3), 137.5 (ArCipso), 128.3 
(2 x ArCH), 127.6 (ArCH), 125.5 (2 x ArCH), 104.5 (OCO), 70.8 (Ph-CH), 69.3 (OCH2), 
64.5 (NCHCH2), 58.6 (NCHCH3), 52.2 (NCH2), 47.3 (CHCH2), 34.2 (NCH3), 27.1 (CH2), 
24.45 (CH2), 22.35 (CH2), 21.7 (CH2), 20.9 (CH3CO), 18.6 (CH2), 12.8 (CHCH3). 
MS (APCI, pos.): m/z 417.3 (M+H)+. 
HRMS (CI): m/z 416.2309 (416.2311 calc. for C23H32N2O5 (M
+)). 
 
2-Hydroxy-2-((R)-4-hydroxy-1-((R)-piperidin-2-yl)butyl)-4,5-dimethyl-6-
phenylmorpholin-3-one (54a): 
 
To the solution of 54 (42 mg, 0.101 mmol) in MeOH (2 mL) was added K2CO3 
(138 mg, 1.01 mmol) at room temperature, reaction was stirred for 3 h at room temperature. 
The solvent was removed under reduced pressure, the residue was dissolved in water (2 
mL) and was extracted with CH2Cl2 (4 x 5 mL). The combined organic layer was dried 
(Na2SO4) and concentrated to afford crude alcohol (37 mg, 98%). This was used further 
without purification. 
 To a stirred solution of alcohol (37 mg, 0.99 mmol) in acetic acid (2 mL) was added 
activated zinc powder (65.0 mg, 9.88 mmol) in two portions at ambient temperature. The 
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mixture was stirred vigorously at ambient temperature for 36 h (monitored by TLC), 
CH2Cl2 (5 mL) was added and the mixture was filtered. The solvent was removed under 
reduced pressure and the mixture was basified (pH=12) with NaOH solution (10%). The 
basic mixture was extracted with CH2Cl2 (3 x 20 mL) and the combined extracts were dried 
(Na2SO4) and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH, 8:2) to provide 15 mg (41%) of 54a as 
colorless foam. 
IR (neat): 3400, 3246, 1641, 1445, 1395, 1161, 1076, 994, 735 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.40-7.29 (m, 5H, ArH), 5.80-5.79 (d, 1H, J = 3.1, PhCH), 
3.82-3.74 (m, 1H, OCH2), 3.63-3.52 (m, 2H, NCH and OCH2), 3.34-3.27 (br t, 1H, J = 
10.2, NCH2), 3.22-3.17 (br d, 1H, J = 14, NCH), 3.02 (s, 3H, NCH3), 2.72-2.63 (m, 1H, 
NCH2), 2.60-2.55 (br t, 1H, J = 7.6, CH2CH), 1.98-1.95 (br m, 2H, CH2CH2), 1.75-1.63 
(m, 2H, CH2CH2), 1.59-1.48 (m, 5H, CH2CH2), 1.38-1.26 (m, 3H, CH2CH2), 0.93 (d, 3H, 
J= 6.6, CHCH3). 
13C NMR (75 MHz, CDCl3): δ 168.8 (C=O), 138.6 (ArCipso), 128.3 (2 x ArCH), 127.4 
(ArCH), 125.7 (2 x ArCH), 101.8 (OCO), 69.5 (PhCH), 61.3 (OCH2), 59.2 (NCH), 58.6 
(NCH2), 45.56 (NCH2), 44.1 (CHCH), 33.9 (NCH3), 31.9 (CH2CH2), 31.2 (CH2CH2), 27.3 
(CH2CH2), 24.86 (CH2CH2), 24.74 (CH2CH2), 12.8 (CHCH3). 
MS (APCI, pos.): m/z 377.1 (M+H)+. 
HRMS (CI): m/z 376.2366 (376.2362 calc. for C21H32N2O4 (M
+)). 
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(3'S,3a'R,5S,6R)-3'-(Methoxymethyl)-4,5-dimethyl-6-phenyltetrahydro-3'H-
spiro[morpholine-2,2'-pyrrolo[1,2-b]isoxazol]-3-one (59): 
 
A solution of 58 (0.15 g, 0.57 mmol) and the nitrone 12 (0.097 g, 1.14 mmol) in 
toluene (4 mL) was subjected to microwave irradiation in a sealed microwave reaction 
vessel for 30 min at 110°C. The mixture was cooled to ambient temperature and 
concentrated under reduced pressure. The residue was purified by flash chromatography 
on silica gel (EtOAc/hexanes, 1:1) to afford 0.141 g (71%) of the spiroisoxazolidine 59 as 
a colorless foam. 
IR (neat): 2930, 1720, 1658, 1449, 1246, 1196, 1144, 1105, 1006 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.36-7.33 (m, 2H, ArH), 7.31-7.27 (m, 3H, ArH), 5.57-
5.56 (d, 1H, J = 3.0, PhCH), 3.82-3.79 (t, 1H, J = 9, OCH2), 3.68-3.64 (m, 1H, NCH), 3.59-
3.56 (dd, 1H, J = 6.6, 9.3, OCH2), 3.47 (dq, 1H, J = 3.0, 6.5, NCHCH3), 3.40-3.37 (m, 2H, 
NCH2), 3.35 (s, 3H, OCH3), 3.08-3.05 (m, 1H, CH2CH), 3.05, (s, 3H, NCH3), 2.14-2.05 
(m, 1H, CH2CH2), 1.95-1.91 (m, 2H, CH2CH2), 1.79-1.72 (m, 1H, CH2CH2), 0.95 (d, 3H, 
J = 6.5, CHCH3). 
13C NMR (75 MHz, CDCl3): δ 163.9 (C=O), 137.6 (ArCipso), 128.2 (2 x ArC), 127.5 (ArC), 
125.7 (2 x ArC), 104.4 (C-C=O), 71.4 (PhCH), 70.4 (OCH2), 67.6 (OCH3), 58.96 (NCH), 
58.85 (OCH3), 57.0 (NCH2), 55.7 (CHCH), 34.2 (NCH3), 29.9 (CH2CH2), 23.0 (CH2CH2), 
12.2 (CHCH3). 
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MS (APCI, pos.): m/z 347.1 (M+H)+. 
HRMS (EI): m/z 346.1890 (346.1893 calc. for C19H26N2O4 (M
+)). 
 
(2R,3S,3aS,5'S,6'R)-3-(Methoxymethyl)-4',5'-dimethyl-6'-
phenylhexahydrospiro[isoxazolo[2,3-a]pyridine-2,2'-morpholin]-3'-one (60): 
 
 A solution of 58 (1.90 g, 7.27 mmol) and nitrone 5 (1.45 g, 14.6 mmol) in toluene 
(8 mL) was subjected to microwave irradiation in a sealed microwave reaction vessel 30 
min at 110°C. The mixture was cooled to ambient temperature and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexanes, 1:1) to afford 1.59 g (61%) of the spiroisoxazolidine 60 as a pale yellow 
foam. 
IR (neat): 2933, 1658, 1489, 1143, 1100, 990 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.45-7.25 (m, 5H, ArH), 5.53 (br s, 1H, PhCH), 3.81-3.75 
(m, 1H, NCH), 3.70-3.43 (m, 2H, OCH2), 3.47 (dq, 1H, J = 3.0, 6.6, NCHCH3), 3.34 (s, 
3H, OCH3), 3.34-3.13 (m, 2H, NCH2), 3.05, (s, 3H, NCH3), 2.00-1.90 (br m, 2H, CH2), 
1.80-1.65 (br m, 2H, CH2), 1.55-1.40 (br m, 2H, CH2), 0.95 (d, 3H, J = 6.6, CHCH3). 
13C NMR (125 MHz, CDCl3): δ 165.4 (CO), 137.7 (ArCipso), 128.3 (2 x ArCH), 127.5 
(ArCH), 125.6 (2 x ArCH), 104.6 (OCO), 71.4 (Ph-CH), 69.7 (OCH2), 61.4 (OCH2), 58.9, 
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58.7 (NCHCH3, NCHCH2), 52.5 (NCH2), 48.1 (CHCH2OCH3), 34.1 (NCH3), 24.8 (CH2), 
24.5 (CH2), 18.9 (CH2), 12.2 (CHCH3). 
 MS (APCI, pos.): m/z 361.2 (M+H)+. 
HRMS (CI): m/z 360.2058 (360.2049 calc. for C20H29N2O4 (M+H)
+). 
 
(5S,6R)-2-Hydroxy-4,5-dimethyl-6-phenyl-2-(1-(piperidin-2-yl)ethyl)morpholin-3-
one (57): 
 
To a stirred solution of cycloadduct 52 (0.10 g, 0.03 mmol) in acetic acid (3 mL) 
was added activated zinc powder (0.198 g, 0.302 mmol) in two portions at ambient 
temperature. The mixture was stirred vigorously at ambient temperature for 5 h (monitored 
by TLC), CH2Cl2 (15 mL) was added and the mixture was filtered. The solvent was 
removed under reduced pressure and the mixture was basified (pH=12) with NaOH 
solution (10%). The basic mixture was extracted with CH2Cl2 (3 x 20 mL) and the 
combined extracts were dried (Na2SO4) and concentrated under reduced pressure to 
provide 0.06 g (60%) of the amino alcohol 53 as a white foam. 
IR (neat): 3440, 1641, 1445, 1387, 1169, 1097, 893, 750 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.39-7.27 (m, 5H, ArH), 5.69-5.68 (d, 1H, J = 3.1, PhCH), 
3.50-3.44 (dq, 1H, J = 3.6, 6.9, NCHCH3), 3.11-3.06 (dt, 1H, J = 2.6, 10.7, NCH), 3.01-
2.99 (s overlapped with m, 4H, NCH3 and NCH2), 2.61-2.55 (dt, 1H, J = 2.6, 11.8, NCH2), 
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2.40-2.34 (m, 1H, CH3CH), 1.91-1.84 (m, 2H, CH2), 1.63-1.54 (m, 2H, CH2), 1.34-1.24 
(m, 2H, CH2), 1.13-1.05 (m, 2H, CH2), 0.90 (d, 3H, J= 6.4, CHCH3), 0.88 (d, 3H, J= 6.9, 
CHCH3). 
13C NMR (125 MHz, CDCl3): δ 167.8 (C=O), 138.8 (ArCipso), 128.2 (2 x ArC), 127.3 
(ArC), 125.8 (2 x ArC), 101.1 (OCO), 69.8 (PhCH), 59.1 (NCHCH3), 57.8 (ring NCH), 
45.4 (NCH2), 41.9 (CHCH3), 33.6 (NCH3), 31.0 (CH2), 26.9 (CH2), 24.3 (CH2), 13.4 
(CHCH3), 12.8 (CHCH3). 
MS (APCI, pos.): m/z 333.3 (M+H)+. 
HRMS (CI): m/z 333.2183 (333.2178 calc. for C19H29N2O3 (M+H)
+). 
 
(5S,6R)-2-Hydroxy-2-(2-methoxy-1-(piperidin-2-yl)ethyl)-4,5-dimethyl-6-
phenylmorpholin-3-one (61): 
 
 To a stirred solution of cycloadduct 60 (1.75 g, 4.85 mmol) in acetic acid (10 mL) 
was added activated zinc powder (3.176 g, 48.57 mmol) in two portions at ambient 
temperature. The mixture was stirred vigorously at ambient temperature for 5 h (monitored 
by TLC), CH2Cl2 (15 mL) was added and the mixture was filtered. The solvent was 
removed under reduced pressure and the mixture was basified (pH=12) with NaOH 
solution (10%). The basic mixture was extracted with CH2Cl2 (3 x 20 mL) and the 
combined extracts were dried (Na2SO4) and concentrated under reduced pressure to 
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provide 1.62 g (92%) of the amino alcohol 61 as a white foam. This was pure by 1H NMR 
and was used further without purification. 
IR (neat): 3429, 1654, 1447, 1398, 1117, 1067, 999, 760 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.39-7.26 (m, 5H, ArH), 5.70 (d, 1H, J = 3.2, PhCH), 3.50-
3.44 (dq, 1H, J = 3.2, 6.6, CHCH3), 3.39-3.31 (ABM system, 2H, J = 10.4, 6.4, OCH2), 
3.26-3.22 (s overlapped with m, 4H, OCH3 and NCHCH2), 3.04-3.01 (s overlapped with 
m, 4H, NCH3 and CHCH2), 2.66-2.57 (m, 2H, NCH2), 1.93-1.83 (m, 2H, CH2), 1.63-1.52 
(m, 2H, CH2), 1.38-1.26 (m, 2H, CH2), 0.90 (d, 3H, J= 6.6, CHCH3). 
13C NMR (125 MHz, CDCl3): δ 168.0 (C=O), 139.0 (ArCipso), 128.2 (2 x ArC), 127.3 
(ArC), 125.8 (2 x ArC), 99.5 (OCO), 71.1 (OCH2), 69.9 (PhCH), 59.0 (OCH3), 58.5 
(NCHCH3), 56.7 (CHCH2OCH3), 46.1 (NCHCH2), 45.4 (NCH2), 33.8 (NCH3), 31.0 (CH2), 
26.9 (CH2), 24.3 (CH2), 12.4 (CHCH3). 
MS (APCI, pos.): m/z 363.1 (M+H)+. 
HRMS (CI): m/z 363.2293 (363.2284 calc. for C20H31N2O4 (M+H)
+). 
 
(5S,6R)-4'-(Methoxymethyl)-1',4,5-trimethyl-6-phenylhexahydro-1'H-
spiro[morpholine-2,3'-pyrido[1,2-c][1,3]oxazin]-3-one (68): 
 
To a solution of 61 (0.363 g, 1.002 mmol) in MeOH (2 mL) was added acetaldehyde 
(0.17 mL, 3.01 mmol). The reaction mixture was stirred at ambient temperature for 12 h 
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and the solvent was removed under reduced pressure. The residue was purified by flash 
chromatography on silica gel (MeOH/CH2Cl2, 6:94) to afford 232 mg (60%) of 68 as a 
colorless foam. 
IR (neat): 1649, 1559, 1495, 1394, 1243, 1146, 1075, 1004, 740 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.42-7.31 (m, 5H, ArH), 5.52 (d, 1H, J = 3.1, PhCH), 4.52-
4.51 (m, 1H, OCHN), 3.50 (dq, 1H, J = 3.4, 6.6, NCH), 3.42 (dd, 1H, J = 10.1, 17.4, OCH2), 
3.38 (dd, 1H, J = 10.1, 15.5, OCH2), 3.25-3.19 (s overlapped with m, 4H, OCH3 and NCH), 
3.02-2.97 (s overlapped with m, 5H, NCH3 and NCH2), 2.39 (br m, 1H, CH2CH), 1.76-
1.69 (m, 2H, CH2), 1.91-1.84 (m, 2H, CH2), 1.67-1.61 (m, 2H, CH2), 1.56-1.50 (m, 1H, 
CH2), 1.45-1.37 (m, 1H, CH2), 1.24 (d, 3H, J = 5.8, CH3), 0.92 (d, 3H, J = 6.6, CHCH3). 
13C NMR (125 MHz, CDCl3): δ 165.7 (C=O), 137.9 (ArCipso), 128.5 (2 x ArC), 127.6 
(ArC), 125.5 (2 x ArC), 98.35 (OCO), 82.5 (OCHN), 71.0 (OCH2), 69.5 (PhCH), 58.81 
(NCHCH3), 58.67 (NCHCH), 56.62 (CH), 33.9 (NCH3), 28.3 (CH2), 25.3 (CH2), 21 (CH2), 
19 (CHCH3), 12 (CHCH3). 
MS (APCI, pos.): m/z 389.2 (M+H)+. 
HRMS (CI): m/z 389.2426 (389.2440 calc. for C22H33N2O4 (M+H)
+). 
 
Acylation of amino alcohol 61: 
 To a cooled (0 oC) solution of 61 (1.34 g, 3.69 mmol) in CH2Cl2 (10 mL) was added 
an aqueous solution of K2CO3 (30%, 6.81 mL, 14.8 mmol) followed by addition of methyl 
malonyl chloride (1.19 mL, 11.1 mmol). The mixture was stirred for 3 h at room 
temperature and the biphase was separated. The aqueous layer was extracted with CH2Cl2 
(3 x 5 mL) and the combined organic layers were dried (Na2SO4) and concentrated under 
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reduced pressure to a pale yellow foam. The crude product was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH, 98:2) to provide 360 mg (21%) of 72 as a 
colorless foam and 980 mg (47%) of 73 as a colorless foam. 
Methyl-3-((S)-2-((S)-1-((2S,5S,6R)-2-hydroxy-4,5-dimethyl-3-oxo-6-
phenylmorpholin-2-yl)-2-methoxyethyl)piperidin-1-yl)-3-oxopropanoate (72): 
 
IR: 3404, 1736, 1642, 1445, 1249, 1009, 759 cm-1. 
1H NMR (500 MHz, CDCl3): major diastereomer: δ 7.38-7.34 (m, 2H, ArH), 7.34-7.26 (m, 
3H, ArH), 7.06 (s, 1H, OH), 5.69 (d, 1H, J = 3.2, PhCH), 4.91 (br m, 1H, NCHCH2), 3.72 
(s, 3H, CO2CH3), 3.62-3.35 (m, 6H, NCHCH3, OCH2, NCHCH2, NCH2,), 3.35-3.25 (m, 
3H, OCH3, C(O)CH2CO2CH3), 3.02 (s, 4H, NCH3), 2.90-2.85 (m, 1H, CHCH2O), 2.05-
1.95 (m, 1H, ring CH2), 1.90-1.75 (m, 2H, ring CH2), 1.75-1.65 (m, 2H, ring CH2), 1.60-
1.50 (m, 1H, ring CH2), 0.90 (d, 3H, CHCH3); visible resonances for the minor 
diastereomer: d 5.63 (br s, PhCH), 3.02 (m, 2H), 0.81 (br d, CHCH3). 
13C NMR (125 MHz, CDCl3): δ 167.9 (N-C(O)CH2CO2CH2), 167.3 (CO2CH3), 137.9 
(ArCipso), 128.3 (2 x ArC), 127.4 (ArC), 125.6 (2 x ArC), 98.2 (OCO), 70.4 (OCH2), 70.2 
(PhCH), 58.9 (CH2OCH3), 58.2 (NCHCH3), 52.5 (CO2CH3), 49.5 (CHCH2OCH3), 48.6 
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(NCHCH2), 42.0 (C(O)CH2C(O), or NCH2), 41.4 (C(O)CH2C(O), or NCH2), 33.8 (NCH3), 
25.1 (ring CH2), 24.5 (ring CH2), 19.2 (ring CH2), 12.7 (CHCH3). 
MS (ESI, neg.): m/z 461.2 (M-H)-. 
HRMS (CI, pos.): m/z 462.2386 (462.2366 calc. for C24H32N2O7 (M
+)). 
(2R,5S,6R)-2-((S)-2-Methoxy-1-((S)-1-(3-methoxy-3-oxopropanoyl)piperidin-2-
yl)ethyl)-4,5-dimethyl-3-oxo-6-phenylmorpholin-2-yl methyl malonate (73): 
 
 
IR (neat): 2941, 1738, 1664, 1634, 1442, 1151, 1111, 1016, 963 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.36-7.27 (m, 5H, ArH), 5.83 (br s, 1H, PhCH), 4.68-4.56 
(m, 1H, NCHCH2), 3.68 (s, 3H, CO2CH3), 3.51 (s, 3H, CO2CH3), 3.25 (s, 3H, NCH3), 3.09 
(s, 3H, CH2OCH3), 3.75-3.10 (br m, 9H, 2 x CH2CO2CH3, NCHCH3, OCH2, NCH2), 2.75 
(apparent br t, 1H, J =12.7, CHCH2O), 1.91 (apparent br d, 1H, J = 12.4, ring CH2), 1.75-
1.45 (br m, 5H, ring CH2), 1.00 (d, 3H, J = 6.3, CHCH3). 
13C NMR (125 MHz, CDCl3): δ 168.7 (N-C(O)CH2C(O)), 166.5 (CO2CH3), 166.4 
(CO2CH3), 165.2 (O-C(O)CH2C(O)), 163.3 (CH3NC(O)), 136.5(ArCipso), 128.4 (2 x ArC), 
128.2 (ArC), 125.9 (ArC), 102.3 (OCO), 74.0 (PhCH), 69.5 (OCH2), 58.9 (CH2OCH3), 
58.7 (NCHCH3), 52.4 (OCH3), 51.9 (OCH3), 51.1 (CHCH2), 42.7 (NCHCH2), 41.2 
(C(O)CH2C(O)N), 40.5 (C(O)CH2C(O), 36.9 (NCH2), 33.9 (NCH3), 28.4 (ring CH2), 25.3 
(ring CH2), 19.9 (ring CH2), 12.4 (CHCH3). 
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MS (APCI, pos.): m/z 563.3 (M+H)+. 
HRMS (EI): 563.2605 m/z (563.2605 calc. for C28H39N2O10 (M+H)
+).   
 
 (1'S,5S,6R,9a'S)-Methyl-1'-(methoxymethyl)-4,5-dimethyl-3,4'-dioxo-6-
phenyloctahydrospiro- [morpholine-2,2'-quinolizine]-3'-carboxylate (74): 
 
 To a solution of 73 (700 mg, 1.25 mmol) in CH2Cl2 (3 mL) at 0 °C was added 
BF3•OEt2 (1.53 mL, 12.5 mmol). The mixture was warmed to room temperature and stirred 
for 12 h. Water (2 mL) was added, the biphase separated, the aqueous layer extracted with 
CH2Cl2 (3 x 5 mL) and combined organic layer dried (Na2SO4) and concentrated under 
reduced pressure. The crude product was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH, 98:2) to give provide 236 mg (46%) of 74 as a white foam. 
IR (neat): 2937, 1740, 1650, 1574, 1496, 1438, 1367, 1345, 1209, 1152, 1113, 1037 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.47-7.32 (br t, 2H, J = 7.2, ArH), 7.30-7.25 (br d, 1H, J 
=7.2, ArH), 7.20-7.18 (br d, 2H, J =7.2, ArH), 5.06 (d, 1H, J = 3.2, PhCH), 4.70 (br d, 1H, 
J = 12.1, CH2NCO), 3.93 (s, 3H, CO2CH3), 3.62-3.55 (dt, 1H, J = 2.9, 11.2, NCHCH2), 
3.55-3.47 (m, 3H, OCH2, NCHCH3), 3.27 (s, 3H, OCH3), 3.07 (s, 3H, NCH3), 2.75-2.67 
(dt, 1H, J = 2.6, 12.7, CHCH2O), 2.55-2.50 (m, 1H, CH2NCO), 2.30 (br m, 1H, J = 14.2, 
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CH2), 1.95-1.90 (br m, 1H, ring CH2), 1.83-1.75 (br m, 1H, ring CH2), 1.55-1.50 (m, 2H, 
ring CH2), 1.39-1.29 (m, 2H, ring CH2), 0.93 (d, 3H, J = 6.5, CHCH3). 
13C NMR (125 MHz, CDCl3): δ 168.4 (C(O)NCH3), 168.4 (C(O)NCH2), 164.5 (CO2CH3), 
137.9 (ArCipso), 128.3 (2 x ArC), 127.6 (ArC), 125.5 (2 x ArC), 79.5 (OCC(O)), 71.8 
(OCH2), 70.9 (PhCH), 58.6 (CO2CH3, CHNCH3, CH(C=O)2), 55.3, 55.2 (OCH3, 
CHNCH2), 46.4 (CHCH2O), 44.4 (CH2NC(O), 34.1 (NCH3), 31.4 (ring CH2), 24.6 (ring 
CH2)), 23.2 (ring CH2), 13.4 (CHCH3). 
MS (ESI, pos.): m/z 445.3 (M+H)+. 
HRMS (EI): m/z 444.2255 (444.2260 calc. for C24H32N2O6 (M
+)). 
 
(1'S,5S,6R,9a'S)-1'-(Methoxymethyl)-4,5-dimethyl-6-phenylhexahydrospiro-
[morpholine-2,2'-quinolizine]-3,4'-(3'H)-dione (76): 
 
 To a solution of 74 (370 mg, 0.83 mmol) in DMSO (3 mL) was added NaCl (53.8 
mg, 0.92 mmol) and H2O (60.0 µL, 3.33 mmol). The solution was then heated at 110 °C 
for 1 h. The DMSO was removed under reduced pressure and water was added to the 
residue (3 mL). The mixture was extracted with CH2Cl2 (4 x 5 mL) and the combined 
extracts were washed with water (30mL), dried (Na2SO4) and concentrated under reduced 
pressure to provide 250 mg (78%) of 76 as a pale brown foam. This was pure by 1H NMR 
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and was used further without purification. An analytical sample (white foam) was obtained 
by flash chromatography on silica gel (CH2Cl2/MeOH, 98:2). 
IR: 1636, 1482, 1444, 1266, 1146, 1107, 1022, 754 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.33 (t, 2H, J = 7.9, ArH), 7.30-7.25 (m, 1H, ArH), 7.22-
7.21 (d, 2H, J = 7.6, ArH), 5.15 (br d, J = 2.8, 1H, PhCH), 4.76 (br d, 1H, J = 13.2, 
CH2NC(O)), 3.7 (dd, 1H, J = 6.7, 10.2, OCH2), 3.55-3.50 (m, 1H, NCHCH3), 3.5-3.45 (dd, 
1H, J = 4.8, 10.2, OCH2), 3.29-3.25 (m, 1H, NCHCH2), 3.27 (s, 3H, OCH3), 3.02 (s, 3H, 
NCH3), 3.02-2.87 (AB system, 2H, J = 17.5, CH2C(O)), 2.65-2.57 (m, 1H, OCH2CH ), 
2.41 (dt, 1H, J = 2.4, 12.8, C(O)NCH2), 2.15 (br d, 1H, J = 11.5, ring CH2), 1.90 (br d, 1H, 
J = 12.1, ring CH2), 1.70 (br d, 1H, J = 11.0, ring CH2), 1.55-1.40 (m, 2H, 1.40-1.25 (m, 
1H, ring CH2), 0.95 (d, 3H, J = 6.5, CHCH3). 
13C NMR (125 MHz, CDCl3): δ 168.9 (C=O), 165.9 (C=O), 137.5 (ArCipso), 128.3 (2 x 
ArC), 127.6 (ArC), 125.4 (2 x ArC), 78.2 (OCC(O)), 71.6 (PhCH), 71.5 (OCH2), 58.9 
(NCH3), 58.7 (NCH), 56.8 (OCH3), 45.4 (OCH2CH), 42.4 (NCH2), 38.4 (CH2C(O), 34.0 
(NCH3), 33.3 (ring CH2), 25.1 (ring CH2), 24.5 (ring CH2), 12.6 (CHCH3). 
MS (APCI, pos.): m/z 387.1 (M+H)+. 
HRMS (CI): m/z 386.2216 (386.2206 calc. for C22H30N2O4 (M
+)). 
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(1S,9aR)-Octahydro-2-hydroxy-1-(methoxymethyl)-N-methyl-4-oxo-1H-quinolizine-
2-carboxamide (77): 
 
 To anhydrous liquid ammonia (6 mL, distilled over sodium) was added Na metal 
(88.3 mg, 3.84 mmol) at -78 C and the mixture was stirred for 15 min. To the resulting 
blue solution was added a solution of compound 76 (185 mg, 0.48 mmol) in anhydrous 
THF (1.5 mL) and the mixture was stirred for 30 min at -78 °C. A mixture of MeOH/H2O 
(3/1, 2 mL) was added and the reaction mixture was brought to ambient temperature and 
stirred for 30 min to remove ammonia. The resulting solution was concentrated under 
reduced pressure and the residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH, 96:4) to provide 100 mg, (77%) of 77 as a white solid.   
IR: 3439, 3334, 2858, 1641, 1526, 1450, 1407, 1246, 1112, 1077, 1021, 971, 906 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.16 (br s, 1H, NH), 4.85 (br m, 1H, NCH2), 4.58 (d, 1H, J 
= 2.2, OH), 3.67-3.62 (ABM system, 2H, OCH2), 3.48 (dt, 1H, J =2.5, 11, NCH), 3.34 (s, 
3H, OCH3), 2.89 (d, 3H, J = 5.0, NCH3), 2.77 (br dd, 1H, J = 2.2, 16.9, C(O)CH2), 2.46 
(br dt, 1H, J = 3, 13, CHCH2O), 2.43 (d, 1H, J = 16.9, C(O)CH2), 2.30 (br d, 1H, J= 10.6, 
NCH2), 2.06-2.0 (br m, 1H, ring CH2), 1.93-1.90 (br m, 1H, ring CH2), 1.78-1.75 (br m, 
1H, ring CH2), 1.52-1.40 (br m, 2H, ring CH2), 1.30-1.20 (br m, 1H, ring CH2). 
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13C NMR (125 MHz, CDCl3): δ 174.5 (C=O), 166.4 (C=O), 76.8 (C-OH), 70.8 (OCH2), 
59.6 (NCH), 53.9 (OCH3), 43.3 (NCH3), 42.4 (NCH2 or C(O)CH2), 42.3 (NCH2 or 
C(O)CH2), 32.1 (CH2), 26.1 (CHCH2O), 25.1 (ring CH2), 24.2 (ring CH2). 
MS (APCI, pos.): m/z 271.1 (M+H)+. 
HRMS (CI): m/z 270.1590 (270.1580 calc. for C13H22N2O4 (M
+)). 
[α]D20 = −10.3 (c 1, CH2Cl2). 
 
(1S,9aR)-Hexahydro-1-(methoxymethyl)-1H-quinolizin-2(6H)-one (79): 
 
 To a stirred solution of the hydroxy amide 77 (136 mg, 0.51 mmol) in 1,2-
dimethoxyethane (3 mL) at 0 ºC was slowly added lithium aluminum hydride (191 mg, 5.1 
mmol) in small portions. The mixture was then brought to room temperature and heated to 
reflux for 72 h. The reaction mixture was then cooled to 0 °C and water (0.1 mL), NaOH 
(2.2 mL, 2.5 M soln.) and water (0.3 mL) were added sequentially at 5 min intervals. The 
resulting mixture was filtered and the solid residue was washed with CH2Cl2 (30 mL).  The 
combined filtrates were dried (Na2SO4) and concentrated under reduced pressure to provide 
70 mg (57%) of (1S,9aR)-octahydro-1-(methoxymethyl)-2-((methylamino)methyl)-1H-
quinolizin-2-ol (78). This was used further without purification. 
IR (neat): 3443, 1448, 1105, 734, 695 cm-1. 
1H NMR (500 MHz, CDCl3): δ 3.70-3.65 (ABM system, 2H, OCH2), 3.31 (s, 3H, OCH3), 
3.30-3.28 (m, 1H, NCH), 2.91-2.85 (m, 1H, NCH2), 2.70 (d, 1H, J = 11.6, NCH2), 2.65-
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2.60 (m, 1H, CHCH2O), 2.56 (d, 1H, J = 11.6, NCH2), 2.46 (s, 3H, NCH3), 2.35-2.20 (m, 
2H, CH2), 2.18-2.09 (m, 1H, CH2), 1.90 (br d, 1H, CH2), 1.80 (br d, 1H, CH2), 1.68-1.55 
(m, 5H, CH2), 1.43 (br d, 1H, CH2), 1.35-1.25 (m, 2H, CH2), 1.18-1.08 (m, 1H, CH2), 0.95-
0.85 (m, 1H, CH2). 
13C NMR (125 MHz, CDCl3): δ 71.8 (C-OH), 69.8 (OCH2), 61.6 (NCH2), 59.1 (OCH3), 
58.4 (NCH), 56.7 (NCH2), 51.4 (NCH2), 47.7 (CHCH2), 37.4 (NCH3), 35.1 (CH2C-OH), 
29.8 (CH2), 25.6 (CH2), 24.6 (CH2). 
MS (APCI, pos.): m/z 243.3 (M+H)+. 
HRMS (EI): m/z 242.2000 (242.1994 calc. for C13H26N2O2 (M
+)). 
[α]D20 = +6.5 (c 1.6, CHCl 3). 
 To a stirred solution of the amino alcohol 78 (70 mg, 0.29 mmol) in MeOH/H2O 
(100/1, 2 mL) at 0 ºC was added NaIO4 (247 mg, 1.16 mmol). The reaction mixture was 
stirred at 0 ºC for 15 min and then warmed to room temperature and stirred for 30 min. A 
cold, saturated aqueous solution of sodium bicarbonate was added and the mixture was 
extracted with ethyl acetate (3 x 15 mL). The combined organic layers were dried (Na2SO4) 
and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/MeOH, 99:1) to provide the ketone 79 (18 mg, 32%) 
as a yellow liquid. 
IR (neat): 2927, 1717, 1454, 1357, 1294, 1154, 1111 cm-1. 
1H NMR (500 MHz, CDCl3): δ 3.76-3.71 (dd, 1H, J = 2.8, 9.7, OCH2), 3.62-3.57 (dd, 1H, 
J = 3.6, 9.7, OCH2), 3.32 (s, 3H, OCH3), 3.07-2.96 (m, 2H, CHCO and NCH), 2.73-2.65 
(m, 1H, C(O)CH2), 2.46-2.38 (m, 2H, NCH2 and CH2CO), 2.28-1.98 (m, 4H, CH2), 1.80-
1.62 (m, 3H, CH2), 1.36-1.22 (m, 2H, CH2); 
13C NMR (125 MHz, CDCl3): δ 207.8 (C=O), 
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67.1 (OCH2), 63.5 (CH-C=O), 59.2 (OCH3), 56.0 (NCH2), 55.4 (NCH), 55.2 (NCH2), 41.2 
(CH2-C=O), 31.4 (CH2), 25.5 (CH2), 23.5 (CH2). 
MS (APCI, pos.): m/z 198.1 (M+H)+. 
HRMS (CI): m/z 197.1418 (197.1416 calc. for C11H19NO2 (M
+)). 
[α]D20 = +17.3 (c 2, CHCl 3). 
 
(1S,9aR)-Hexahydro-1-(hydroxymethyl)-1H-quinolizin-2(6H)-one (80): 
 
 To a stirred solution of the ketone 79 (21 mg, 0.11 mmol) in CH2Cl2 (2 mL) at 0 ºC 
was added BBr3 (1.0 M soln. in CH2Cl2, 43 L, 0.43 mmol). The reaction mixture was 
warmed to room temperature and stirred for 30 min (monitored by TLC). An aqueous 
solution of ammonia (30%, 3 mL) was added and the mixture was extracted with CH2Cl2 
(4 x 5 mL). The combined organic layers were dried (Na2SO4) and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/MeOH, 85:15) to provide the hydroxy ketone 80 (6 mg, 31%) as a white solid. 
IR (neat): 3169, 1709, 1091 cm-1. 
1H NMR (300 MHz, CDCl3): δ 3.97-3.92 (dd, 1H, J = 2.8, 11.9, OCH2), 3.74-3.68 (dd, 
1H, J = 5.7, 11.9, OCH2), 3.14-3.07 (m, 1H, CHC(O)), 3.01-2.97 (br m, 1H, NCH), 2.83-
2.72 (m, 1H, CH2C(O)), 2.47-2.35 (m, 3H, CH2C(O) and CH2), 2.18-2.07 (m, 2H, CH2), 
1.99-1.94 (m, 1H, CH2), 1.85-1.75 (m, 1H, CH2), 1.75-1.55 (m, 2H, CH2), 1.42-1.17 (m, 
3H, CH2). 
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13C NMR (75 MHz, CDCl3): δ 212.1 (C=O), 63.1 (OCH2), 58.5 (CHC(O) or NCH), 56.6 
(CHC(O) or NCH), 55.77 (NCH2), 55.75 (NCH2), 41.7 (C(O)CH2), 31.1 (CH2), 25.3 (CH2), 
23.3 (CH2). 
MS (APCI, pos.): m/z 184.1 (M+H)+. 
HRMS (EI): m/z 183.1256 (183.1259 calc. for C10H17NO2 (M
+)). 
[α]D20 = +16.7 (c 0.6, CHCl 3, lit.29 [α]D20 = +8.8 (c 0.04, CHCl 3). 
 
(2S,5S,6R)-2-((8R,8aR)-Octahydroindolizin-8-yl)-2-hydroxy-4,5-dimethyl-6-
phenylmorpholin-3-one (84): 
 
 To the solution of the alcohol 53a (1.52 g, 4.22 mmol) in CH2Cl2 (10 mL) was 
added Et3N (1.47 mL, 10.5 mmol) followed by MsCl (0.36 mL, 4.64 mmol) at -20 °C. The 
reaction mixture was stirred at -20 °C for 3 h and water (5 mL) was added. The mixture 
was warmed to ambient temperature and was extracted with CH2Cl2 (3 x 20 mL). The 
combined extracts were washed with saturated aqueous NaHCO3 (2 x 10 mL), water (4 x 
10 mL), dried (Na2SO4) and concentrated under reduced pressure to provide 1.35 g (73%) 
of the mesylate 83 as a yellowish foam. Due to its instability, the mesylate 83 was 
immediately used further without any purification. 
1H NMR (500 MHz, CDCl3): δ 7.39-7.28 (m, 5H, ArH), 5.64-5.63 (d, 1H, J = 3.2, PhCH), 
4.27 (t, 2H, J = 6.0, OCH2), 3.66-3.61 (m, 1H, CHNO), 3.55-3.47 (dq, 1H, J = 6.5, 3.2, 
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CHCH3), 3.37-3.29 (m, 1H, NCH2) 3.09 (m, 1H, NCH2), 3.02 (s, 3H, NCH3), 3.00 (s, 3H, 
CH3SO2), 2.11-1.90 (m, 2H, CH2CH2), 1.89-1.69 (m, 7H, CH2CH2), 0.94 (d, 3H, J = 6.5, 
CHCH3). 
  To a stirred solution of the mesylate 83 (1.35 g, 3.08 mmol) in acetic acid (10 mL) 
was added activated zinc powder (2.02 g, 30.8 mmol) in two portions at ambient 
temperature. The mixture was stirred at 55 °C for 5 h and then cooled to ambient 
temperature. CH2Cl2 (15 mL) was added and the mixture was filtered. The solvent was 
removed under reduced pressure and the mixture was basified (pH = 12) with aqueous 
NaOH solution (10%). The basic mixture was extracted with CH2Cl2 (3 x 20 mL) and the 
combined extracts were dried (Na2SO4) and concentrated under reduced pressure to 
provide 1.14 g of crude product as a pale yellow foam. This was purified by extraction into 
aqueous acid followed by neutralization to the free base and extraction into CH2Cl2 to 
provide 1.0 g (94%) of the amino hemiacetal 84. This was pure by 1H NMR and was used 
further without purification. 
IR (neat): 3396 (br), 1632, 1470, 1377, 1287, 1168, 1107, 1046 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.38-7.29 (m, 5H, ArH), 5.73-5.72 (d, 1H, J = 3.2, PhCH), 
3.55-3.49 (dq, 1H, J = 3.2, 6.6, CHCH3), 3.01-2.95 (s superimposed on a m, 5H, NCH3 and 
NCH2), 2.76-2.70 (br m, 3H, NCH2), 2.39-2.20 (br m, 3H, CH2), 2.03-1.92 (m,2H, CH2), 
1.84-1.81 (m, 2H, CH2), 1.71-1.64 (m, 2H, CH2), 1.37-1.29 (m, 1H, CH2), 0.90 (d, 3H, J= 
6.6, CHCH3). 
13C NMR (75 MHz, CDCl3): δ 168.1 (C=O), 137.4 (ArCipso), 128.3 (2 x ArC), 127.7 (ArC), 
125.7 (2 x ArC), 97.6 (O-C-OH), 70.9 (PhCH), 65.0 (NCH), 59.2 (NCHCH3), 53.7 (NCH2), 
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52.6 (NCH2), 48.6 (CHCHCH2), 33.8 (NCH3), 28.9 (CH2), 24.7 (CH2), 23.8 (CH2), 20.6 
(CH2), 12.5 (CHCH3). 
MS (ESI, pos.): m/z 345.2 (M+H)+. 
HRMS (CI): m/z 345.2188 (345.2178 calc. for C20H29N2O3 (M+H)
+).   
 
(R)-2-Hydroxy-N-methyl-2-((8R,8aR)-octahydroindolizin-8-yl)acetamide (86): 
 
 To a solution of 84 (1.00 g, 2.90 mmol) in triethylsilane (4.64 mL, 29.0 mmol) was 
added BF3•OEt2 (3.6 mL, 29 mmol) at 0 °C. The mixture was warmed to ambient 
temperature and stirred vigorously for 72 h. Water (3 mL) was added at 0 °C, the mixture 
warmed to room temperature and then extracted with CH2Cl2 (5 x 20 mL). The combined 
extracts were dried (Na2SO4) and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel (CH2Cl2/MeOH/aq. NH3, 8/2/1) to provide 
460 mg (48%) of (2S,5S,6R)-2-((8R,8aR)-octahydroindolizin-8-yl)-4,5-dimethyl-6-
phenylmorpholin-3-one (84) as a white foam. 
IR (neat): 1644, 1489, 1449, 1377, 1153, 1112, 1075, 1012 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.40-7.28 (m, 5H, ArH), 4.99 (d, 1H, J = 3.0, PhCH), 4.33 
(d, 1H, J = 3.0, HC-C=O), 3.53-3.46 (dq, 1H, J = 3.0, 6.5, NCHCH3), 3.03 (s, 3H, NCH3), 
2.93-2.80 (m, 3H, NCH and NCH2) 2.64-2.56 (m, 2H, NCH2), 2.41-2.35 (m, 1H, CH2CH), 
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1.99-1.78 (m, 4H, CH2), 1.75-1.59 (m, 3H, CH2), 1.49-1.40 (m, 1H, CH2), 0.95 (d, 3H, J = 
6.5, CHCH3). 
13C NMR (75 MHz, CDCl3): δ 169.3 (NC=O), 138.1 (ArCipso), 128.3 (2 x ArC), 127.5 
(ArC), 125.4 (2 x ArC), 79.7 (HC-C=O), 76.6 (PhCH), 64.6 (CONCH), 58.7 (NCH), 54.4 
(NCH2), 49.6 (NCH2), 38.9 (CH2CH), 33.8 (NCH3), 25.1 (CH2), 24.1 (CH2), 21.55 (CH2), 
21.46 (CH2), 13.2 (CHCH3). 
MS (ESI, pos.): m/z 329.2 (M+H)+. 
HRMS (TOF, EI+): m/z 328.2142 (328.2151 calc. for C20H28N2O2 (M
+)). 
HRMS (TOF, CI+): m/z 329.2234 (329.2229 calc. for C20H29N2O2 (M+H)
+). 
[α]D20 = −176.3 (c 1, CHCl3). 
 To anhydrous liquid ammonia (6 mL, distilled over sodium) was added sodium 
metal (193 mg, 8.40 mmol) at -78 C and the mixture was stirred for 15 min. To the 
resulting blue solution was added a solution of 85 (460 mg, 1.40 mmol) in anhydrous THF 
(1.5 mL) and the mixture was stirred for 3 hr at -78 °C. A mixture of MeOH/H2O (3:1, 2 
mL) was added and the reaction mixture was brought to ambient temperature and stirred 
for 30 min to remove ammonia. The resulting solution was concentrated under reduced 
pressure and the residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH/NH3, 96:4:1) to provide 210 mg (71%) of 86 as a white solid. 
IR: 3358, 3151, 2927, 2868, 1645, 1528, 1458, 1396, 1335, 1248, 1150, 1087, 1016 cm-1. 
1H NMR (500 MHz, CDCl3): δ  7.07 (br s, 1H, CONH), 4.60 (br d, 1H, J = 3.4, CHOH), 
3.15-3.12 (br dd, 1H, J = 4.5, 10.7, NCH2), 3.08-3.04 (m, 1H, NCH), 2.88-2.87(d, 3H, J = 
5.0, NCH3), 2.41-2.37 (m, 1H, CHCH2), 2.31 (br m, 1H, NCH2), 2.06-2.00 (m, 2H, 
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CH2CH2), 1.98-1.91 (m, 1H, CH2CH2), 1.90-1.85 (m, 2H, CH2CH2), 1.83-1.78 (m, 3H, 
CH2CH2), 1.69-1.62 (m, 1H, CH2CH2), 1.57-1.53 (br m, 1H, CH2CH2), 1.40-1.33 (m, 1H, 
CH2CH2). 
13C NMR (75 MHz, CDCl3): δ 174.5 (C=O), 74.2 (CH-OH), 67.3 (NCH), 54.1 (NCH2), 
53.5 (NCH2), 35.2 (NCH3), 26.2 (CH2CH2), 25.5 (CH2CH2 and CHCH2), 23.2 (CH2), 20.9 
(CH2). 
MS (APCI, pos.): m/z 213.1 (M+H)+. 
HRMS (TOF, CI+): m/z 213.1606 (213.1603 calc. for C11H21N2O2 (M+H)
+). 
[α]D20 = −51.8 (c 1, CHCl3).  
 
((8R,8aR)-Octahydroindolizin-8-yl)-methanol (2): 
 
To a stirred solution of the hydroxy amide 86 (135 mg, 0.64 mmol) in 1,2-
dimethoxyethane (3 mL) at 0 ºC was slowly added lithium aluminum hydride (242 mg, 
6.40 mmol) in small portions. The mixture was then brought to room temperature and 
heated to reflux for 30 h. The reaction mixture was then cooled to 0 °C and water (0.12 
mL), NaOH (2.55 mL, 2.5 M soln.) and water (0.36 mL) were added sequentially at 5 min 
intervals. The resulting mixture was filtered and the solid residue was washed with CH2Cl2 
(30 mL).  The combined filtrates were dried (Na2SO4) and concentrated under reduced 
pressure to provide 88 mg (70%) of the amino alcohol 87. This was used further without 
purification. 
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To a stirred solution of the above amino alcohol 87 (88 mg, 0.44 mmol) in 
MeOH/H2O (100/1, 2 mL) at 0 °C was added NaIO4 (380 mg, 1.76 mmol). The mixture 
was stirred at 0 ºC for 15 min and then warmed to room temperature and stirred for 30 min. 
The solution was then cooled to 0 °C and NaBH4 (42.0 mg, 1.11 mmol) was added. The 
mixture was stirred at ambient temperature for 1.5 h. Water (2 mL) was added and the 
mixture was extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were dried 
(Na2SO4) and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH/NH3, 80:20:1) to provide 35 mg (36% from 
86) of (+)-epitashiromine (2) as a colorless liquid.  
IR: 3175, 3071, 1659, 1278, 1038 cm-1. 
1H NMR (300 MHz, CDCl3): δ  4.17 (dd, 1H, J = 10.7, 3.3, CH2OH), 3.74 (br d, 1H, J = 
10.7, CH2OH), 3.12 (m, 1H, NCH), 2.96 (m, 1H, NCH2), 2.35-2.25 (br m, 1H, NCH2), 
2.18-2.00 (m, 2H, NCH2), 2.00-1.75 (m, 6H, CH2), 1.75-1.50 (m, 2H, CH2). 
13C NMR (75 MHz, CDCl3):  66.8 (OCH2), 65.6 (NCH), 54.5 (NCH2), 53.6 (NCH2), 35.3 
(CH2), 30.3 (CH2), 25.9 (CH2), 23.3 (CH2), 20.7 (CH2). 
MS (APCI, pos.): m/z 156.1 (M+H)+. 
2 is reported to have a very low specific rotation (~1o) which is also known to change with 
sample history. Hence, the specific rotation of 2.HCl was measured, [α]D20 = +26.0 (c 0.5, 
EtOH); lit.13b [α]D20 = +29.1 (c 0.45, EtOH). 
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2.8 Selected 1H NMR and 13C NMR Spectra 
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Chapter 3 
Enantioselective Synthesis of Functionalized Quaternary Stereocenters 
3.1 Introduction 
Many natural products and pharmaceuticals contain one or more quaternary 
stereocenters.1 The structural complexity and diversity of these compounds combined with 
notable biological activities drive the need for new and efficient methods for their 
synthesis.2 From a methodology-development standpoint, the stereoselective synthesis of 
quaternary stereocenters is challenging due to issues with reliability of any carbon-carbon 
bond forming reaction that is part of the synthetic protocol. This is due to steric congestion 
during formation of the carbon-carbon bond leading to a quaternary stereocenter.1 Over the 
years, various methodologies for the construction of quaternary stereocenters have 
appeared in the literature. These include carbon-carbon bond-forming reactions such as the 
aldol reaction, the Mannich reaction, carbanion alkylation reactions, and metal-catalyzed 
reactions such as the Heck reaction. Among these, the aldol reaction is most closely related 
to the methodology described in this chapter and hence aldol-based syntheses of quaternary 
stereocenters have been summarized in Chapter 1. 
3.2 Objective 
The objective of the work reported in this Chapter was to develop a methodology 
for the construction of functionalized quaternary stereocenters. These can be used as 
precursors for the synthesis of small organic molecules with quaternary stereocenters or 
they can be incorporated into more complex structures. Given the difficulties in the 
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synthesis of quaternary stereocenters, it may or may not be possible to construct a 
quaternary stereocenter in a complex molecule at a later stage of the synthetic sequence. In 
this regard, functionalized quaternary stereocenters are of great importance due to the 
availability of functional groups for further transformations.  
 Our approach to the synthesis of quaternary stereocenters relies on two pivotal 
reactions of halo-alkylidene morpholinones 1 (Scheme 3.1): (1) a metal-catalyzed cross 
coupling reaction for the synthesis of diastereomerically pure alkylidene morpholinones 2; 
and (2) a stereoselective Prins reaction of alkylidene morpholinones 2 (Scheme 3.1) which 
constructs the quaternary stereocenter. 
 
Scheme 3.1 Synthetic strategy applied in this Chapter. 
 Previously in the Pansare group, Prins adducts such as 3 have been used as 
important intermediates for the synthesis of medium-sized oxacycles,3 (S)-(+)-
pantolactone3b and its analogues3c and β, β-dialkyl α-hydroxy-γ-butyrolactones.3d Lessons 
learned from these and other reactions of alkylidene morpholinones were that the addition 
at the carbon-carbon double bond takes place from the less-hindered face of the 
morpholinone, i.e. the face opposite to the methyl and phenyl groups. Hence, the focus of 
this investigation was the stereoselective synthesis of alkylidene morpholinones such as 2 
and their conversion to 3 and 4. Details of these studies are presented in this Chapter. 
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3.3 Results and Discussion 
 To access functionalized quaternary stereocenters with a variety of substituents, it 
was necessary to prepare stereochemically defined alkylidene morpholinones with 
different substituents on the alkene. Methods previously developed in the Pansare group 
for the preparation of alkylidene morpholinones 2 (Scheme 3.1) provide access only to 
isomeric mixtures of disubstituted alkylidene morpholinones such as 2. Hence, a new 
method had to be developed which would provide either the E or Z isomers of 2 as required. 
Towards this objective, it was decided to explore metal-catalyzed cross-coupling reactions 
to synthesize the required diastereomerically pure alkylidene morpholinones. Accordingly, 
an immediate goal was the synthesis of haloalkylidene morpholinones 1, which would be 
used as substrates for metal-catalyzed cross coupling reactions.  
 
3.3.1 Synthesis of Haloalkylidene Morpholinones 
Initially, we reasoned that a strategy involving alkynoic amides as substrates for a 
haloetherification reaction to form haloalkylidene morpholinones would be suitable, since 
the related, halolactonization reactions of alkynoic acids have been reported.4 Hence, the 
plan was to prepare the alkynoic amide derivative from (1R, 2S)-ephedrine (5) and            
but-2-ynoic acid (6) and then subject this alkynoic amide to an intramolecular 
haloetherification reaction.5 Accordingly, acylation of 5 with 6, employing 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) as the coupling agent, in the presence of ethyl 
2-cyano-2-(hydroxyimino)acetate (Oxyma®) as an acyl-transfer agent, provided the 
required amide 7 (Scheme 3.2). 
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Scheme 3.2 
Treatment of 7 with N-bromosuccinimide did not result in formation of either 
bromoalkene 8, or the corresponding E isomer (Scheme 3.2) and 7 was recovered 
unreacted. However, treatment of 7 with a solution of bromine in CH2Cl2 generated the 
product 9 arising from the dibromination of the alkyne group in 7. These observations 
suggested that accessing the conformer of 7 required for cyclization, namely, the conformer 
in which the acyl group and the ephedrine portion are syn, is difficult. Hence, the 
haloetherification approach was not pursued further. As an alternative, we reasoned that 
dehydration of a bromohydrin, or elimination of the elements of an alcohol from a bromo 
acetal, may be a more fruitful strategy for accessing 8. To this effect, a bromoacetal 
derivative was prepared from the alkylidene morpholinone 12 (Scheme 3.3) which was 
readily made by dehydration of the hemiacetal 11 obtained from a reaction of the 
ephedrine-derived morpholinedione 11 with ethylmagnesium bromide. Treatment of 12 
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with N-bromosuccinimide in CH2Cl2/MeOH provided the bromoacetal 13 as a 6:1 mixture 
of diastereomers (Scheme 3.3). 
 
Scheme 3.3  
 
Table 3.1 Elimination studies of bromoacetal 13. 
No Reagents  Solvent  Results  
1 BF3•OEt2a CH2Cl2 14 (80%) 
2 conc. H2SO4b THF 14 (73%) 
3 CF3CO2Hb THF 14 (84%) 
4 TiCl4a CH2Cl2 13 recovered 
5 ZnCl2b CH2Cl2 13 recovered 
6 InCl3b THF 13 recovered 
7 LDAa THF 13 recovered 
a -78 °C to room temperature, 24 h. b room temperature, 24 h. 
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With the bromoacetal 13 in hand, the possibility was examined of converting it into 
8 by generating an oxonium ion from the acetal in 13, followed by the loss of a proton, a 
process that would be similar to the BF3•OEt2 mediated conversion of 11 to 12 (as in 
Scheme 3.3). Surprisingly, the reaction of bromoacetal 13 with BF3•OEt2 provided only 
the hemiacetal 14 instead of the required bromoalkene 8 (entry 1, Table 3.1). Protic acid-
mediated reactions of 13 were also unsuccessful and the treatment of 13 with concentrated 
H2SO4 or trifluoroacetic acid (entry 2 and 3, Table 3.1) also resulted in the formation of 
the hemiacetal 14. In addition, treatment of 13 with selected metal-based Lewis acids also 
did not generate bromoalkene 8 (entries 3-6, Table 3.1) and unreacted 13 was recovered 
from these reactions. The formation of 14 in some of these reactions indicates ionization 
of the acetal to provide an oxocarbenium ion which is stable under the reaction conditions, 
and its subsequent reaction with water generates 14. An attempted elimination of the 
elements of methanol from 13 under basic conditions, by treatment with LDA, was also 
unsuccessful, presumably due to the low acidity of the methine proton in the bromomethyl 
side chain in 13. 
Next, the bromohemiacetal 14 (dr 1.7:1) was prepared by treating alkene 12 with                                          
N-bromosuccinimide in CH2Cl2/H2O (Scheme 3.4). The bromohydrin 14 was then 
subjected to dehydration conditions. Interestingly, 14 was also resistant to dehydration 
under Lewis acidic conditions. It was reasoned that activation of the hemiacetal as a 
mesylate would facilitate oxocarbenium ion formation from 14. Surprisingly, treatment of 
14 with methanesulfonyl chloride in the presence of triethylamine as a base afforded a 
mixture of 12 (45%, 1H NMR of the crude product, Scheme 3.4) and unreacted 14 (55%). 
The exact reasons for the formation of alkene 12 are unclear. 
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Scheme 3.4 
However, when the bromohydrin 14 was treated with acetic anhydride in the 
presence of catalytic amounts of concentrated H2SO4, a dehydration protocol reported by 
Mamedov et al.,6 the bromoalkene was obtained as mixture of isomers 8 and 15 (E:Z = 1:5, 
Scheme 3.4). The stereochemistry of alkene 8 was assigned as Z on the basis of a downfield 
resonance of the olefinic methyl group (2.88 ppm), compared to the corresponding methyl 
group resonance (2.49 ppm) for the isomeric E alkene 15.3c,7 Morpholinones 8 and 15 are 
not separable by flash chromatography and the bromohemiacetal 14 is always obtained as 
an inseparable mixture with succinimide that is obtained from NBS during the preparation 
of 14. In order to simplify the preparation of the bromoalkene, the bromohemiacetal 
synthesis was modified by treating 12 with a solution of bromine in water to provide 14. 
Interestingly, the dehydration of 14 obtained by this procedure provided 8 as the only 
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product. The precise reasons for the formation of both 8 and 15 from 14 obtained from the 
NBS reaction are not known. It is possible that the succinimide contaminant in 14 
influences the stereochemical course of the dehydration step, but this has not been verified. 
Thus, the optimal procedure for the conversion of 12 to 8 involves treating 12 with a 
solution of bromine in water to provide 14, followed by dehydration of crude 14 with 
Ac2O/H2SO4 (Scheme 3.5). This two-step protocol provides 8 in 67% yield from 12.   
 
 
Scheme 3.5 
In related studies, the treatment of 12 with N-iodosuccinimide in CH2Cl2/H2O 
provided the iodohemiacetal 16. However, dehydration of 16 furnished a mixture of the   
E-iodoalkene 17 and Z-iodoalkene 18 in poor yield (Scheme 3.6). Although the E and Z 
iodoalkenes were separable by column chromatography, the E-iodoalkene 17 was always 
obtained as a mixture with unreacted iodohemiacetal 16.  
 
 
Scheme 3.6 
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 The formation of both 17 and 18 in the dehydration of 16 is surprising, as only the 
Z-alkene is obtained in the dehydration of the bromohemiacetal 14. The exact reasons for 
this difference in reactivity are unclear, but one probable cause could be the carbon-iodine 
bond length. Since the carbon-iodine bond (2.10 Å) is longer than a carbon-bromine bond 
(1.88 Å),8 it is plausible that electronic repulsion between iodine and the lone pair on the 
carbonyl group in 17 is less severe as compared to a similar repulsion between bromine 
and the carbonyl lone pair in 15. Assignment of the E and Z stereochemistry of 17 and 18 
is based on the resonance of the olefinic methyl protons (2.40 ppm for 17 (E) vs 3.08 ppm 
for 18 (Z)) in the 1H NMR spectrum. 
 A brief study was conducted to optimize the selective formation of 17 or 18 by 
variation of the dehydration conditions. In the best result, the use of 
trifluoromethanesulfonic acid (entry 8, Table 3.2) offered a mixture of iodoalkenes 17 and 
18 with moderate selectivity (E:Z = 5:1) and no side-product formation. For further studies, 
17 and 18 were separated by flash column chromatography. These results are summarized 
in Table 3.2. 
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Table 3.2 Survey of dehydration conditions for 16. 
 
No.  
 
Conditionsa  
 
Solvent  
 
Result  
Yield (%) or 
product ratio 
1 TFA  CH2Cl2 12 90 
2 Et3N, MsCl CH2Cl2 12 95 
3 TiCl4
c CH2Cl2 12 62 
4 conc. H2SO4 CH2Cl2 12 90 
5 pyridine, AcCl  CH2Cl2 16 - 
6 AcCl pyridine 16 - 
7 Ac2O, H2SO4 CH2Cl2 12  90 
8 TfOH Ac2O 17 + 18  5:1
b 
9 TFA Ac2O 12 + 16 2.8:1
b 
10 CSA Ac2O 12 83 
11 CH3SO3H Ac2O 12 + 17 + 18 2.5:2.5:1
b 
12 p-TsOH Ac2O 12 + 17 4:1
b 
13 (CF3CO)2O Ac2O 16 - 
14 HClO4 THF 16 - 
15 2,4-dinitrobenzenesulfonic acid Ac2O 17 + 18 2:1
b 
16 2,4,6-triisopropylbenzene 
sulfonic acid 
Ac2O 12 69 
a
  room temp., 24 h., 
b 1H NMR spectrum of crude product., c -78 °C to room temp., 4 h.  
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3.3.2 Cross-Coupling Reactions of Haloalkylidene Morpholinones 
3.3.2.1 Negishi Coupling Reactions 
With the haloalkenes 8 and 18 in hand, their metal-catalyzed cross-coupling 
reactions were investigated. First, the reactivity of haloalkylidene morpholinones under 
Negishi coupling conditions was explored. Alkenyl halides are known to undergo Negishi 
coupling reactions with various organozinc reagents to produce substituted alkenes.9 
However, attempted Negishi coupling of the bromoalkene 8 in the presence of Ni(acac)2  
or a variety of Pd catalysts did not furnish the desired coupled product.  
 
 
Scheme 3.7 Negishi coupling reaction of bromoalkene 8. 
Table 3.3 Survey of reaction conditions for Negishi coupling reaction of 8. 
No Conditionsa  Catalysts  Result  
1 EtZnBr, TMEDA  PdCl2(PPh3)2 8 recovered 
2 EtZnBr PdCl2(PPh3)2 8 recovered 
3 EtZnBrb Pd(PPh3)4 8 recovered 
4 EtZnI Ni(acac)2 8 recovered 
5 i-PrZnBr PdCl2(dppf) 8 recovered 
6 n-BuLi, ZnBr2 PdCl2(PPh3)2 8 recovered 
7 cyclohexylZnBr PdCl2(dppf) 8 recovered 
a room temp., THF, 24 h., b room temp., 16 h, 60 °C, 12 h, THF.  
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In all of these reactions unreacted bromoalkene 8 was recovered. These results are 
summarized in Table 3.3. In related studies, the iodoalkene 18 was also subjected to the 
Negishi coupling reaction. In initial studies, iodoalkene 18 generated the expected products 
20 and 21 as a mixture of isomers (E:Z 1:2.4-2.7) with nickel or palladium catalysts (entries 
3 and 4, Table 3.4). Unfortunately, these results could not be reproduced in repeated 
attempts. 
 
 
Scheme 3.8 Negishi coupling reaction of iodoalkene 13. 
Table 3.4 Survey of reaction conditions for Negishi coupling of 18. 
No. Conditions a Catalysts  Result 
1 EtZnBr, TMEDA b PdCl2(PPh3)2 18 recovered 
2 EtZnBr, THF Pd(PPh3)4 18 recovered 
3 EtZnI, THF, rt PdCl2(dppf) 20:21 2.4:1
c 
4 EtZnI, TMEDA Ni(acac)2 20:21 2.7:1
 c 
a room temp., THF, 24 h., b room temp., THF, 24 h and 16 h, 60 °C., c 1H NMR of crude 
product. 
 The mechanistic aspects involved in the formation of product 21 are unclear, since 
the starting iodoalkene 18 is diastereomerically pure. Furthermore, it is surprising that the 
reaction was not reproducible. Considering the lack of reactivity of 8 and the capricious 
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reactivity of 18, Negishi coupling reactions for the preparation of alkylidene 
morpholinones from 8 and 18 were not examined further. 
 
3.3.2.2 Kumada Coupling Reactions of bromoalkylidene morpholinone 8 
Kumada coupling reactions of bromoalkene 8 with selected Grignard reagents were 
next investigated.10 The results of this study are summarized in Table 3.5. The bromoalkene 
8 failed to form any of the expected cross-coupled products in the presence of nickel 
catalysts (entries 1-3, Table 3.5). Bromoalkene 8 also failed to generate any coupling 
products with cyclohexylmagnesium bromide in the presence of palladium catalysts 
(entries 10-12, Table 3.5). A coupling reaction of 8 with ethylmagnesium bromide did not 
provide any of the coupled products with Pd(OAc)2 as catalyst (entry 6, Table 3.5). 
Treatment of 8 with isopropylmagnesium chloride in presence of PdCl2(PPh3)2 as a catalyst 
provided the coupled product 22 as a mixture with reduction product 26, and unreacted 8 
(30%) was also recovered (entry 5, Table 3.5). Bromoalkene 8 also furnished the coupled 
product 20 (with EtMgBr) as a mixture with the reduction product 26 and unreacted 8 
(entry 7, Table 3.5). An increase in catalyst loading for this reaction resulted in complete 
consumption of bromoalkene 8, but 20 was once again obtained as a mixture with 26 (entry 
8, Table 3.5). Interestingly, bromoalkene 8 furnished exclusively the coupled product 20 
in the presence of PdCl2(dppf)•CH2Cl2 as a catalyst, albeit in low yield (30%, entry 9, Table 
3.5). It is evident from these studies that bromoalkene 8 is less reactive with sterically 
demanding Grignard reagents under the Kumada coupling conditions. 
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Scheme 3.9 Kumada coupling reactions of bromoalkene 8. 
Table 3.5 Catalyst survey for Kumada coupling reaction of bromoalkene 8. 
No. RMgX Catalystsa Results Ratio of Products 
1  
 
iPrMgCl 
NiCl2 8 - 
2 Ni(acac)2 8 - 
3 Ni(acac)2
b 8 - 
4 Pd(PPh3)4 8 - 
5 PdCl2(PPh3)2 22 + 26 + 8 3:1:1 
6  
 
EtMgBr 
Pd(OAc)2 8 - 
7 PdCl2(PPh3)2 20 + 26 + 8  4.3:1:3 
8 PdCl2(PPh3)2
c  20 + 26 3:1 
9 PdCl2(dppf) 20  30%
 d 
10  
cyclohexylMgBr 
Pd (OAc)2
c 8 - 
11 PdCl2(dppf) 8 - 
12 PdCl2(PPh3)2
c 8 - 
a 10 mol% catalyst, THF, 24 h, room temp., b 10 mol% TMEDA as additive,  
c 30 mol% catalyst, d isolated yield.  
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Although Kumada coupling reactions of 8 did produce the required coupled 
products 20 and 22, their yields were a major concern. In order to obtain alkylidene 
morpholinones in higher yields, as well as to improve the substrate scope, the bromoalkene 
8 and iodoalkene 18 were also tested in Suzuki-Miyaura coupling reactions.  
 
3.3.2.3 Suzuki-Miyaura Coupling Reactions  
In initial studies, the Suzuki-Miyaura coupling reactions of 8 and 18 with 4-
methoxyphenylboronic acid were investigated. Iodoalkene 18 failed to provide any of the 
expected product 27 (entry 1, Table 3.6). Instead, the only product obtained was the E-
alkene 26, presumably arising from reduction of the iodoalkene 18. Under similar reaction 
conditions, with Pd(PPh3)4 as a catalyst the bromoalkene 8 provided the alkene 27 (entry 
2, Table 3.7). However, this reaction was incomplete even after 48 h of heating. In a related 
reaction, alkene 26 was obtained in good yield (75%, entry 3, Table 3.7) from bromoalkene 
8 using PdCl2(dppf)•CH2Cl2 as the catalyst and Cs2CO3 as the base. Fortunately, in these 
coupling reactions of 8, there was no formation of alkene 26 (as was seen with 18). 
Following the optimized reaction conditions (entry 3, Table 3.6), the alkylidene 
morpholinone 28 was prepared from 8 and phenylboronic acid (entry 5, Table 3.6). 
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Scheme 3.10 Suzuki-Miyaura coupling reactions of alkenes 8 and 17. 
Table 3.6 Survey of catalysts and reaction conditions for Suzuki-Miyaura coupling 
reactions of 8 and 18. 
No Substrate  Catalysts  Base Solventa Time  Result  
1 18 Pd(PPh3)4 Na2CO3 1,4-dioxane 6 h 26 (81%) 
2  
 
8 
Pd(PPh3)4 Na2CO3 1,4-dioxane 48 h 8 + 27 
3 PdCl2(dppf)•CH2Cl2 Cs2CO3 CH3CN 2 h 27 (75%) 
4 PdCl2(dppf)•CH2Cl2 Cs2CO3 THF 5 h 27 (70%) 
5 PdCl2(dppf)•CH2Cl2 Cs2CO3 CH3CN 5 h 28 (75%) 
a All reactions were carried at the reflux temperature of the corresponding solvent.  
With the alkenes 27 and 28 in hand, the synthesis of alkylidene morpholinones with 
alkyl substituents such as the morpholinone 20 (Scheme 3.9) through Suzuki-Miyaura 
coupling reactions were evaluated. Treatment of bromoalkene 8 with butylboronic acid 
under a variety of Suzuki-Miyaura conditions furnished the required product 29 as a 
mixture with 26 (Scheme 3.11). These results are summarized in Table 3.7. 
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Scheme 3.11 Suzuki-Miyaura coupling reaction of alkene 8 with butylboronic acid.  
Table 3.7 Survey of reaction conditions for Suzuki-Miyaura coupling of 8 with 
butylboronic acid. 
 
No 
 
Catalysts  
 
Base 
 
Solventa 
 
Time  
 
Result  
Ratio of 
Productsb 
1 PdCl2(dppf) Cs2CO3 CH3CN 2 h 8 - 
2 PdCl2(PPh3)2 Cs2CO3 THF 24 h 8 - 
3 PdCl2(PPh3)2 K2CO3 CH3CN 5 h 8 - 
4 Pd(OAc)2 K2CO3 THF 48 h 8 - 
5 Pd(OAc)2 Cs2CO3 THF 48 h 8 - 
6 Pd(PPh3)4 K2CO3 THF 48 h 29 + 26 + 8
c 2.7:2.3:1 
7 Pd(PPh3)4 Cs2CO3 CH3CN 24 h 29 + 26
c 2.5:1 
8 Pd(PPh3)4 K2CO3 1,2-DME 5 h 29 + 26 3.3:1 
9 Pd(PPh3)4 Cs2CO3 1,2-DME 5 h 29 + 26 1.3:1 
a All reactions were conducted at the reflux temperature for the solvent used., b 1H NMR 
analysis of crude., c isolated yield (42%).  
 Notably, Palladium (II) catalysts such as Pd(OAc)2, PdCl2(PPh3)2 or 
PdCl2(dppf)•CH2Cl2 did not provide any of the coupled product 29 (entries 1-5, Table 3.7). 
This was unexpected because the use of Palladium (II) salts (as a source of Pd (0)) in 
Suzuki-Miyaura coupling reactions is well known.11 In a related reaction, bromoalkene 8 
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provided the cross-coupled product 29 in the reaction catalyzed by Pd(PPh3)4 (entries 6-9, 
Table 3.7). The reaction was incomplete when K2CO3 was used as a base (entry 6, Table 
3.7) but complete consumption of bromoalkene 8 was observed when Cs2CO3 was used as 
base (entry 7, Table 3.8). Although the yield of product 29 was identical for these two 
reactions (42%), when Cs2CO3 was employed, higher amounts of reduction product 26 
were obtained. The use of 1,2-dimethoxyethane reduced the reaction time to 5 hours 
(entries 8-9, Table 3.8), but resulted in higher amounts of the reduction product 26 (entry 
7, (26%) and entry 9, (43%)).  
 Microwave assisted Suzuki-Miyaura coupling reactions are known, and the most 
important effect of microwave heating on a Suzuki-Miyaura reaction is a reduction in 
reaction times.12 Apart from reduced reaction times, a sealed microwave reaction vessel 
provides an opportunity to carry out reactions at high temperatures and pressures. Hence, 
the possibility of microwave heating for the cross-coupling of bromoalkene 8 with 
butylboronic acid  were explored and the results of these studies are summarized in Table 
3.8.  
 Attempted cross-coupling of 8 and butylboronic acid in THF (entry 1 and 2, Table 
3.8) with Pd(PPh3)4 as the catalyst and with microwave irradiation did not result in the 
formation of 29. The bromoalkene 8 was recovered from these reactions. A similar reaction 
performed in 1,2-dimethoxyethane as the solvent with 10 mol% of Pd(PPh3)4 as the catalyst 
furnished the cross-coupled product 29 (65%) in good yield and with minimal formation 
of reduction products (entry 3, Table 3.8). In an attempt to suppress the side product 
formation completely, the catalyst loading was lowered. However, it was observed that at 
lower catalyst loadings (entries 4 and 5, Table 3.8) side product formation was more than 
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under the standard conditions (10 mol% catalyst loading, entry 3, Table 3.8). The reasons 
for the formation of 12 and 26 in these reactions are not known at this time. Therefore 10 
mol% catalyst loadings were employed for the Suzuki-Miyaura coupling reactions of 8 
with selected alkylboronic acids. 
 
Table 3.8 Optimization studies for microwave assisted Suzuki-Miyaura coupling reaction 
of 8. 
No Catalyst 
loading  
Base  Solvent Temp. Time  Ratio of productsa  
12         26         29 
1 10 mol% K2CO3 THF 100 °C 4 h - - - 
2 10 mol% Cs2CO3 THF 100 °C 4 h - - - 
3 10 mol% K2CO3 1,2-DME 150 °C 1.5 h 1 1.7 33 
4 1 mol% K2CO3
c 1,2-DME 150 °C 1.5 h 1 2.3 10 
5 5 mol% K2CO3
d 1,2-DME 150 °C 1.5 h 1 1.2 3.5 
a 1H NMR analysis of the crude product.  
 With the conditions optimized for the coupling reaction, isopropyl-, cyclopropyl- 
2-methylpropyl- and cyclohexylboronic acids were examined in the cross-coupling 
reactions of 8. Of these, only (2-methylpropyl)boronic acid furnished the cross-coupled 
product 30 in low yield (20%, Scheme 3.12).  
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Scheme 3.12 Cross coupling reaction of bromoalkene 8 with (2-methylpropyl) boronic 
acid.  
For the reactions with cyclopropylboronic acid and cyclohexylboronic acid, 
consumption of bromoalkene 8 was observed, but only the reduction products 12 and 26 
were detected and/or isolated. These results are summarized in the Table 3.10. Although 
the use of microwave irradiation reduces the reaction time, it also provides a very harsh 
reaction environment and the stability of cyclic boronic acids under microwave heating 
was in doubt. Hence, a few reactions were also conducted under conventional heating. 
Unfortunately, none of the reactions provided cross-coupled products (entries 1 and 3-5, 
Table 3.9). Since alkyl boronate esters are also good coupling partners in Suzuki-Miyaura 
coupling reactions,13 cyclohexylboronic acid was converted to the corresponding pinacol 
boronate which was tested in the coupling reactions. However, the bromoalkene 8 failed to 
provide any of the expected cross-coupled product with cyclohexyl pinacol boronate under 
microwave irradiation as well as conventional heating conditions (entries 8 and 9, Table 
3.9). Cyclopropylboronic and isopropylboronic acids also failed to give any of the coupling 
products (entries 10-12, Table 3.9). 
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Scheme 3.13 
Table 3.9 Survey of reaction conditions for alkyl boronic acids. 
No. Boronic Acid Catalysts Basea Resultb 
1  
 
 
Pd(OAc)2 K2CO3
c 8 
2 Pd (PPh3) 4 K2CO3 12 + 26 
3 Pd (PPh3)4 K2CO3
c  12 + 26 
4 PdCl2(PPh3)2 K2CO3
c 12 + 26 
5 PdCl2(dppf) K2CO3
c 12 + 26 
6 Pd (PPh3)4 DBU
d  8 
7 Pd (PPh3) 4 DBU
e 12 + 26 
8 
 
 
Pd (PPh3)4 
K2CO3 12 + 26 
9 K2CO3
c 12 + 26 
10 
 
Pd (PPh3)4 K2CO3
c No reaction 
11 Pd (PPh3)4 Cs2CO3
f  12 + 26 
12 
 
Pd (PPh3)4 K2CO3 No reaction 
a 1,2-DME, MW, 150 °C, 1.5 h., b analysis of 1H NMR of crude c 1,2-DME, reflux, 24 h., 
6 h., d THF, MW, 100 °C, 7 h., e 1,2-DME, MW, 120 °C, f 1,2-DME, reflux, 6 h.  
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The use of an organic base, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, entries 6 
and 7, Table 3.9) instead of K2CO3 or Cs2CO3 failed to provide any coupling product with  
cyclohexylboronic acid.  
 
3.3.3 Synthesis of Prins Adducts and Quaternary Stereocenters 
 With the requisite alkylidene morpholinones 27, 28 and 29 in hand, the next task 
was to perform the carbon-carbon bond forming reaction which would construct the 
quaternary stereocenter, namely the Prins reaction. Initially, alkene 27 was chosen as the 
substrate for the Prins reaction. Alkene 27 on treatment with paraformaldehyde in acetic 
acid in the presence of a catalytic amount of sulphuric acid afforded a mixture of products 
33 (19%) and 34 (25%, Scheme 3.14) as single diastereomers which were separable by 
column chromatography. Careful analysis of compound 34 suggested that it was the 
expected Prins product, but with an acetoxymethyl substituent on the anisyl ring.  
 
 
Scheme 3.14 Prins reaction of alkene 27. 
The electron-rich nature of the 4-methoxyphenyl group and the high reaction temperature 
may have promoted the formation of 34. In order to suppress the formation of 34, the Prins 
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reaction was conducted at room temperature. Although this suppressed the formation of 
34, it also affected the formation of 33 which was obtained in very low yield (7%).  
  In related reactions, alkenes 28 and 29 furnished the Prins products 36 (58%) and 
37 (57%, Scheme 3.15) in moderate yields. Although the yields for the conversion of 28 
and 29 were moderate, these reactions were reproducible.  
 
Scheme 3.15 
At this stage, the stereochemistry of  33, 35 and 36 was tentatively assigned as 
shown, on the basis of a stereoselective reaction of the alkylidene morpholinone and 
formaldehyde from the less hindered face of the alkene to provide 37a (Fig. 3.1). Further 
reaction of 37a with formaldehyde and subsequent capture of the oxocarbenium ion from 
the Re face generates the spiromorpholinones. 
 
Figure 3.1 Proposed model for stereoselectivity in Prins reaction. 
With 35 and 36 in hand, efforts were now focused on isolating the key, quaternary 
carbon-bearing structural unit in these compounds. Accordingly, removal of the ephedrine 
portion in 35 was accomplished by means of a dissolving-metal reduction reaction.  It was 
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expected that the dissolving-metal reduction would furnish the hydroxy amide 39 (Scheme 
3.16), but instead, amide 40 was obtained. Formation of 40 was unexpected but much 
appreciated, as it saved a few synthetic steps. Presumably, the alkoxide intermediate 38, 
formed in the dissolving-metal reduction of 35, undergoes fragmentation to provide the α-
ketoamide 40 which is reduced in situ to the hydroxy amide 41. In repeated reactions, 41 
was obtained either as a single diastereomer or as a 2:1 mixture of diastereomers. The 
stereochemistry at the α-carbon in 41 was not established in this study. 
 
Scheme 3.16 
The amide 41 was reduced with borane to provide the aminoalcohol 42 (Scheme 
3.17). Oxidative cleavage of 42 generated the aldehyde 43, which was oxidized to provide 
α-methyltropic acid 44. Comparison of the observed optical rotation of 44 (+23.6) with that 
reported14 for the R enantiomer of 44 (+27.0) confirmed that the stereochemistry at the 
quaternary stereocenter in 44 was R. The formation of R-44 also confirms the 
stereochemical course of the Prins reaction (Fig. 3.1). 
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Scheme 3.17 Synthesis of α–methyltropic acid 44.  
Following a similar reaction sequence, the spiromorpholinone 36 was converted to 
the acid 47 (Scheme 3.18). Dissolving-metal reduction of adduct 36 produced the hydroxy 
amide 45 as a single diastereomer. The stereochemistry at the α-carbon in 45 was not 
determined. Reduction of 45 to the corresponding aminoalcohol followed by an oxidative 
cleavage provided the aldehyde 46. Pinnick oxidation of 46 provided (R)-2-
(hydroxymethyl)-2-methylhexanoic acid (47, Scheme 3.18). The R configuration of 47 was 
assigned by analogy to 44. 
 
Scheme 3.18 
3.4 Conclusions 
 Isomerically pure haloalkylidene morpholinones 8, 17 and 18 were prepared from 
alkene 12. Stereoselective cross-coupling reactions of 8 provides access to the 
diastereomerically pure alkylidene morpholinones 27, 28 and 29. The Suzuki-Miyaura 
coupling protocol is the method of choice for this conversion, but optimization of reaction 
conditions as well as extensive catalyst screening is required.  A Prins reaction of the 
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alkylidene morpholinones afforded the expected spiromorpholinones in moderate yields. 
Conversion of the spiromorpholinone 35 to (R)-α-methyltropic acid 44 confirmed the 
stereochemistry of the Prins reaction.  
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3.5 Experimental Section 
 All commercially available reagents were used without purification. All reactions 
requiring anhydrous conditions were performed under an atmosphere of dry nitrogen using 
oven dried glassware. Dichloromethane and tetrahydrofuran were distilled from CaH2 and 
sodium/benzophenone respectively. Commercial precoated silica gel plates were used for 
TLC. Silica gel for flash column chromatography was 230-400 mesh. For column 
chromatographic purifications employing CH2Cl2/MeOH/aq. NH3, the eluent was dried 
over Na2SO4 before use. All melting points are uncorrected. Optical rotations were 
measured at the sodium D line on a digital polarimeter at ambient temperature. A CEM 
Discover® microwave reactor was used for the microwave experiments. All reactions 
involving microwave heating were conducted in sealed reaction vessels. The temperature 
of the reaction mixture was monitored with an infrared sensor and the mixture reached the 
preset temperature (150 oC) in approximately 90 s. Compounds 10 and 12 were prepared 
according to literature methods. 
 
(5S,6R,Z)-2-(1-Bromoethylidene)-4,5-dimethyl-6-phenylmorpholin-3-one (8): 
 
To a solution of the alkene 12 (2.50 g, 10.8 mmol) in CH2Cl2 (10 mL) at room 
temperature was added a solution of bromine (6.50 mL of a 2.00 M soln. in H2O, 13.0 
mmol). The mixture was stirred for 30 min at room temperature (monitored by TLC) and 
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then extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were washed with 
aqueous saturated Na2S2O3 (3 x 10 mL), dried (Na2SO4) and concentrated under reduced 
pressure to provide 3.43 g (97%) of the crude bromohemiacetal 14.  
Major diastereomer: 
1H NMR (300Hz, CDCl3) ): δ 7.46-7.31 (m, 5H, ArH), 5.60 (d, 1H, J = 3.2, PhCH), 5.11 
(q, 1H, J = 6.9, CHBr), 3.72-3.68 (m, 1H, NCH), 3.08 (s, 3H, NCH3), 2.13 (d, 3H, J = 6.9, 
BrCHCH3), 1.12 (d, 3H, J = 6.7, CHCH3). 
Minor diastereomer: 
1H NMR (300Hz, CDCl3) ): δ 7.46-7.31 (m, 5H, ArH), 5.64 (d, 1H, J = 3.2, PhCH), 4.91 
(q, 1H, J = 6.7, CHBr), 3.72-3.68 (m, 1H, NCH), 3.07 (s, 3H, NCH3), 2.02 (d, 3H, J = 6.9, 
BrCHCH3), 1.05 (d, 3H, J = 6.7, CHCH3). 
The hemiacetal 14 (3.43 gm, 10.5 mmol) was dissolved in acetic anhydride (10 mL) and 
conc. H2SO4 (0.25 mL) was added to the solution. The mixture was stirred at room 
temperature for 16 h and the acetic anhydride was removed under reduced pressure. The 
residue was basified with an aqueous NaOH (10%) and the mixture was extracted with 
CH2Cl2 (3 x 20 mL). The combined extracts were dried (Na2SO4) and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel 
(hexane/EtOAc, 7:3) to provide 2.30 g (69%) of (5S,6R,Z)-2-(1-bromoethylidene)-4,5-
dimethyl-6-phenylmorpholin-3-one (8) as a pale yellow gum. 
IR (neat): 1660, 1610, 1441, 1389, 1284, 1212, 1151, 1065, 1023 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.45-7.39 (m, 4H, ArH), 7.36-7.32 (m, 1H, ArH), 5.28 (d, 
1H, J = 2.8, PhCH), 3.60 (dq, 1H, J = 2.8, 6.5, NCH), 3.08 (s, 3H, NCH3), 2.88 (s, 3H, 
C=CH3), 0.99 (d, 3H, J = 6.5, CHCH3). 
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13C NMR (75 MHz, CDCl3): δ 158.5 (C=O), 140.2 (C-C=O), 136.4 (ArC), 128.5 (2 x ArC), 
128.0 (ArC), 125.5 (2 x ArC), 117.2 (C=CBr), 77.02 (Ph-C), 58.8 (NCH), 33.6 (NCH3), 
24.9 (C=CH3), 11.9 (CHCH3). 
MS (EI, pos.): m/z 310.1 and 312.1 (M+H)+. 
HRMS (CI): m/z 310.0436 (310.0443 calc. for C14H17
79BrNO2 (M+H)
+) and 312.0423 
(312.0422 calc. for C14H17
81BrNO2 (M+H)
+). 
 
(5S,6R,Z)-2-(1-Iodoethylidene)-4,5-dimethyl-6-phenylmorpholin-3-one (18): 
 
To a solution of the alkene 12 (0.200 g, 0.865 mmol) in CH2Cl2/H2O (1:1, 5 mL) at 
room temperature was added N-iodosuccinimide (0.234 g, 1.04 mmol). The mixture was 
stirred for 30 min at room temperature (monitored by TLC) and extracted with CH2Cl2 (3 
x 20 mL). The combined extracts were washed with saturated aqueous Na2S2O3 (3 x 10 
mL), dried over Na2SO4 and concentrated under reduced pressure to provide the crude 
iodohemiacetal 16. This was dissolved in acetic anhydride (10 mL) and conc. H2SO4 (0.25 
mL) was added to the solution. The reaction was stirred at room temperature for 16 h and 
the acetic anhydride was removed under reduced pressure. The residue was basified with 
aqueous NaOH (10%) and the mixture was extracted with CH2Cl2 (3 x 20 mL). The 
combined extracts were dried (Na2SO4) and concentrated under reduced pressure. The 
residue was purified by flash chromatography on silica gel (hexane/EtOAc, 7:3) to provide 
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0.6 g (20%) of (5S,6R,Z)-2-(1-iodoethylidene)-4,5-dimethyl-6-phenylmorpholin-3-one 
(18) as a pale yellow gum. 
IR (neat): 1655, 1603, 1440, 1387, 1283, 1262, 1211, 1193, 1063, 1021 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.49-7.46 (m, 2H, ArH), 7.43-7.38 (m, 2H, ArH), 7.35-
7.30 (m, 1H, ArH), 5.29 (d, 1H, J = 2.7, PhCH), 3.60 (dq, 1H, J = 2.7, 6.6, CHCH3), 3.11 
(s, 3H, NCH3), 3.08 (s, 3H, C=CH3C), 0.97 (d, 3H, J = 6.6, CHCH3). 
13C NMR (75 MHz, CDCl3): δ 157.2 (C=O), 142.9 (C-C=O), 136.3 (ArCipso), 128.6 (2 x 
ArC), 128.0 (ArC), 125.6 (2 x ArC), 94.5 (C=CI), 78.1 (PhC), 58.9 (NCH), 33.4 (NCH3), 
28.9 (C=CH3), 11.9 (CHCH3). 
MS (CI, pos.): m/z 358.0 (M+H)+. 
HRMS (EI): m/z 357.0217 (357.0226 calc. for C14H16INO2 (M
+)). 
 
(5S,6R,Z)-2-(Butan-2-ylidene)-4,5-dimethyl-6-phenylmorpholin-3-one (20): 
 
To a solution of the bromoalkene 8 (35.0 mg, 0.11 mmol) in THF (2 mL) was added 
PdCl2(dppf)•CH2Cl2  (9.60 mg 0.01 mmol) followed by ethylmagnesium bromide (0.34 
mL, 1.00 M solution, 0.34 mmol). The reaction was stirred at room temperature for 24 h 
and aqueous saturated NH4Cl (2 mL) was added. The mixture was extracted with CH2Cl2 
(3 x 5 mL) and the combined extracts were dried (Na2SO4) and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (hexane/EtOAc, 
95:5) to provide 10 mg (35%) of (5S,6R,Z)-2-(butan-2-ylidene)-4,5-dimethyl-6-
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phenylmorpholin-3-one 20 as colorless gum. The spectral data was in agreement with the 
reported data.3c 
IR (neat): 1660, 1616, 1448, 1387, 1295, 1167, 1070, 1015 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.42-7.28 (m, 5H, ArH), 5.13 (d, 1H, J = 2.7, PhCH), 3.54 
(dq, 1H, J = 2.7, 6.6, NCH), 3.06 (s, 3H, NCH3), 2.38-2.28 (m, 2H, CH2CH3), 2.25 (s, 3H, 
C=CCH3), 1.05 (t, 3H, J = 7.5, CH2CH3), 0.95 (d, 3H, J = 6.6, CHCH3). 
13C NMR (75 MHz, CDCl3): δ 161.0 (C=O), 138.0 (C-C=O), 137.7 (ArCipso), 132.5 
(C=CCH3), 128.4 (2 x ArC), 127.7 (ArC), 125.4 (2 x ArC), 76.8 (PhCH), 58.9 (NCH), 33.5 
(NCH3), 26.9 (CCH3), 17.9 (CH2CH3), 11.97 (CH2CH3), 11.89 (CHCH3). 
MS (CI, pos.): m/z 260.2 (M+H)+. 
HRMS (EI): m/z 259.1579 (259.1572 calc. for C16H21NO2 (M
+)). 
 
(5S,6R,Z)-2-(1-(4-Methoxyphenyl)ethylidene)-4,5-dimethyl-6-phenylmorpholin-3-
one (27): 
 
To a solution of the bromoalkene 8 (0.13 g, 0.42 mmol) in THF (3 mL) were added 
4-methoxyphenylboronic acid (0.076 g, 0.50 mmol), Cs2CO3 (0.41 g, 1.26 mmol) and 
PdCl2(dppf)•CH2Cl2 (0.035 mg 0.042 mmol). The mixture was heated to reflux for 5 h, 
cooled to room temperature and aqueous saturated NH4Cl (5 ml) was added to the reaction 
mixture. The mixture was extracted with EtOAc (3 x 10 mL) and the combined extracts 
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were washed with aqueous HCl (10%), followed by aqueous NaOH (10%) and then dried 
(Na2SO4) and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (hexane/EtOAc, 1:1) to provide 110 mg (78%) of (5S,6R,Z)-
2-(1-(4-methoxyphenyl)ethylidene)-4,5-dimethyl-6-phenylmorpholin-3-one (27) as a 
colorless gum. 
IR (neat): 1654, 1606, 1508, 1438, 1386, 1289, 1246, 1175, 1107, 1026, 830, 758,              
696 cm-1.  
1H NMR (300 MHz, CDCl3) δ 7.36 (m, 2H, ArH), 7.33-7.23 (m, 3H, ArH), 7.21-7.15 (m, 
2H, ArH), 6.90-6.83 (m, 2H, ArH), 5.18 (d, 1H, J = 2.7, PhCH), 3.81 (s, 3H, OCH3), 3.60 
(dq, 1H, J = 2.7, 6.5, NCH), 3.11 (s, 3H, NCH3), 2.56 (s, 3H, C=CCH3), 0.96 (d, 3H, J = 
6.5, CHCH3). 
13C NMR (75 MHz, CDCl3): δ 161.3 (C=O), 158.4 (C-C=O), 138.5 (ArCipso), 137.0 
(ArCipso), 133.8 (ArCipso), 129.8 (2 x ArC), 128.3 (2 x ArC), 127.7 (ArC), 127.5 (ArC), 
125.3 (2 x ArC), 113.0 (C=CCH3), 77.1 (PhCH), 58.8 (NCH), 55.2 (OCH3), 33.7 (NCH3), 
20.1 (CCH3), 11.9 (CHCH3). 
MS (CI, pos.): m/z 338.3 (M+H)+. 
HRMS (EI pos.): m/z 337.1677 (337.1678 calc. for C21H23NO3 (M
+)). 
 
(5S,6R,Z)-4,5-Dimethyl-6-phenyl-2-(1-phenylethylidene)morpholin-3-one (28): 
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To a solution of the bromoalkene 8 (0.10 g, 0.32 mmol) in CH3CN (3 mL) was 
added phenylboronic acid (0.078 g, 0.645 mmol), Cs2CO3 (0.21 g, 0.64 mmol) and 
PdCl2(dppf)•CH2Cl2 (27.0 mg 0.032 mmol). The mixture was heated to reflux for 2 h, 
cooled to room temperature and aqueous saturated NH4Cl (5 mL) was added. The mixture 
was extracted with EtOAc (3 x 10 mL) and the combined extracts were washed with 
aqueous HCl (10%), followed by aqueous NaOH (10%) and then dried (Na2SO4) and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (hexane/EtOAc, 1/1) to provide 99.0 mg (75%) of (5S,6R,Z)-
4,5-dimethyl-6-phenyl-2-(1-phenylethylidene)morpholin-3-one (28) as a light brown gum. 
IR (neat): 1649, 1606, 1490, 1440, 1295, 1256, 1176, 912 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.42-7.34 (m, 3H, ArH), 7.34-7.29 (m, 2H, ArH), 7.29-
7.19 (m, 4H, ArH), 7.14-7.09 (m, 2H, ArH), 5.18 (d, 1H, J = 2.7, PhCH), 3.60 (dq, 1H, J 
= 2.7, 6.5, NCH), 3.12 (s, 3H, NCH3), 2.57 (s, 3H, C=CCH3), 0.96 (d, 3H, J = 6.5, CHCH3). 
13C NMR (75 MHz, CDCl3): δ 161.2 (C=O), 141.7 (C-C=O), 138.7 (ArCipso), 137.0 
(C=CCH3), 128.4 (2 x ArC), 128.3 (2 x ArC), 128.1 (ArC), 127.7 (2 x ArC), 127.6 (ArC), 
126.9 (ArC), 125.3 (2 x ArC), 77.03 (PhCH), 58.8 (NCH), 33.7 (NCH3), 20.1 (C=CCH3), 
12.0 (CHCH3). 
MS (CI, pos.): m/z 308.4 (M+H)+. 
HRMS (EI): m/z 307.1574 (307.1572 calc. for C20H21NO2 (M
+)). 
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(5S,6R,Z)-2-(Hexan-2-ylidene)-4,5-dimethyl-6-phenylmorpholin-3-one (29): 
 
To a solution of the bromoalkene 8 (1.00 g, 3.22 mmol) in DME (10 mL, purged 
with N2 for 10 min) was added butylboronic acid (986 mg, 9.66 mmol), K2CO3 (0.89 g, 
6.44 mmol) and Pd(PPh3)4 (372 mg 0.32 mmol). The mixture was subjected to microwave 
irradiation in a sealed microwave reaction vessel for 90 min at 150 °C and then cooled to 
room temperature. Aqueous saturated NH4Cl (10 mL) was added and the mixture was 
extracted with EtOAc (3 x 10 mL). The combined extracts were washed with aqueous HCl 
(10%), followed by aqueous NaOH (10%) and then dried (Na2SO4) and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel 
(hexane/EtOAc, 7/3) to provide 620 mg (67%) of (5S,6R,Z)-2-(hexan-2-ylidene)-4,5-
dimethyl-6-phenylmorpholin-3-one (29) as pale yellow gum.  
IR (neat): 1659, 1617, 1443, 1386, 1286, 1211, 1165 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.40-7.28 (m, 5H, ArH), 5.12 (d, 1H, J = 2.7, PhCH), 3.58-
3.50 (dq, 1H, J = 2.7, 6.6, NCH), 3.06 (s, 3H, NCH3), 2.39-2.24 (m, 2H, C=CCH2), 2.24 
(s, 3H, C=CCH3), 1.52-1.40 (m, 2H, CH2CH2), 1.38-1.28 (m, 2H, CH2CH2), 0.95 (d, 3H, 
J = 6.6, CHCH3), 0.90 (t, 3H, J = 7.2, CH2CH3). 
13C NMR (75 MHz, CDCl3): δ 161.0 (C=O), 138.4 (C-C=O), 137.7 (ArCipso), 131.2 
(C=CCH2CH3), 128.4 (2 x ArC), 127.7 (ArC), 125.4 (2 x ArC), 76.8 (PhCH), 58.9 (NCH), 
33.44 (NCH3), 33.42 (C=CCH2), 29.6 (CH2), 22.6 (CH2), 18.4 (C=CCH3), 14.0 (CH2CH3), 
11.9 (CHCH3). 
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MS (CI, pos.): m/z 288.3 (M+H)+. 
HRMS (EI pos.): m/z 287.1887 (287.1885 calc. for C18H25NO2 (M
+)). 
 
(5S,6R,Z)-4,5-Dimethyl-2-(4-methylpentan-2-ylidene)-6-phenylmorpholin-3-one 
(30): 
 
To the solution of bromoalkene 8 (70.0 mg, 0.23 mmol) in DME (3 mL) was added 
(2-methylpropyl)boronic acid (70.0 mg, 0.69 mmol), K2CO3 (63 mg, 0.46 mmol) and 
Pd(PPh3)4 (26.0 mg 0.02 mmol). The reaction was subjected to microwave irradiation in a 
sealed microwave reaction vessel for 90 min at 150 °C and then cooled to room 
temperature. Aqueous saturated NH4Cl (2mL) was added and the mixture was extracted 
with EtOAc (3 x 10 mL). The combined extracts were washed aqueous HCl (10%), 
followed by aqueous NaOH (10%) and then dried (Na2SO4) and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel 
(hexane/EtOAc, 7:3) to provide 14.0 mg (20%) of (5S,6R,Z)-4,5-dimethyl-2-(4-
methylpentan-2-ylidene)-6-phenylmorpholin-3-one (30) as a gum. 
IR (neat): 1658, 1616, 1446, 1385, 1292, 1243, 1165 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.43-7.29 (m, 5H, ArH), 5.10 (d, 1H, J = 2.7, PhCH), 3.57-
3.50 (dq, 1H, J = 2.7, 6.5, NCH), 3.06 (s, 3H, NCH3), 2.28-2.14 (m, 5H, C=CCH2), 2.22 
(s, 3H, C=CCH3), 1.95-1.82 (m, 1H, CH2CH), 0.96 (d, 3H, J = 6.6, CHCH3), 0.94 (d, 3H, 
J = 6.6, CHCH3), 0.89 (d, 3H, J = 6.5, CHCH3). 
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13C NMR (75 MHz, CDCl3): δ 161.0 (C=O), 138.8 (C-C=O), 137.7 (ArCipso), 130.5 
(C=CCH3), 128.4 (2 x ArC), 127.7 (ArC), 125.4 (2 x ArC), 76.8 (PhCH), 58.9 (NCH), 42.9 
(CHCH2), 33.5 (NCH3), 27.1 (C=CCH3), 22.7 (2 x CHCH3), 18.9 (CH2CH), 12.0 (CHCH3). 
MS (APCI, pos.): m/z 288.3 (M+H)+. 
HRMS (EI pos.): m/z 287.1883 (287.1885 calc. for C18H25NO2 (M
+)). 
 
(8R,9S)-5,9,10-Trimethyl-5,8-diphenyl-1,3,7-trioxa-10-azaspiro[5.5]undecan-11-one 
(35): 
 
To a solution of the alkene 28 (360 mg, 1.17 mmol ) and paraformaldehyde (176 
mg, 5.86 mmol) in glacial acetic acid (3 mL) was added conc. H2SO4 (two drops) and the 
mixture was heated for 45 min in a preheated oil bath set at 85 °C. The mixture was cooled 
to room temperature and the acetic acid was removed under reduced pressure. The residue 
was neutralized with aqueous NaOH (10%) and then was extracted with CH2Cl2 (4 x 5 
mL). The combined extracts were dried (Na2SO4) and concentrated under reduced pressure. 
The residue was purified by flash chromatography on silica gel (hexane/EtOAc, 6:4) to 
provide 270 mg (63%) of 35 as a colorless foam. 
IR (neat): 1656, 1493, 1448, 1383, 1238, 1161, 1091, 1029, 986 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.38-7.29 (m, 7H, ArH), 7.22-7.20 (m, 3H, ArH), 5.23 (d, 
1H, J = 2.9, PhCH), 5.14 (d, 1H, J = 5.7, OCH2), 5.03 (d, 1H, J = 10.3, OCH2), 4.92 (d, 
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1H, J = 5.7, OCH2), 3.83 (d, 1H, J = 10.3, OCH2), 3.22 (dq, 1H, J = 2.9, 6.6, NCH), 2.93 
(s, 3H, NCH3), 2.04 (s, 3H, C-CH3), -0.07 (d, 3H, J = 6.6, CHCH3). 
13C NMR (75 MHz, CDCl3): δ 164.2 (C=O), 142.2 (ArCipso), 137.0 (ArCipso), 128.5 (2 x 
ArC), 128.2 (2 x ArC), 127.8 (ArC), 126.9 (2 x ArC), 126.8 (ArC), 125.4 (2 x ArC), 99.8 
(O-C-O), 86.9 (OCH2O), 71.8 (OCH2), 71.3 (PhCH), 59.1 (NCH), 44.8 (Ph-C-CH3), 33.9 
(NCH3), 22.2 (C-CH3), 10.6 (CHCH3). 
MS (CI, pos.): m/z 368.4 (M+H)+. 
HRMS (CI pos.): m/z 368.1862 (368.1862 calc. for C22H26NO4 (M+H)
+). 
[α]D20 = + 11.0 (c 1, CH2Cl2). 
 
(8R,9S)-5-Butyl-5,9,10-trimethyl-8-phenyl-1,3,7-trioxa-10-azaspiro[5.5]undecan-11-
one (36): 
 
To a solution of the alkene 29 (50.0 mg, 0.17 mmol ) and paraformaldehyde (30.0 
mg, 0.87 mmol) in glacial acetic acid (3 mL) was added conc. H2SO4 (two drops) and the 
mixture was heated for 15 min in a preheated oil bath set at 85 °C. The mixture was cooled 
to room temperature and the acetic acid was removed under reduced pressure. The residue 
was neutralized with aqueous NaOH (10%) and the mixture was extracted with CH2Cl2 (3 
x 5 mL). The combined extracts were dried (Na2SO4) and concentrated under reduced 
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pressure. The residue was purified by flash chromatography on silica gel (hexane/EtOAc, 
7:3) to provide 31.0 mg (57%) of 36 as a colorless foam. 
IR (neat): 1656, 1457, 1380, 1288, 1139, 1090, 1024, 976 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.42-7.33 (m, 5H, ArH), 5.42 (d, 1H, J = 3.0, PhCH), 5.00 
(d, 1H, J = 5.6, OCH2O), 4.97 (d, 1H, J = 5.6, OCH2O), 4.03 (d, 1H, J = 10.8, OCH2), 3.72 
(d, 1H, J = 10.8, OCH2), 3.50 (dq, 1H, J = 3.0, 6.5, NCH), 3.00 (s, 3H, NCH3), 1.51-1.48 
(m, 2H, CH2), 1.44 (s, 3H, C-CH3), 1.32-1.21 (m, 4H, CH2), 1.18-1.15 (m, 1H, CH2), 0.98 
(d, 3H, J = 6.5, CHCH3), 0.90 (t, 3H,  J = 7.1, CH2CH3). 
13C NMR (75 MHz, CDCl3) δ 164.8 (C=O), 137.1 (ArCipso), 128.6 (2 x ArC), 127.8 (ArC), 
125.4 (2 x ArC), 99.8 (O-C-O), 87.5 (OCH2O), 73.0 (OCH2), 70.5 (PhCH), 59.0 (NCH), 
41.0 (CCH3), 33.9 (NCH3), 33.6 (C-CH2), 25.3 (CH2), 23.7 (CH2), 19.4 (C-CH3), 14.1 
(CHCH3), 12.5 (CH2CH3). 
MS (CI, pos.): m/z 348.3 (M+H)+. 
HRMS (EI): m/z 347.2105 (347.2097 calc. for C20H29NO4, (M
+)); 348.2172 (348.2175 calc. 
for C20H30NO4 (M+H)
+). 
[α]D20 = – 46.8 (c 1, CH2Cl2).  
 
(3R)-2,4-Dihydroxy-N,3-dimethyl-3-phenylbutanamide (41): 
 
To anhydrous liquid ammonia (6 mL, distilled over sodium) was added sodium 
metal (25.0 mg, 1.09 mmol) at –78 C and the mixture was stirred for 15 min. To the 
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resulting blue solution was added a solution of 35 (50.0 mg, 0.14 mmol) in anhydrous THF 
(1.5 mL) and the mixture was stirred for 10 min at –78°C. A mixture of MeOH/H2O (3:1, 
2 mL) was added and the reaction mixture was brought to ambient temperature and stirred 
for 30 min to remove ammonia. The resulting solution was concentrated under reduced 
pressure and the residue was purified by flash chromatography on silica gel 
(hexane/EtOAc, 2:8) to provide 15.0 mg (50%) of 41 as a white solid (dr = 2:1) 
Minor diastereomer: 
IR (neat): 3351 (br), 2935, 1643, 1541, 1455, 1409, 1371, 1247, 1155, 1081, 1028, 910  
cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.54-7.51 (m, 2H, ArH), 7.41-7.36 (m, 2H, ArH), 7.32-
7.29 (m, 1H, ArH), 6.80 (br s, 1H, NH), 4.59 (br s, 1H, CHOH), 4.32-4.29 (br t, 1H, J = 
5.8, OH), 4.00 (br dd, 1H, J = 3.3, 11.5, OCH2), 3.64 (br dd, 1H, J = 5.5, 11.5, OCH2), 2.87 
(d, 3H, J = 5.0, NCH3), 1.60 (br s, 1H, OH), 1.30 (s, 3H, C-CH3). 
13C NMR (75 MHz, CDCl3): δ 173.1 (C=O), 143.6 (ArCipso), 129.0 (2 x ArC), 127.3 (ArC), 
126.6 (2 x ArC), 77.0 (C(O)CH), 70.3 (OCH2), 47.8 (Ph-C), 25.8 (NCH3), 15.8 (CCH3). 
 [α]D20 = – 52.2 (c 1, CH2Cl2). 
Major diastereomer: 
IR (neat): 3353 (br), 2932, 1645, 1539, 1453, 1408, 1290, 1246, 1159, 1085, 1023 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.47-7.38 (m, 4H, ArH), 7.35-7.29 (m, 1H, ArH), 5.05 (br 
s, 1H, NH), 4.52 (br s, 1H, CHOH), 4.12 (d, 1H, J = 11.3, OCH2), 3.82 (s, 1H, OH), 3.65 
(d, 1H, J = 11.3, OCH2), 3.10 (s, 1H, OH), 2.63 (d, 3H, J = 4.9, NCH3), 1.40 (s, 3H, C-
CH3). 
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13C NMR (75 MHz, CDCl3): δ 172.6 (C=O), 141.9 (ArCipso), 129.1 (2 x ArC), 127.6 (ArC), 
126.9 (2 x ArC), 76.9 (PhCH), 70.7 (OCH2), 47.2 (Ph-C), 26.2 (NCH3), 16.7 (C-CH3). 
MS (CI, pos.): m/z 206.1 (M–OH); 224.1 (M+H)+. 
HRMS (CI): m/z 224.1292 (224.1287 calc. for C12H18NO3 (M+H)
+). 
[α]D20 =  – 31.5 (c 1, CH2Cl2). 
 
(R)-3-hydroxy-2-methyl-2-phenylpropanoic acid (44): 
 
To a stirred solution of the hydroxy amide 41 (45.0 mg, 0.20 mmol) in THF (1 mL) 
at 0 ºC was added a solution of BH3•THF (1.21 mL of 1M solution in THF, 1.21 mmol) 
and the mixture was heated to reflux for 24 h. The mixture was cooled to 0 °C, aqueous 
HCl (3M, 2 mL) was added, the mixture was stirred at room temperature for 45 min and 
then concentrated under reduced pressure. The residue was basified (pH >10) with aqueous 
NaOH then extracted with CH2Cl2 (4 x 5 mL).  The combined extracts were dried (Na2SO4) 
and concentrated under reduced pressure to provide 30.0 mg (71%) of the amino alcohol 
(42). This was used further without purification.  
To a stirred solution of the amino alcohol 42 (30.0 mg, 0.14 mmol) in MeOH/H2O (100/1, 
2 mL) at 0 ºC was added NaIO4 (122 mg, 5.73 mmol). The mixture was stirred at 0 ºC for 
30 min and cold, aqueous saturated sodium bicarbonate was added. The mixture was 
extracted with ethyl acetate (3 x 15 mL) and the combined extracts were dried (Na2SO4) 
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and concentrated under reduced pressure to provide 21.0 mg of the aldehyde 43 as colorless 
oil. This was used further without any purification.  
To a solution of the aldehyde 43 (21.0 mg, 0.13 mmol) in t-butyl alcohol (3 mL) were 
added a solution of 2-methyl-2-butene (0.07 mL of 2 M solution in THF, 1.40 mmol) 
followed by a solution of NaClO2 (80%, 64.0 mg, 0.56 mmol) and NaH2PO4 (67.0 mg, 1.40 
mmol) in H2O (1 mL). The resulting solution was stirred at room temperature for 12 h and 
the mixture was then concentrated under reduced pressure. The residue was dissolved in 
CH2Cl2 (3 mL), and aqueous HCl (10%, 0.75 ml) and brine (0.75 mL) were added. The 
resulting mixture was extracted with CH2Cl2 (3 × 5 mL). The combined extracts were dried 
(Na2SO4) and concentrated under reduced pressure to provide 19.0 mg (52% from 41) of 
(R)-3-hydroxy-2-methyl-2-phenylpropanoic acid (44) as a colorless solid.  
IR (neat): 3061 (br), 1701, 1498, 1454, 1379, 1254, 1157, 1122, 1027 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.39-7.29 (m, 5H, ArH), 4.12 (d, 1H, J = 11.5, OCH2), 3.70 
(d, 1H, J = 11.5, OCH2), 1.70 (s, 3H, CH3). 
13C NMR (75 MHz, CDCl3): δ 180.9 (C=O), 139.6 (ArCipso), 128.7 (2 x ArC), 127.7 (ArC), 
126.3 (2 x ArC), 69.1 (OCH2), 52.4 (Ph-C), 20.1 (C-CH3). 
MS (CI, neg.): m/z 179.1 (M–H) ̶. 
HRMS (CI pos.): m/z 181.0872 (181.0865 calc. for C10H13O3 (M+H)
+). 
[α]D20 = +23.6 (c 1.9, EtOH), lit.15 [α]D20 = +26.6 (c 2, EtOH), lit.14 [α]D20 = +27.0 (c 2, 
EtOH). 
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(3R)-2-Hydroxy-3-(hydroxymethyl)-N,3-dimethylheptanamide (45): 
 
To anhydrous liquid ammonia (6 mL, distilled over sodium) was added sodium 
metal (100 mg, 4.32 mmol) at –78 C and the mixture was stirred for 15 min. To the 
resulting blue solution was added a solution of 36 (250 mg, 0.72 mmol) in anhydrous THF 
(1.5 mL) and the mixture was stirred for 10 min at –78°C. A mixture of MeOH/H2O (3:1, 
2 mL) was added and the reaction mixture was brought to ambient temperature and stirred 
for 30 min to remove ammonia. The resulting solution was concentrated under reduced 
pressure and the residue was purified by flash chromatography on silica gel 
(hexane/EtOAc, 2:8) to provide 51.0 mg (35%) of 45 as a colorless solid. 
IR (neat): 3353, 2930, 1642, 1540, 1462, 1409, 1297, 1027 cm-1. 
1H NMR (300 MHz, CDCl3): δ 6.85 (br s, 1H, NH), 4.06 (s, 1H, CHOH), 3.76 (br s, 1H, 
CO2H), 3.57 (dd, 2H, J = 11.5, OCH2 ), 2.86 (d, 3H, J = 5.0, NCH3), 1.50-1.42 (m, 1H, 
CH2), 1.39-1.16 (m, 5H, 3 x CH2), 0.98 (s, 3H, C-CH3), 0.90 (t, 3H, J = 6.7, CH2CH3). 
13C NMR (75 MHz, CDCl3): δ 174.0 (C=O), 78.0 (CHOH), 69.1 (OCH2), 41.8 (C-CH3), 
32.9 (NCH3), 25.8 (CH2), 25.6 (C-CH3), 23.6 (CH2CH3), 19.1 (CH2), 14.1 (CH2). 
MS (CI, pos.): m/z 186.1 (M–OH)+; 204.1 (M+H)+. 
HRMS (CI): m/z 204.1600 (204.1600 calc. for C10H22NO3 (M+H)
+). 
[α]D20 = + 15.5 (c 1.3, CH2Cl2). 
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(R)-2-(Hydroxymethyl)-2-methylhexanoic acid (47): 
 
To a stirred solution of the hydroxy amide 45 (43.0 mg, 0.21 mmol) in THF (1 mL) 
at 0 ºC was added a solution of BH3•THF (2.1 mL of 1 M solution in THF, 2.1 mmol). The 
mixture was heated to reflux for 24 h. The reaction mixture was cooled to 0 °C and a 
solution of 3M HCl (2 mL) was added. The reaction mixture was stirred at room 
temperature for 45 min and the solvent was removed under reduced pressure. The residue 
was basified (pH >10) with aqueous NaOH and the mixture was extracted with CH2Cl2 (4 
x 5 mL).  The combined extracts were dried (Na2SO4) and concentrated under reduced 
pressure to provide 20.0 mg (50%) of the amino alcohol. This was used further without 
purification.  
To a stirred solution of the amino alcohol (20.0 mg, 0.11 mmol) in MeOH/H2O (100/1, 2 
mL) at 0 ºC was added NaIO4 (90.0 mg, 0.42 mmol) and the mixture was stirred at 0 ºC for 
30 min. A cold, saturated aqueous solution of sodium bicarbonate was added and the 
mixture was extracted with ethyl acetate (3 x 5 mL). The combined extracts were dried 
(Na2SO4) and concentrated under reduced pressure to provide 15.0 mg of the aldehyde 46 
as a colorless oil. This was used further without any purification.  
To a solution of the aldehyde 46 in t-butyl alcohol (3 mL) was added a solution of 2-methyl-
2-butene (0.06 mL, 2 M solution in THF, 0.12 mmol) followed by a solution of NaClO2 
(80%, 38.0 mg, 0.42 mmol) and NaH2PO4 (51.0 mg, 0.42 mmol) in H2O (1 mL). The 
solution was stirred at room temperature for 12 h and the resulting mixture was 
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concentrated under reduced pressure. The residue was dissolved in CH2Cl2 (3 mL), and 
aqueous HCl (10%, 0.75 mL) and brine (0.75 mL) were added. The mixture was extracted 
with CH2Cl2 (3 × 5 mL) and the combined extracts were dried (Na2SO4) and concentrated 
to provide 6.0 mg (18% from 45) of (R)-2-(hydroxymethyl)-2-methylhexanoic acid (47) as 
a colorless oil.  
IR (neat): 3439 (br), 2929, 1699, 1461, 1407, 1381, 1282, 1220, 1160, 1032 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.0-5.5 (br, CO2H), 3.77-3.76 (br d, 1H, J = 9.5, OCH2), 
3.54-3.53 (br d, 1H, J = 9.5, OCH2), 1.69-1.53 (m, 2H, CH2), 1.30-1.26 (m, 4H, CH2) 1.22 
(s, 3H, C-CH3), 0.90 (t, 3H, J = 6.5, CH2CH3). 
13C NMR (75 MHz, CDCl3): δ 182.9 (C=O), 68.0 (OCH2), 47.7 (C-C=O), 35.5 (C-CH3), 
26.3 (CH2), 23.2 (CH2), 19.4 (CH2), 13.9 (CH2CH3). 
MS (CI, neg.): m/z 159.1 (M–H) ̶. 
HRMS (CI neg.): m/z 159.1028 (159.1021 calc. for C8H15O3 (M–H) ̶ ). 
[α]D20 = –16.7 (c 0.6, CH2Cl2). 
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3.7 Selected 1H NMR and 13C NMR Spectra 
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Chapter 4 
Studies on Alkylidene Dioxolanones as Potential Substitutes for 
Ephedrine-Derived Alkylidene Morpholinones 
4.1 Introduction 
In addition to the chemistry described in Chapter 2 and Chapter 3 of this thesis, the 
Pansare group has explored the synthetic utility of (1R,2S)-ephedrine hydrochloride as an 
efficient chiral controller in the synthesis of a variety of enantiomerically pure, 
functionalized molecules. Examples of such applications include the synthesis of 
enantiomerically-enriched -hydroxy acid derivatives, (S)-pantalactone and its analogues,1 
functionalized medium-sized oxacycles,1c an advanced intermediate to the marine natural 
product Laurencin,1d (-)-quinic acid,1e and a variety of β-substituted γ-butyrolactones.1f 
However, a limitation of this methodology is the destructive removal of ephedrine at the 
end of the synthetic sequence. In addition, ephedrine has gone from being a cheap and 
easily available substance to a controlled substance which can no longer be purchased from 
the usual suppliers of research chemicals. In light of this, it is necessary to find either a 
replacement for ephedrine, or to develop an alternative synthetic methodologies that are 
based on the knowledge derived from the ephedrine-based system. Investigations aimed at 
both these objectives are ongoing in the Pansare group. 
4.2 Objective 
The objective of the present study was to investigate the synthesis of -hydroxy 
acid derivatives from alkylidene dioxolanone derivatives rather than ephedrine-derived 
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morpholinones. It was reasoned that achiral spirodioxolanones such as 2 could be used as 
substrates for asymmetric epoxidation reactions (Scheme 4.1) to provide enantiomerically 
enriched epoxides 3. This assumption was based on the known reactivity of the 
corresponding alkylidene morpholinones in which the exocyclic double bond functions as 
an enol ether (Chapter 2 and Chapter 3 of this thesis) and not as an electron-deficient 
acrylate.  The enantiomerically-enriched epoxide intermediates can potentially be 
converted into ,β-difunctionalized α-hydroxy acids or β-functionalized α-hydroxy acids 
as shown in Scheme 4.1.  
Scheme 4.1 Proposed synthesis of functionalized hydroxy acids from epoxy 
dioxolanones 
Such hydroxy acids have numerous synthetic applications2 and are important 
building blocks for natural product synthesis.3 Notably, -hydroxy β-amino acids 
constitute an important class of amino acids with a wide range of applications. They are 
present in many natural products and are also key components of many pharmaceuticals.4 
β-Amino acids are also used as building blocks for chiral heterocycles4c and in peptides 
with biological and catalytic properties.5 
 
4.3 Results and Discussion 
 Synthesis of the required alkylidene dioxolanones was initiated by condensation of 
glycolic acid (5) and cyclohexanone (6) according to the literature procedure6 to provide 
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the spirodioxolanone 1. Bromination of 1 using N-bromosuccinimide (NBS)6 followed by 
treatment of the crude bromide 7 with triphenylphosphine provided the phosphonium salt 
8 (Scheme 4.2). 
 
 
Scheme 4.2 
Conversion of 8 into the alkylidene dioxolanones was achieved via a conventional 
Wittig reaction. Treatment of 8 with DABCO (1,4-diazabicyclo[2.2.2]octane) generated 
the phosphorane 9 which was treated in situ with benzaldehyde to obtain the Z-alkene 10 
(Scheme 4.3) as the only product. However, treatment of 9 with isobutyraldehyde furnished 
a mixture of the Z-alkene 11 and the E-alkene 12. Separation of 11 and 12 by 
chromatography is difficult and, although some separation was achieved, 11 and 12 are 
both obtained as mixtures which contain approximately 10% of the isomeric alkene. 
 
Scheme 4.3 
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 With the alkylidene dioxolanones in hand, the next task was to test the feasibility 
of conducting an asymmetric epoxidation reaction of the double bond. It was decided to 
employ the Shi epoxidation7 for this purpose since it is known to work for electron-rich as 
well as electron-deficient alkenes. In the Shi epoxidation, the epoxidizing agent is a chiral 
dioxirane which is formed in situ using an oxidant and the chiral ketone 14. This ketone 
was prepared from D-fructose (13) in two steps (Scheme 4.4) following the reported 
procedure.8 In the presence of Oxone®9 (KHSO5•1/2KHSO4•1/2K2SO4) or H2O210 as an 
oxidant, 14 forms the chiral dioxirane 15 which can epoxidize a variety of alkenes (Scheme 
4.4). This catalyst system also shows tolerance to a wide range of functional groups on the 
alkene.7  
 
Scheme 4.4 Epoxidation of alkenes using dioxirane 16. 
 Unfortunately, alkene 10 did not furnish the required epoxide 17 under the Shi 
epoxidation conditions and starting alkene 10 was recovered.  It may be noted that the Shi 
epoxidation of electron-deficient alkenes as well as electron-rich alkenes is known11 and 
hence, the reasons for the lack of reactivity of 10 are not clear. The epoxidation of alkenes 
11 and 12 was not examined because these alkenes could not be obtained as single 
diastereomers. 
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Scheme 4.5. Attempted epoxidation of alkene 11 with Shi’s catalyst 14. 
In spite of the difficulties in obtaining an enantiomerically enriched epoxy 
spirodioxolanone, it was decided to examine the epoxidation of alkene 11 with traditional 
epoxidation reagents with the intention of investigating the reactivity of the epoxy 
dioxolanone system. Interestingly, 11 furnished the epoxide 17 in moderate yield (54%, 
Scheme 4.7) on treatment with m-CPBA. 
 
 
Scheme 4.6 Epoxidation of 11 with m-CPBA. 
It was anticipated that the epoxide 17 would function as an ambident electrophile. 
Treatment of 17 with nucleophiles was expected to provide ring-opening products such as 
20 arising from addition to the ‘terminal’ carbon of the epoxide,12 whereas nucleophilic 
addition in the presence of a Lewis acid was anticipated to proceed at the acetal carbon end 
of the epoxide (23, Scheme 4.7).1c   
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Scheme 4.7 
However, treatment of epoxide 17 with nitrogen nucleophiles (BnNH2, Bu4NSCN) 
lead to complex mixtures, presumably due to competing reactions of the amine with the 
lactone carbonyl. The expected ring-opened products 20 or 23 could not be detected by 1H 
NMR spectroscopy of the crude products. Furthermore, a Lewis acid mediated allylation 
of 17 resulted in allylation at the non-acetal end of the epoxide to provide 24 (5:1 mixture 
of diastereomers) instead of the anticipated product 25 (Scheme 4.8). The mixture of 
diastereomers may arise either from an SN1-type substitution at the benzylic carbon or due 
to a thermodynamically controlled equilibration of the hemiacetal stereocenter.  
 
Scheme 4.8 Allylation of epoxide 17. 
The formation of 24 was confirmed by analysis of its 1H NMR spectrum in which 
the benzylic methine appeared as a doublet of doublet due to coupling with the allylic 
methylene group. In addition, the COSY 1H NMR spectrum of 24 showed a correlation 
between the benzylic methine and the allylic methylene group. These interactions are not 
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possible for the isolated benzylic methine in 25. The formation of 24 from 17 is unexpected 
and is in contrast to the reactivity of the spiro epoxide 26 obtained from an ephedrine-
derived alkylidene morpholinones. Allylation of 26 proceeds at the acetal carbon to provide 
27 as the only isolable product (Scheme 4.9).1c 
 
 
 
Scheme 4.9 
 It is plausible that the benzylic position in 17 is activated towards 
nucleophilic addition which leads to the formation of 24 before the generation of an 
oxonium ion from the ring oxygen-assisted opening of the epoxide. The reactivity of an 
alkyl analog of 17, in which the phenyl group is replaced by an alkyl group, needs to be 
explored to gain insight into the observed reactivity of 17.   
Due to the difficulties encountered in the stereoselective synthesis of dialkyl 
alkylidene spirodioxolanones such as 11 and 12 and the unreactivity of the 
spirodioxolanone 10 in the Shi epoxidation, further studies with 10, 11 and 12 were 
discontinued. 
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4.4 Conclusion 
 Although the alkylidene dioxolanones 10, 11, and 12 prepared in this study may 
have synthetic potential, as evidenced by the conversion of 17 to 24, an extensive screening 
of the reactivity of these alkylidene dioxolanones is required. Asymmetric epoxidation 
methods such as the Jacobson epoxidation or epoxidation under phase transfer conditions 
can be explored to access enantiomerically enriched epoxides such as 17. Apart from 
epoxidation, asymmetric dihydroxylation also presents an interesting way to prepare β-
functionalized α-hydroxy acids 4 from alkenes 10, 11 and 12.  
 
Scheme 4.10 
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4.5 Experimental Section 
 All commercially available reagents were used without purification. All reactions 
requiring anhydrous conditions were performed under an atmosphere of dry nitrogen using 
oven-dried glassware. CH2Cl2 and THF were distilled from CaH2 and 
sodium/benzophenone respectively. Commercial precoated silica gel plates were used for 
TLC. Silica gel for flash column chromatography was 230-400 mesh. All melting points 
are uncorrected. Optical rotations were measured at the sodium D line on a digital 
polarimeter at ambient temperature. Compounds 10 and 12 were prepared according to 
literature methods.8 
 
1,4-Dioxaspiro[4.5]decan-2-one (1): 
 
  To a solution of cyclohexanone (32.01 g, 0.326 mol) and p-TsOH (0.075 g, 0.4 
mmol) in toluene (150 mL) was added, dropwise over 1 h, a solution of glycolic acid (20 
g, 0.262 mol) in water (10 mL). The mixture was heated to reflux for a further 5 h (the 
water produced in the reaction was removed via a Dean and Stark apparatus) and cooled to 
ambient temperature. Anhydrous sodium acetate (0.119 g, 1.45 mmol) was added and the 
mixture was stirred for 1 h. The mixture was filtered and the filtrate was evaporated under 
reduced pressure to provide a yellow oil which was fractionally distilled to yield 
cyclohexanone (b.p. 20 °C, 0.5 mmHg), followed by the dioxolanone 1 (15.4 g, 38%) as a 
colourless liquid which solidified upon storage in the referigerator.  
B.p. 70 °C, 0.5 mm Hg. 
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IR (neat): 1788, 1451, 1371, 1269, 1215, 1150, 1080, 1037 920 cm-1. 
1H NMR (300 MHz, CDCl3): δ 4.33 (s, 2H, C(O)CH2), 1.87-1.82 (m, 2H, CH2), 1.77-1.72 
(m, 2H, CH2), 1.70-1.64 (m, 4H, CH2), 1.52-1.41 (m, 2H, CH2). 
13C NMR (75 MHz, CDCl3): δ 172.6 (C=O), 113.5 (O-C-O), 63.2 (C(O)CH2), 35.3 (2 x 
CH2), 24.4 (CH2), 22.9 (2 x CH2). 
MS (EI, pos.): m/z 157.1 (M+H)+. 
 
(3-Oxo-1,4-dioxaspiro[4.5]decan-2-yl)triphenylphosphonium bromide (8):  
 
 A mixture of N-bromosuccinimide (3.89 g, 21.8 mmol), freshly-distilled 
dioxolanone 1 (3.10 g, 19.8 mol) and AIBN (8 mg, 0.05 mmol) in CCl4 (30 mL) was heated 
to reflux and irradiated with a 300 W tungsten lamp. The ensuing vigorous reaction was 
controlled by switching off the lamp occasionally. After 30 min, the resulting pale yellow 
suspension was cooled to 5 °C and the colorless precipitate of succinimide was filtered off 
and washed with CCl4 (2 x 20 mL). The filtrate and the washings were combined and the 
solution was concentrated under reduced pressure to provide 4.51 g (97%) of the bromide 
7 as a pale yellow, lachrymatory oil. This was pure by 1H NMR and was used further 
without any purification. 
1H NMR (500 MHz, CDCl3): δ 6.52 (s, 1H, CHBr), 2.20-2.08 (m, 2H, CH2), 1.82-1.72 (m, 
6H, CH2), 1.56-1.44 (m, 2H, CH2).  
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The bromide 7 (4.51 g, 19.2 mmol) was dissolved in toluene (50 mL) and a solution 
of triphenylphosphine (5.03 g, 19.2 mmol) in toluene (25 ml) was added dropwise over 1 
h. The resulting solution was stirred overnight and the colourless precipitate was filtered 
and washed with toluene (2 x 100 ml), and ether (3 x 100 mL). The residue was purified 
by dissolution in ethanol followed by precipitation with ether to provide 5.1 g (52%) of 
phosphonium bromide 8 as a colourless solid. 
IR (neat): 1783, 1436, 1266, 1204, 1150, 1106, 1057, 920 cm-1. 
1H NMR (300 MHz, (CD3)2CO): δ 8.07-8.03 (m, 9H, ArH), 7.91-7.87 (m, 7H, ArH and 
CHC(O)), 2.10-2.08 (m overlapped with (CD3)2CO, 2H, CH2), 1.78-1.71 (m, 1H, CH2), 
1.64-1.58 (m, 1H, CH2), 1.56-1.50 (m, 1H, CH2), 1.49-1.40 (m, 3H, CH2), 1.38-1.35 (m, 
1H, CH2), 1.33-1.28 (m, 1H, CH2). 
13C NMR (75 MHz, CDCl3) δ 165.7 (C=O), 135.7 (ArC), 134.8 (ArC), 130.4 (ArC), 116.1 
(ArCipso), 114.9 (OCO), 71.2 (d, J = 63.0, CHPPh3), 36.2 (CH2), 35.5 (CH2), 24.2 (CH2), 
23.08 (CH2), 23.04 (CH2). 
MS (EI, pos.): m/z 417.5 (M-Br)+. 
 
(Z)-3-Benzylidene-1,4-dioxaspiro[4.5]decan-2-one (10): 
 
  To the solution of phosphonium bromide 8 (1 g, 2.012 mmol) was added a solution 
of DABCO (0.237 g, 2.112 mmol) in toluene (25 mL) at 110 °C  under nitrogen. The yellow 
colour of the phosphorane 9 was seen immediately and the mixture was stirred for 3-5 min. 
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Freshly distilled benzaldehyde (0.20 mL, 1.91 mmol) was added and the solution was 
heated to reflux for 1 h. The mixture was cooled to 5 °C and filtered to remove the 
precipitated DABCO hydrobromide. The filtrate was concentrated under reduced pressure 
to provide with an oily residue which was triturated with petroleum ether (5 x 10 mL) to 
remove most of the triphenylphosphine oxide. The resulting oily solid was purified by flash 
chromatography (hexane/ether, 4:1) to give a pale yellow solid. This was crystallized from 
ethanol-water to provide 0.330 g (67%) of (Z)-3-benzylidene-1,4-dioxaspiro[4.5]decan-2-
one (10) as a colorless solid. 
IR (neat): 1781, 1669, 1448, 1367, 1271, 1239, 1188, 1114, 1039 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.67 (d, 2H, J = 7.5, ArH), 7.39 (t, 2H, J = 7.5,  ArH), 7.31 
(t, 1H, J = 7.5,  ArH), 6.45 (s, 1H, C=CH), 1.94-1.86 (m, 4H, CH2), 1.84-1.75 (m, 4H, 
CH2), 1.59-1.50 (m, 2H, CH2). 
13C NMR (75 MHz, CDCl3): δ 163.8 (C=O), 137.0 (C-C=O), 133.1 (ArCipso), 129.6 (2 x 
ArC), 128.7 (2 x ArC), 128.5 (ArC), 112.7 (C=CH), 108.1 (O-C-O), 36.3 (2 x CH2), 24.2 
(CH2), 23.0 (2 x CH2). 
MS (EI, pos.): m/z 245.1 (M+H)+. 
 
(E)-3-(2-Methylpropylidene)-1,4-dioxaspiro[4.5]decan-2-one (11) and  
(Z)-3-(2-methylpropylidene)-1,4-dioxaspiro[4.5]decan-2-one (12): 
To a solution of the phosphonium bromide 8 (2.74 g, 5.51 mmol) (70 mL) was 
added a solution of DABCO (0.65 g, 5.79 mmol) in toluene (5 mL) at 110 °C under 
nitrogen. The yellow colour of the phosphorane 9 was seen immediately and the mixture 
was stirred for 3-5 min. Isobutyraldehyde (2.01 g, 27.9 mmol) was added and the solution 
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was heated to reflux for 1.5 h. The mixture was cooled to 5 °C and filtered to remove the 
precipitated DABCO hydrobromide. The filtrate was concentrated under reduced pressure 
to provide with an oily residue which was triturated with petroleum ether (5 x 10 mL) to 
remove most of the triphenylphosphine oxide. The resulting oil was purified by flash 
chromatography (hexane/ether, 4:1) gave 30 mg (2%) of 11, 25 mg (2%) of 12 and 710 mg 
of mixture of 11 and 12 (61%) all as a colourless oils. 
(Z)-3-(2-Methylpropylidene)-1,4-dioxaspiro[4.5]decan-2-one (11): 
 
IR (neat): 1789, 1454, 1368, 1299, 1224, 1148, 1104, 1036, 940 cm-1. 
1H NMR (500 MHz, CDCl3): δ 5.50 (d, 1H, J = 9.0, C=CH), 2.73-2.66 (m, 1H, CH3CH), 
2.33-2.17 (m, 1H, CH2), 1.83-1.72 (m, 10H, CH2), 1.07 (d, 6H, J = 6.7, 2 x CH3). 
13C NMR (75 MHz, CDCl3): δ 163.5 (C=O), 136.9 (C-C=O), 117.4 (C=CH), 111.5 (O-C-
O), 36.1 (CH3CH), 25.7 (2 x CH2), 24.3 (2 x CH2), 22.8 (CH3 overlapped with CH2), 22.1 
(CH3). 
MS (EI, pos.): m/z 211.1 (M+H)+. 
Visible peaks of 12: 
1H NMR (500 MHz, CDCl3) δ 5.36 (d, 1H, J = 10.6, C=CH), 3.55-3.45 (m, 1H, CH3CH), 
1.02 (d, 6H, J = 6.7, 2 x CH3). 
13C NMR (75 MHz, CDCl3) δ 122.1 (C=CH), 110.6 (OCO), 36.1 (CH3CH), 24.0, 23.4, 
22.8. 
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(E)-3-(2-Methylpropylidene)-1,4-dioxaspiro[4.5]decan-2-one (12): 
 
IR (neat): 1782, 1454, 1368, 1306, 1207, 1139, 1046, 977, 935 cm-1. 
1H NMR (500 MHz, CDCl3): δ 5.36 (d, 1H, J = 10.6, C=CH), 3.55-3.45 (m, 1H, CH3CH), 
1.84-1.68 (m, 9H, CH2), 1.51-1.42 (m, 2H, CH2), 1.02 (d, 6H, J = 6.7, 2 x CH3). 
13C NMR (75 MHz, CDCl3): δ 162.5 (C=O), 136.0 (C-C=O), 122.0 (C=CH), 110.6 (O-C-
O), 36.1 (CH3CH), 24.2 (2 x CH2), 24.0 (2 x CH2), 23.4 (CH3), 22.8 (CH3 overlapped with 
CH2). 
Visible peaks of 11: 
1H NMR (500 MHz, CDCl3) δ 5.50 (d, 1H, J = 9, C=CH), 2.73-2.66 (m, 1H, CH3CH), 1.07 
(d, 6H, J = 6.7, 2 x CH3). 
13C NMR (75 MHz, CDCl3) δ 117.4 (C=CH), 111.4 (OCO), 25.7, 22.8, 22.1. 
 
2-Phenyl-1,4,11-trioxadispiro[2.1.55.23]dodecan-12-one (17): 
 
To a solution of (Z)-3-benzylidene-1,4-dioxaspiro[4.5]decan-2-one (10) (310 mg, 
1.27 mmol) in DCM (5 mL) was added m-chloroperbenzoic acid (426 mg, 1.91 mmol) at   
– 78C. The reaction mixture was then warmed to room temperature and stirred for 12 h. 
An aqueous saturated NaHCO3 was added and the mixture was extracted with ethyl acetate 
(3x10mL). The combined organic layers were dried (Na2SO4) and concentrated under 
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reduced pressure to provide a white solid which was purified by flash chromatography on 
silica gel (EtOAc/hexanes, 1:9) to provide 180 mg (54%) of 17 as a white solid. 
IR (neat): 1805, 1448, 1369, 1273, 1179, 1130, 1091, 1042, 944, 906 cm-1. 
1H NMR (500 MHz, CDCl3):  7.39-7.44 (m, 5H, ArH), 4.42 (s, 1H, ArCH), 2.03-1.94 (m, 
2H, CH2), 1.84-1.79 (m, 1H, CH2), 1.77-1.70 (m, 3H, 2-CH2), 1.68-1.61 (m, 1H, CH2), 
1.60-1.56 (m, 1H, CH2), 1.50-1.42 (m, 2H, CH2). 
13C NMR (125.5 MHz, CDCl3):  166.3 (C=O), 131.5 (ArCipso), 129.1 (ArC), 128.4 (2 x 
ArC), 127.7 (2 x ArC), 112.1 (O-C-O), 84.1 (O=C-C-O), 60.9 (ArC-O), 36.9 (CH2CO), 
36.1 (CH2CO), 24.1(CH2CH2CO), 22.9 (CH2CH2CO), 22.(CH2CH2CH2). 
MS (EI, pos.): m/z 261.5 (M+). 
HRMS (CI, pos): m/z 261.1126 (261.1127 calc. For C15H17O4 (M+H)
+). 
 
(3aR,4'S,7aR)-2,2,2',2'-Tetramethyldihydrospiro[[1,3]dioxolo[4,5-c]pyran-6,4'-
[1,3]dioxolan]-7(7aH)-one (14): 
 
Perchloric acid (70%, 4.3 mL) was added to a suspension of D-fructose (18.01 g, 
99.96 mmol) in acetone (350 mL) and 2,2-dimethoxypropane (7.4 mL, 59.98 mmol) at        
0 °C. The resulting mixture was stirred under nitrogen at 0 °C for 6 h and concentrated 
ammonium hydroxide was added until pH was ~7-8. The resulting mixture was stirred for 
5 min and the solvent was removed under reduced pressure. The solid residue was 
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dissolved in CH2Cl2 (200 mL) and the solution was washed with a saturated solution of 
brine (2 x 50 mL), dried (Na2SO4) and concentrated under reduced pressure to a volume of 
40 mL. Boiling hexane was added to this solution and the mixture was cooled to ambient 
temperature followed by cooling at -25 °C for 4 h. The solids obtained were filtered, 
washed with cold hexane and dried to provide 5.74 g (22%) of 13a. 
IR (KBr) 3454, 1376, 1216, 1070, 973 cm-1. 
1H NMR (500 MHz, CDCl3):  4.21 (dd, 1H, J = 5.8, 2.4), 4.20 (d, 1H, J = 8.8), 4.14 (d, 
1H, J = 6.8), 4.11 (dd, 1H, J = 10.9, 3.2), 4.00 (d, 1H, J = 14.9), 3.98 (d, 1H, J = 8.9), 3.67 
(dd, 1H, J = 8.1, 7.1), 2.01 (d, 1H, J = 8.3), 1.54 (s, 3H), 1.52 (s, 3H), 1.44 (s, 3H), 1.37 (s, 
3H). 
13C NMR (75 MHz, CDCl3):  111.9, 109.4, 104.6, 77.32, 73.4, 72.2, 70.4, 60.7, 28.0, 26.4, 
26.3, 26.0. 
MS (EI, pos.): m/z 260.1 (M+), 243.1 (M-17)+. 
PCC (4.14 g, 19.2 mmol) was added in small portions over 15 min to a mixture of 
alcohol 13a (2.01 g, 7.69 mmol) and powdered 3 Å molecular sieves (3 g, activated at 180-
200 °C under vacuum) in CH2Cl2 (40 mL). The reaction mixture was stirred for 3 h under 
nitrogen and filtered through Celite. The residue was washed carefully with ether. The 
combined filtrates were concentrated under reduced pressure and the residue was purified 
on short flash silica gel column (hexane/ether, 1:1) to provide 1.1 g (55%) of 14 as a 
colorless solid.  
IR (KBr) 1746, 1377, 1218, 1098, 1061, 1001, 965 cm-1. 
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1H NMR (500 MHz, CDCl3):  4.72 (d, 1H, J = 5.8, CHC(O)), 4.61 (d, 1H, J = 9.6, OCH2), 
4.54 (ddd, 1H, J = 5.8, 1.3, 0.64, OCH), 4.38 (dd, 1H, J = 13.5, 1.9, OCH2), 4.11 (d, 1H, J 
= 13.5, OCH2), 3.99 (d, 1H, J = 9.6, OCH2), 1.55 (s, 3H, CH3), 1.46 (s, 3H, CH3), 1.40 (s, 
6H, 2 x CH3). 
13C NMR (75 MHz, CDCl3):  197.0 (C=O), 113.8 (OCCO), 110.6 (OCO), 104.1 (OCO), 
77.9 (OCC=O), 75.9 (OCCH2), 70.0 (OCH2), 60.1 (OCH2), 27.1 (CH3), 26.5 (CH3), 26.04 
(CH3), 26.00 (CH3). 
MS (EI, pos.): m/z 259.2 (M+H)+. 
 
3-Hydroxy-3-(1-phenylbut-3-en-1-yl)-1,4-dioxaspiro[4.5]decan-2-one (24): 
 
 To a solution of 17 (0.19 g, 0.73 mmol) in CH2Cl2 (5 mL) at -78 ºC was added 
allytrimethylsilane (0.69 mL, 4.38 mmol) followed by BF3•Et2O (0.55 mL, 4.38 mmol). 
The mixture was stirred at -78 ºC for 15 min and then warmed to ambient temperature and 
stirred for 2 h. Cold water (3 mL) was added and the resulting mixture was extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layers were dried (Na2SO4) and concentrated 
under reduced pressure. The residue was purified by flash chromatography on silica gel 
(hexane/EtOAc, 9:1) to provide 0.160 g (72%) of 24 as a colorless gum. 
IR (neat): 3521, 1780, 1448, 1371, 1282, 1210, 1158, 1078, 948, 911 cm-1. 
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1H NMR (500 MHz, CDCl3):  7.68-7.66 (m, 2H, ArH), 7.40-7.32 (m, 3H, ArH), 5.76-
5.68 (m, 1H, C=CH), 5.13-5.04 (m, 2H, C=CH2), 4.13-4.09 (m, 1H, ArCH), 2.11-2.02 (m, 
1H, CH2), 2.01-1.95 (m, 3H, CH2), 1.83-1.77 (m, 1H, CH2), 1.74-1.69 (m, 4H, CH2), 1.63-
1.58 (m, 1H, CH2), 1.53-1.46 (m, 2H, CH2).  
13C NMR (75 MHz, CDCl3):  172.3 (CO), 136.8 (ArCipso), 134.1 (C=CH), 128.5 (2 x 
ArC), 128.4 (ArC), 125.1 (2 x ArC), 118.4 (C=CH2), 111.6 (O-C-O), 85.9 (O-C-C=O), 
74.9 (ArCH), 37.5 (C=C-CH2), 36.8 (CH2), 34.7 (CH2), 24.5 (CH2), 23.2 (CH2), 22.1(CH2). 
MS (EI, pos.): m/z 325.2 (M+Na)+. 
HRMS (CI): m/z 303.1592 (303.1596 calc. for C18H23O4 (M+H)
+), 301.1440 (301.1440 
calc. For C18H21O4 (M-H)
+). 
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4.6 Selected 1H NMR and 13C NMR Spectra 
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CDCl3, 75 MHz 
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CDCl3, 500 MHz 
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CDCl3, 500 MHz 
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CDCl3, 75 MHz 
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14 
CDCl3, 500 MHz 
 
14 
CDCl3, 500 MHz 
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CDCl3, 500 MHz 
 
17 
CDCl3, 125 MHz 
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CDCl3, 500 MHz 
 
24 
CDCl3, 75 MHz 
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Chapter 5 
Conclusions 
5.1 Summary of the Thesis 
A regio- and stereoselective 1,3-dipolar cycloaddition of achiral nitrones with 
ephedrine-derived alkylidene morpholinones (5 and 6) provided the intermediate 
isoxazolidines which are converted into either an indolizidine or a quinolizidine alkaloid 
depending on the nitrone and the substituent on the chiral alkene. The methodology was 
applied to the synthesis of (+)-epitashiromine (1) and the formal syntheses of (+)-
epilupinine (2) and (+)-tashiromine (3, Figure 5.1). Details of these syntheses are provided 
in Chapter 2 of this thesis. The synthesis begins with the morpholine dione 4 which was 
converted into the alkylidene morpholinones 5 or 6 either by addition of a carbon 
nucleophile to the lactone carbonyl followed by dehydration (as for 5) or by a Wittig 
reaction of the lactone carbonyl (as for 6, Scheme 5.1 ). Cycloaddition reactions of 5 and 
6 with cyclic nitrones 7 and 8, under microwave irradiation, provided the spiro 
isoxazolidines 9 and 10 respectively, both as single diastereomers. The assignment of 
stereochemistry for the isoxazolidines was based on two assumptions: i) addition of the 
nitrone exo to the alkene substituent and ii) reaction of the alkene from the face opposite 
to the methyl and phenyl groups in the morpholinone. 
Figure 5.1 Our synthetic targets. 
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Scheme 5.1 
The strategy for converting 9 into the indolizidine motif involved a ring formation 
of the nitrone-derived pyrrolidine ring with the alkyl group on the dipolarophile and hence, 
the side chain in 9 was first activated as a mesylate. Reductive cleavage of isoxazolidine 
ring in 9 liberated the secondary amine which cyclized in situ to provide the functionalized 
indolizidine 11. Conversely, the tactic for building the quinolizidine core from 10 involved 
ring formation with the morpholinone section. In this approach, the methoxymethyl group 
from the dipolarophile would eventually become a substituent in the target. Accordingly, 
10 was first reduced and then bis-acylated to provide 12.  
Reduction of the hemiacetal in 11 followed by a reductive removal of the ephedrine 
portion provided 13 (Scheme 5.2). Conversion of the hydroxy amide side chain into a 
hydroxymethyl group was achieved by reduction to the amino alcohol, oxidative cleavage 
to the aldehyde and reduction to the alcohol. This three-step procedure provided  
(+)-epitashiromine (1) from 13. 
227 
 
 
 
Scheme 5.2 
 In the other synthetic route, generation of an oxonium ion from the activated 
hemiacetal in 12 and its intramolecular capture provided 14 which was decarboxylated to 
15 (Scheme 5.3). Reductive removal of the ephedrine portion and oxidative removal of the 
hydroxy amide functionality provided 17 which was converted to the ketone 18, a known 
precursor to (+)-epilupinine (2, shown in Scheme 5.3). This constitutes a formal synthesis 
of (+)-epilupinine (2). Notably, this is the only synthetic strategy that provides access to 
either isomer (syn or anti) of the hydroxymethyl-substituted indolizidines and 
quinolizidines. Completion of both synthetic routes confirms our initial stereochemical 
assignments for isoxazolidines 9 and 10. 
 
 
Scheme 5.3 
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The methodology for the synthesis of quaternary stereocenters is described in 
Chapter 3. The strategy for the synthesis of quaternary stereocenters involves two key 
transformations of alkylidene morpholinones: i) metal catalyzed, stereoselective cross 
coupling reactions and ii) an asymmetric Prins reaction. Alkylidene morpholinone 19 was 
prepared by addition of ethylmagnesium bromide to dione 4 followed by dehydration. 
Halohydrin formation from alkene 19 (bromine/water) and subsequent dehydration 
furnished the Z-alkenyl bromide 20 (Scheme 5.4). This smoothly furnished tetrasubstituted 
alkenes (21-24) under Suzuki and/or Kumada cross coupling conditions in moderate to 
good yields. The alkylidene morpholinones 21 and 24 were subjected to a Prins reaction 
with paraformaldehyde in acetic acid. The Prins adducts 25 and 26, on dissolving metal 
reduction, furnished the corresponding -dihydroxy amides 27 and 28 with an all-carbon 
quaternary stereocenter at the  carbon.   
 
Scheme 5.4 
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Reduction of the amide in 28 followed by oxidative cleavage using NaIO4 furnished 
the -hydroxy aldehyde. Oxidation of the aldehyde provided the (R)-(+)--methyltropic 
acid (30). Following a similar reaction sequence acid 29 was prepared from amide 27. 
Chapter 4 of this thesis describes the efforts directed towards identifying possible 
substitutes for ephedrine in the synthesis of -hydroxy acid derivatives. Studies on 
alkylidene dioxolanones as a possible substitute for ephedrine-derived alkylidene 
morpholinones was undertaken. The alkylidene dioxolanones 32, 33 and 34 were 
successfully prepared from dioxolanone 31 (Scheme 5.5). Alkene 32 furnished the epoxide 
35 on treatment with m-CPBA but it failed to react under Shi epoxidation conditions. 
Because of side reactions during nucleophilic epoxide ring opening reactions and the 
unexpected reactivity of epoxide 35, to yield 36 during Lewis acid catalyzed epoxide ring 
opening, further studies with alkenes 32, 33 and 34 were discontinued. If further studies of 
alkylidene dioxolanones are to be carried out, a thorough survey of asymmetric epoxidation 
as well as dihydroxylation methods using 32-34 as substrates is necessary. 
 
Scheme 5.5 
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5.2 Future Work 
 The use of a functionalized cyclic nitrone such as 38 in the 1,3-dipolar 
cycloaddition reaction with alkylidene morpholinones can lead to alkaloids with ring 
substitution (Scheme 5.6).  
 
 
Scheme 5.6 
The methodology described in Chapter 2 can also be applied to the synthesis of 
polysubstituted piperidines 46 (Scheme 5.7) by using acyclic nitrones in the cycloaddition 
reaction (Scheme 5.7). The piperidines obtained by this method can be used as synthetic 
intermediates or they can be tested for biological activity.1 
 
Scheme 5.7 
For the synthesis of quaternary stereocenters, an extensive survey of metal-
catalyzed cross-coupling reactions of the bromoalkylidene morpholinone starting material 
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is necessary. Optimization of the Prins reaction conditions to improve the overall yield of 
the target compounds is also worth pursuing.  
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